Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2018

Family Planning and HIV Interventions among Women in Lowincome Settings
Steven P. Masiano

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Health Services Research Commons, International Public Health Commons, and the
Women's Health Commons
© Mwatiyesa Steven Pirirani Masiano

Downloaded from
https://scholarscompass.vcu.edu/etd/5688

This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars
Compass. For more information, please contact libcompass@vcu.edu.

Family Planning and HIV Interventions among Women in Low-income Settings

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University

By
Mwatiyesa Steven Pirirani Masiano
Master of Science, Brandeis University, 2013
Bachelor of Social Sciences, University of Malawi, 2007
Doctoral Candidate, 2018

Advisor: April D. Kimmel, PhD
Assistant Professor, Department of Health Behavior and Policy
Virginia Commonwealth University School of Medicine

Virginia Commonwealth University School of Medicine,
Richmond, Virginia
December 2018

i

To my lovely wife, Noella, and two beautiful children Winston and Condoleezza-Gwen.

ii

Acknowledgments
First, thanks and praises to Jehovah for His love, care, and blessings throughout this dissertation
research. You granted me the wisdom, health, and strength to undertake this research and saw me
through till the end. You never abandoned me. As thou saith in the Book of Mathews 7:7-8 “Ask,
and it shall be given to you; seek, and you shall find; knock, and it shall be opened unto you: For
every one that asketh receiveth; and he that seeketh, findeth; and to him that knocketh it shall be
opened,” Thank you, Jehovah.

This journey was long and winding but getting to the promised land would not have been
possible without the tremendous support and guidance of several people. I deeply appreciate and
many thanks to you all. I owe special thanks to my committee chair and advisor, April D.
Kimmel, for her guidance, encouragement, and untiring support. Without her, this dissertation
work would not have been completed. I would also like to express my profound gratitude to my
committee: Bassam Dahman, Daniel Nixon, Tiffany Green, and the late Saba Masho. I deeply
appreciate your guidance and insights which have helped me to become an independent
researcher. I would also like to thank Kate Grant for her support and encouragement, as well as
the dedication and commitment to help with activities and jobs outside the routine of her regular
position. Kate, you are the best. I also gratefully acknowledge the support of Yangyang who
oriented me to the Medicaid claims data. Without him, this journey could have been harder.

This work would not have been possible without the support of classmates and peers. I could not
have asked for more supportive classmates and colleagues. Specifically, I would like to thank
Anushree and Lauryn who were great pillars of support and cheerleaders in some of the most
trying times on this journey. I will miss you.

iii

To family and friends outside of VCU, what can I say? My wife, “Queen Noella as I like to call
her”, stayed with me along this difficult journey, continued to love me, and gave me comfort
when I needed it most. I will forever be grateful. To my two children, Winston and Gwen, I am
very grateful for your love, patience, and understanding. I was not able to spend as much time
with you as both of us would have wanted; I will make it up to you. To my mum, I say thank
you. I know it was not easy not to see your son and grandchildren for nearly five years. But your
phone calls and unceasing prayers gave me hope and courage. To my late father, Omar Steven
Bitoni Masiano, and late uncle Joseph Lameck Kalulu, I say thank you. Although you could not
live long enough to see the fruits of your hard work, your legacy lives on. To Bud and Susie
Whitehouse, I say thank you. You gave us your love and trust without knowing us. You
supported us morally, spiritually, and materially. It is through you that my faith in Jesus Christ
strengthened. Through you, my family learned that you don’t have to know someone to help
them. My family and I shall forever be grateful.

iv

TABLE OF CONTENTS

Family Planning and HIV Interventions among Women in Low-income Settings .................... 1
Abstract ........................................................................................................................................... 1
Chapter 1: The effects of community-based distribution of family planning services on
contraceptive use in Malawi .......................................................................................................... 3
Abstract ....................................................................................................................................... 3
1.

Introduction .......................................................................................................................... 4

2.

Background to community-based distribution of family planning services ........................ 7

3.

Theoretical and conceptual framework ................................................................................ 9

4.

Materials and methods ....................................................................................................... 11

5.

Results ................................................................................................................................ 20

6.

Discussion .......................................................................................................................... 26

7.

Conclusion ......................................................................................................................... 31

Table 1. Comparison of the pilot and national CBDs in Malawi .............................................. 33
Table 2: Descriptive statistics (Weighted sample size: n=52,978) ........................................... 34
Table 3: Effect of CBDAs on contraceptive use in Malawi (2005-2016) ................................. 36
Table 4: Average predicted probabilities of contraceptive use before and after CBDs, by urban
status .......................................................................................................................................... 38
Table 5: Assessment of education and income (wealth) as moderators of CBD effects on
contraceptive use in rural areas ................................................................................................. 39
Figure 1: District participation in a community-based distribution (CBD) pilot of family
planning services in Malawi, 1999-2003 .................................................................................. 40
Figure 2. A conceptual framework for understanding the effect of CBDs on contraceptive use
in rural areas of Malawi ............................................................................................................ 41
Figure 3: A flowchart for deriving a sample for examining the effect of community-based
distribution (CBDs) on contraceptive use in Malawi ................................................................ 42
Figure 4. Timeline for implementation of community-based distribution (CBD) of family
planning services and data collection in the Malawi Demographic and Health Surveys
(MDHS)..................................................................................................................................... 43
Figure 5: Urban-rural trends in contraceptive use before and after national CBDs in Malawi 44
Figure 6: Average community contraceptive use ...................................................................... 45
Figure 7: Average district contraceptive use ............................................................................. 46
Figure 8: Predicted probability of contraceptive use by women’s education. .......................... 47
v

Figure 8: Predicted probability of contraceptive use by women’s income. .............................. 48
Figure 9: A goodness-of-fit test using deviance residuals ........................................................ 49
Appendices ................................................................................................................................ 50
Stata do file................................................................................................................................ 60
Chapter 2: Conditional cash transfers to increase the uptake of services for the prevention of
mother-to-child transmission of HIV: a trial-based cost-effectiveness analysis ....................... 75
Abstract ..................................................................................................................................... 75
1.

Introduction ........................................................................................................................ 76

2.

Overview of the trial .......................................................................................................... 77

3.

Methods.............................................................................................................................. 78

4.

Results ................................................................................................................................ 90

5.

Discussion .......................................................................................................................... 94

6.

Conclusion ......................................................................................................................... 99

Table 1: Definition of standard PMTCT care ......................................................................... 100
Table 2: Included costs, societal perspective* ........................................................................ 101
Table 3. Unit Costs, in I$2016 ................................................................................................ 102
Table 4: Effectiveness of conditional cash transfers ............................................................... 103
Table 5: Number-needed-to-treat (NNT), and steps for deriving the NNT ............................ 104
Table 6. Mean cost per participant, by trial arm (2016 I$) ..................................................... 105
Table 7. Adjusted costs of conditional cash transfers, I$2016 ................................................ 106
Table 8. Incremental cost-effectiveness ratios of conditional cash transfers .......................... 107
Table 9. Multi-way sensitivity analysis of the cost-effectiveness of CCTs: best and worst cases
................................................................................................................................................. 108
Figure 1: One-way sensitivity analysis of changes in unit costs on the ICER ........................ 109
Figure 2: Differences in costs and effects, PMTCT uptake .................................................... 110
Figure 3: Differences in costs and effects, PMTCT retention................................................. 111
Figure 4: Society’s willingness-to-pay for uptake of PMTCT services and retention in PMTCT
care .......................................................................................................................................... 112
Appendices .............................................................................................................................. 113
Stata do file.............................................................................................................................. 130
Chapter 3: Guideline concordance of time to follow-up of anal cancer screening in women
living with HIV at high-risk for acquiring anal cancer ........................................................... 141
vi

Abstract ....................................................................................................................................... 141
1.

Introduction ...................................................................................................................... 142

2.

Methods............................................................................................................................ 145

3.

Results .............................................................................................................................. 151

4.

Discussion ........................................................................................................................ 155

5.

Conclusion ....................................................................................................................... 163

Table 1: Summary statistics for high-risk women living with HIV followed-up for anal cancer
screening, by risk group .......................................................................................................... 164
Table 2: Odds of guideline-concordant time to follow-up anal cancer screening in high-risk
women with HIV ..................................................................................................................... 165
Table 3: The percent of women living with HIV with guideline-concordant time to follow-up
screening at varying restrictions of years of continuous enrollment in Medicaid .................. 166
Table 4: The percent of women living with HIV with guideline-concordant time to follow-up
screening, using varying numbers of ICD-9 codes to define high-risk women ...................... 167
Table 5: Average predicted probability of receiving follow-up anal cancer screening in women
with HIV at different cut-off points ........................................................................................ 168
Figure 1: Recommendations for anal cancer screening in people living with HIV at high risk
for anal cancer ......................................................................................................................... 169
Figure 2: A framework for understanding the frequency of follow-up anal cancer screening in
high-risk women living with HIV ........................................................................................... 170
Figure 3: Kaplan-Meier estimates of the frequency of follow-up anal cancer screening, by risk
group........................................................................................................................................ 171
Figure 4: Percent receiving guideline-concordant follow-up anal cancer screening, by risk
group and the result of the first screen .................................................................................... 172
Appendices .............................................................................................................................. 173
Stata do file.............................................................................................................................. 181
Chapter 5: Conclusion ............................................................................................................... 201
References ............................................................................................................................... 202

vii

Family Planning and HIV Interventions among Women in Low-income Settings
Abstract
This dissertation examines the effectiveness of interventions related to family planning and the
uptake of HIV-related preventive services among women in low-income settings. Women in
low-income settings and living with HIV face many barriers to care, including limited access to
services for family planning and HIV-related preventive care. At the same time, national,
regional, and global efforts are looking for interventions to help control rapid population growth,
create an HIV-free generation, and provide adequate preventive care for those living with HIV.
This dissertation cuts across these issues and can help to inform debate and policies to address
these issues.
This dissertation comprises three discrete papers. Paper 1 (chapter 1) examines the effectiveness
of a national scale-up of community-based distribution of family planning services on
contraceptive use in Malawi’s rural areas during the period 2005-2016. The national-scale up of
the intervention followed the success of a pilot of a similar intervention implemented in the
period 1999-2004. As in the pilot, the scaled-up program distributed condoms and oral
contraceptives and provided family planning education. Further, because education and income
are important determinants of individual contraceptive use, the paper also examines whether the
effectiveness of the national scale CBDs varies over these dimensions. The paper uses the
Malawi Demographic and Health Surveys. The study finds that the intervention increased
contraceptive use by 6.8 percentage points and the effects were greater among uneducated and
low-income women.
Paper 2 (chapter 2) conducts a cost-effectiveness analysis of a trial of cash incentives aimed at
increasing the uptake of services for the prevention of mother-to-child transmission (PMTCT) of
1

HIV. The trial was conducted in the Democratic of the Congo (DRC) as part of an effort to find
ways of increasing uptake of PMTCT services in sub-Saharan Africa where uptake of these
services remains low. The study is conducted from the societal perspective, relies on multiple
sources within and outside of the DRC for cost data, and reports economic costs in 2016
International Dollars (I$). At a threshold of 3*GDP per capita for the DRC (I$2409), the study
finds that the intervention is cost-effective.
Paper 3 (chapter 3) examines the guideline concordance of the time to follow-up anal cancer
screening in women living with HIV at high risk for anal cancer. In the US, the incidence of anal
cancer in women living with HIV has increased significantly in the past 2-3 decades. However,
early detection of anal cancer, through regular screening, can lead to effective secondary
prevention of the disease. While guidelines for anal cancer screening exist, very little is known
about the guideline concordance of the time to follow-up anal cancer screening in women at high
risk of acquiring anal cancer. Hence this study. The study uses Medicaid Analytic eXtract files
which compile claims of individuals enrolled in Medicaid—a public health insurance program
largely for eligible low-income adults and the largest single payer for HIV/AIDS in the US. The
study finds that time to follow-up screening is not guideline-concordant for most women living
with HIV, particularly those with one of the two risk factors for anal cancer: a history of
abnormal cervical test results or a history of genital warts.
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Chapter 1: The effects of community-based distribution of family planning services on
contraceptive use in Malawi
Abstract
Background: To address rapid population growth, Malawi implemented and scaled-up a pilot
project of community-based distribution (CBD) of family planning services. However, the
effects of the scaled-up (national) CBDs on contraceptive use remain unclear. To address this
knowledge gap, we evaluated the effectiveness of the national CBDs of family planning on
contraceptive use. We also investigated whether education and income, two important
determinants of individual-level contraceptive use behaviors, moderate these effects.
Methods: We used the 2000/2004 and 2010/2016 Malawi Demographic and Health Surveys
(N=57,978) and difference-in-differences analyses to estimate the effects of the 2005 national
scale-up of CBDs on modern contraceptive use. We used rural and urban communities as the
intervention and comparison groups since the national CBDs were implemented only in rural
communities. Contraceptive use is defined as current use of any modern contraceptive method—
e.g., pills—and was modeled using multilevel logistic regression.
Results: Prior to the national CBD scale-up (2000/2004), the probability of using
contraceptives was 21.5% in rural communities and 26.3% in urban communities. In the postscale-up period (2010/2016), the probability of using contraceptives increased in both rural and
urban communities but was greater in rural communities (44.9% vs. 42.9%). The effect
attributable to CBDs was 6.8 percentage points (95% CI=3.3, 9.7). The effects of the CBD scaleup were greater among uneducated and low-income women.
Conclusions: These findings suggest that national CBDs increase overall contraceptive use,
particularly in rural communities. Poor and uneducated women benefit more from family
planning interventions that reduce communication and financial barriers. Further research on the
effects of national CBDs on fertility, as well as the value and affordability of the national CBDs,
is needed.
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1. Introduction
Since gaining independence from the British in 1964, Malawi has experienced rapid population
growth [1], [2], which has strained the country’s resources in important sectors of education and
health and has undermined the country’s efforts to reduce poverty [3]. Malawi’s population grew
by about 500%, from 3.7 million in 1964 to over 17 million in 2015 [1], [2]. To find ways to
slow the population growth, the Malawi government with financial support from the World Bank
rolled out a pilot of the Learning and Innovation Population and Family Planning (Pop/FP)
Project [4]–[6]. The pilot’s objective was to test the feasibility of implementing a comprehensive
community approach aimed at increasing the demand for and improving access to family
planning services among hard-to-reach populations [6], [7]. The project trained communitybased distribution1 (CBD) agents to carry modern contraceptive methods (pills and condoms)
and conduct family planning education in local languages of their designated communities of
service [5], [6]. Some CBD agents of family planning referred clients to health facilities for
services the agents could not provide [4].
The pilot project was implemented from 1999 to 2003 in 3 districts, one in each region. The
districts were Chiradzulu in the South, Dowa in the Center and Chitipa in the North [5], [6],
figure 1. The districts were selected based on the presence of a committed District Health
Management Team (DHMT), low contraceptive prevalence rate (CPR), high population density,
and low literacy rates [7]. Each pilot district had one control selected based on proximity and
comparable socio-demographic characteristics (e.g., education) [5], [7]. The controls were

1

The idea of a community approach to delivering family planning services was not entirely new in Malawi. It was
first introduced in the late 1980s [4]. In 1991, the Christian Health Association of Malawian—an umbrella body of
faith organizations providing healthcare services in Malawi—started a similar initiative [4]. The difference,
however, is that prior efforts were not well coordinated, did not have a large presence in the communities, and had
little or no involvement of public sector institutions [4].
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Mulanje for Chiradzulu, Ntchisi for Dowa and Karonga for Chitipa [5], [7]. An end-of-pilot
evaluation in 2003 suggested that the pilot was effective in increasing contraceptive use [5], [6].
Given the pilot project’s effectiveness, it was scaled-up to the national level in late 2004.
However, no study has evaluated the effect of the national CBD scale-up. Therefore, the current
study investigates the effect of the full national scale-up of the CBDs of family planning
(henceforth, CBDs) on contraceptive use during the period 2005-2016. Furthermore, because
education and income are important determinants of individual contraceptive use behavior [8]–
[11] and the intervention was designed to reduce or eliminate information and financial barriers
to accessing contraceptives [5], [6], we also examine whether the effect of the CBDs varies by
the education or income of the target population. The first hypothesis is that CBDs increased the
number of women using modern contraceptives. The second hypothesis is that the effects of
CBDs on contraceptive use are moderated (influenced) by both the education and income of the
women receiving the services and these effects greater among highly educated and high-income
women. The scale of the CBDs was done simultaneously across the country [personal
communication, Malawi’s Ministry of Health, January 2016].
Understanding the effect of the full scale-up of Malawi CBDs is important for several reasons.
First, many projects implemented in low- and middle-income countries (LMICs) show promise
of success when implemented as pilots [12]–[16], [17, p. 360], [18], [19], but when scaled to the
national level, the evidence on the performance of such projects is lacking. This makes it
difficult for policymakers to respond to emerging challenges and set new goals for the countries
to achieve. Moreover, the few studies that have evaluated large-scale or scaled-up CBDs in
Africa were not rigorous enough to provide reliable evidence that can be extrapolated to Malawi
for evidence-based decision making. The studies either lacked control groups [20], [21] or did
5

not use pre- and post-intervention study designs [22]. This study addresses the methodological
shortcomings of the previous studies by implementing a difference-in-differences technique to
mimic an experimental study design to identify the effect of the CBDs on contraceptive use.
The second reason for evaluating the effects of the national CBDs in Malawi is that the selection
criteria of the pilot districts (e.g., the presence of a committed DHMT and low district CPR)
predisposed the pilot of the CBDs to demonstrate a level of effectiveness higher than would have
been the case had the districts been randomly selected [6], [7]. Therefore, as these criteria
suggest that the pilot districts were systematically different from the non-pilot districts and that
the effect of CBDs in the pilot project might have been overstated, it is important to investigate
the effect of the CBDs in the non-pilot districts after the scale-up.
Third and importantly, the national scale-up was implemented as a variant of the pilot project as
not all conditions in the pilot project were maintained in the national scale-up which raises
questions about the effectiveness of the scaled-up CBDs. A comparison of the pilot and national
CBDs is provided in table 1. Notably, a monthly $6 cash payment to each CBD agent during the
pilot was discontinued. Moreover, during the pilot the CBDs were primarily supervised by
project employees who were given adequate resources, including motorcycles; in the national
scale-up, primary CBD supervisors are government employees (Health Surveillance Assistants
[HSA]—a cadre of community health workers) who use push bicycles to conduct the supervision
[6]. Without the cash incentives and questions about supervision adequacy in the national scaleup, it is unclear whether the CBDs continued to be as effective as they were in the pilot.
In sum, an investigation into the effects of Malawi CBDs is needed as evidence on the
effectiveness of the CBDs at the national level is lacking, but this evidence is important to
Malawi. The evidence can be used by the Malawi government in the reorganization of the
6

country's priorities as the country works to achieve its target of eliminating poverty, providing
quality education, and ensuring healthy lives for Malawians [3].
The rest of the study is organized as follows. Section 2 presents a background to the communitybased distribution of family planning. Sections 3 and 4 present the theoretical/conceptual
framework and methods. Results are presented in section 5. A discussion of the study's findings,
strengths and limitations, and implications for policy is presented in section 6. Section 7
concludes.
2. Background to community-based distribution of family planning services
Community-based distribution (CBD) refers to strategies that rely on community structures,
including community leaders and trained non-professional members of the community, to
provide health services in the communities [23], [24]. CBDs of family planning promote the use
of simple and safe non-clinical family planning methods such as oral contraceptives and
condoms [24]. CBDs were introduced to reduce the unmet need for family planning in many
parts of the world, particularly in rural areas of LMIC where the healthcare workforce is limited,
stock-outs of modern contraceptives are frequent, and travel distances to health facilities are long
[25]–[29]. CBDs were started in Latin America in the 1960s, then in Asia in the 1970s and more
recently after 1980 in Africa [24], [30].
The promotion of CBDs in LMICs is based on theory and evidence which suggest that the CBDs
have many advantages over services received in clinical settings. First, by bringing services to
the communities, CBDs are more convenient for many people to access family planning services
[23], [24], [27]. Second, family planning services received from CBDs cost less because many
CBD agents work as volunteers or accept a small payment for their services and do not require
extensive training [27], [31]. Third, it is easier for people in the communities to accept family
7

planning messages from the CBD agents since in many cases, the CBD agents are respectable
and trusted members of their communities, especially when they are selected by the communities
themselves [24]. Moreover, because CBD agents usually have many commonalities (e.g.,
language and cultural beliefs) with the rest of the community, it is easier for them to overcome
social customs and traditions hindering the uptake of contraceptives [24], [27], [29], [32], [33].
Fourth, there is repeated messaging: because the CBD agents often reside in communities in
which they provide the family planning services, there are more opportune occasions (e.g., social
gatherings) where they can talk about family planning [4], [27]. The CBD agents may also
informally talk about family planning which can be more appealing than the demand-based and
static clinical set-up [27].
2.1. The effectiveness of community-based distribution of family planning
Despite CBDs being considered an important innovation in the delivery of family planning
services, evidence of their effectiveness is mixed and mainly comes from pilot projects. Data
show that CBDs have increased contraceptive use in many parts of Africa [14]–[16], [21], [34],
[35], and that the positive effects of the CBDs persist when the portfolio of methods carried by
CBDs is expanded beyond the non-clinical methods to include depot medroxyprogesterone
acetate (DMPA)—an injectable contraception [12], [17], [36]. Furthermore, CBDs are still
effective even when the CBDs integrate family planning services with other services [36], or
when social institutions are the medium for channeling family planning information [24], or in
makeshift settings in times of crisis [37]. However, evidence suggests that CBDs have not
increased contraceptive use in some parts of Africa [20], [38], [39].
The effectiveness of CBDs depends on many factors. CBDs are more effective in communities
with low CPR [24], [29], in more rural and isolated communities [14], [27], and in earlier periods
8

of CBD implementation [14]. Characteristics of the CBD agents also affect the effectiveness of
the CBDs, although this evidence is mixed. Reports show that CBD agents are less effective if
the agents are not well educated [39], [40]. However, other evidence shows that the agents’ age,
education, and marital status have no association with CBDs’ productivity [41], although the sex
of the CBD agent is important in influencing the choice of the contraceptive method [29].
Despite the evidence that contextual factors and characteristics of the CBD agents influence the
effectiveness of CBDs, it is unclear whether the education and income of the target population
also affect the effectiveness of CBDs. It is important to understand the role of education and
income of the people receiving services from the CBDs because education and income are
important determinants of individual contraceptive use behavior [8]–[11], and the CBD agents
disseminate family planning information in ways that are easier to understand and overcome
financial barriers associated with accessing contraceptives [13], [24]. Therefore, apart from
investigating the effects of Malawi CBDs on contraceptive use, we also investigate whether the
education and income of the target population affect the effectiveness of the CBDs.
3. Theoretical and conceptual framework
To understand the effect of CBDs on contraceptive use, we draw upon the economic framework
for fertility analysis and the human capital model of demand for health. The economic
framework for fertility analysis expands on consumer choice approaches [42] by incorporating
supply factors and the cost of regulating fertility to understand household fertility behavior [43].
The theory notes that a household’s need to regulate fertility arises when its biological supply of
children exceeds its demand for the children [43]. However, there are costs to fertility regulation.
The costs could be objective (e.g., transportation and contraceptive costs) or subjective (e.g.,
coping with using contraceptives against one’s beliefs) [44]. While having many children may
9

provide utility to some households [45] or alleviate the subjective feeling of poverty in some
societies of LMICs [46], the relatively high costs of obtaining modern contraceptives prevent
many households in LMICs from regulating their fertility [47]–[49]; this is where CBDs become
relevant and important in Malawi. By bringing contraceptives to the communities, the CBDs
bring down the objective costs of fertility regulation to almost zero. CBD clients are not required
to pay for services received from the CBDs because public health services in Malawi are free at
the point of delivery [50].
We also draw upon the human capital model of demand for health by Grossman which identifies
two pathways through which education impacts health behaviors like contraceptive use. First,
through productive efficiency: educated people are better decision makers and thus have higher
marginal products in the health production process [51]. Second, through allocative efficiency:
educated people tend to have more knowledge about health which helps them to change their set
of choices as well as behaviors to produce more health [51], [52]. The information shared by
CBDs adds to the knowledge educated people already had, making it easier for them to dispense
with traditional customs and beliefs that may impede contraceptive use [8]. In sum, although
both educated and uneducated people might have improved access to contraceptives through
CBDs, educated people are likely to process family planning information better, discuss and
follow recommendations for contraceptive use [8], [53], [54].
Based on the two economic theories, we developed a conceptual framework of the effect of
CBDs on contraceptive use while incorporating contextual or community factors which may also
influence contraceptive use as documented in the literature [8], [9], [55]–[58], figure 2. The
conceptual framework is specific to rural communities as CBDs work in rural communities only.
The framework shows that contraceptive use is influenced by CBDs, the intervention, as well as
10

individual-level characteristics (maternal and paternal) of the target population and communitylevel factors. As the study has hypothesized that the direct effect of CBDs on contraceptive use is
moderated by education and income, education and income were extracted from the other
individual-level characteristics so that their moderating effects on the effect of CBDs on
contraceptive use could be depicted as hypothesized. Further, the framework shows that
individual-level characteristics of the target population affect contraceptive use directly or
indirectly via community characteristics.
4. Materials and methods
4.1. Overview
The study used data from four waves (2000, 2004, 2010, and 2016) of the Malawi Demographic
and Health Surveys (MDHS) and the difference-in-differences (DD) method to estimate the
effect of the CBDs on contraceptive use in a weighted sample of 52,768 women aged 15–49
years. As CBDs were implemented only in rural communities, the rural communities were
designated as the intervention group and urban communities as controls; primary sampling units
were used as a proxy for communities. As CBDs were introduced in 2005, data collected before
2005 (MDHS2000 and MDHS2004) represented the pre-intervention period while MDHS2010
and MDHS2015 represented the post-intervention period. Contraceptive use was defined as
current use of any modern contraceptive method—for example, pills. Contraceptive use was
modeled as a binary variable (“no method” and “modern method”) in a multi-level logistic
regression with women nested in communities and communities nested in districts.
4.2. Data sources
Four waves of the Malawi Demographic and Health Surveys (MDHS2000, MDHS2004,
MDHS2010 and MDHS2016) were used in this study. The surveys were conducted by the
11

National Statistical Office (NSO) in partnership with the United States Agency for International
Development (USAID) and the country’s other development partners [57], [59]–[61]. In years
2000, 2004, 2010, and 2016, the surveys covered 14,213, 15,091, 27,000 and 26,361 households,
respectively [57], [59]–[61]. From the selected households, eligible women aged 15-49 years and
men aged 15-54 years in a sub-sample of about one-third of the households were interviewed.
The surveys provided comprehensive up-to-date information on education, wealth, and
contraceptive use, among other indicators [57], [59]–[61]. The surveys use two-stage stratified
cluster sampling to produce representative samples of urban and rural populations at the district,
regional and national levels. Urban areas are defined as any of the country's major cities or areas
encompassing district administrative headquarters or any official town planning areas; all the
other areas are rural [62].
4.3. Hierarchical structure of the data
Since the surveys use multi-stage sampling designs to generate nationally representative samples,
data from the surveys have a hierarchical or clustered structure [63]–[65]. Elements sampled in
the first-stage, districts, constitute the highest level while those sampled in the final-stage,
women, are the lowest units [63]. Thus, women are nested in communities and the communities
in districts. The nesting means that women from the same community or district are similar and
do not act as independent observations in their use of contraceptives. The similarity might be due
to unobserved factors, like having similar cultural and traditional beliefs, which can facilitate or
hinder contraceptive use [66], [67]. Therefore, statistical modeling of these data should account
for this dependence to avoid producing biased estimates [63], [68]. As discussed below,
contraceptive use was modeled using a multilevel model to account for the hierarchical structure
of the data.
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4.4. Sample
The final sample comprised 57,524 women, representing about 79% of women in the four
MDHS files, figure 3. The data for this study came from the “women recode” files. Figure 3
shows how the sample was derived and the number of women from each wave of the MDHS.
Infecund women, defined as women wanting to have another child but not being able to get
pregnant [69], were excluded. Pregnant women were also excluded because the dependent
variable was constructed from a question which focused on current contraceptive use. All
women, regardless of marital status, were included in the study as they can all demand
contraceptives. However, the association between CBDs and contraceptive use was also
examined in a subsample of married women to make the findings more comparable to those from
the pilot of the CBDs which reported contraceptive use among married women only [5].
4.5. Variable definition
4.5.1. Dependent Variable
The dependent variable is current use of modern contraceptive methods, and it is binary (1=using
a modern method and 0= not using a modern method). The women were asked this question:
Are you currently [at the time of the interview] doing something or using any method to
delay or avoid getting pregnant [70]?
Women answering “YES” to this question were further asked to mention the methods they were
using [70]. The contraceptive methods were classified as either modern or traditional. Modern
methods include injections, pills, intrauterine device, diaphragm, condoms, sterilization,
implants, foam or jelly, and lactational amenorrhea; traditional methods include abstinence and
withdrawal [69]. Abortion was not considered as contraception because contraception was
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defined as any effort to reduce the risk of conception. The three categories of contraceptive use
(“no method”, “traditional method”, and “modern method”) were collapsed into two categories
“no method” and “modern method” as <2% of the women used “traditional methods”. A test for
combining categories of the dependent variable proposed by Long and Freese [71] showed that
“traditional methods” and “no method” could be collapsed into one category as the two
categories were indistinguishable.
4.5.2. Explanatory variables
Consistent with the conceptual framework in figure 2, explanatory variables were classified into
two broad groups: individual-level variables and community-level variables. Among the
individual-level variables, the woman’s partner’s education and occupation were included as
these may also affect contraceptive use regardless of the woman’s characteristics [72], [73].
Community variables were also included because these may exert influence on women’s
behaviors related to contraceptive use [74], [75]. For example, community literacy was included
because women without any education may get assistance or encouragement to use
contraceptives from other women with education in the same community. All explanatory
variables, including definitions and how they were constructed, are presented in Appendix A1.
4.6. Identification strategy: difference-in-differences
We used the difference-in-differences (DD) method to identify the effect of CBDs on
contraceptive use. The method rests on the parallel paths assumption, which states that the
intervention and comparison groups would have followed the same time trends were there no
intervention [76]–[78]. An effective policy intervention, therefore, causes the intervention group
to deviate from its time trend [76], [78], [79]. The assumption, however, requires that the policy
change should be exogenous or that any of the groups should not systematically select to adopt
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the policy change. The study identified rural and urban communities as the intervention and
comparison groups, respectively, although the government did not explicitly say that it was
introducing CBDs in rural communities. However, by the scope of their work and as
corroborated by a family planning expert [personal communication, Directorate of Reproductive
Health and Family Planning in Malawi, January 2017], CBDs operate in rural communities only.
CBDs target populations residing in hard-to-reach communities and urban communities are not
hard-to-reach; many urban communities have wealthier households, better roads, and a higher
supply of both health facilities and healthcare workforce, all of which permit easy access to
healthcare services [80], [81] and diminish the need for CBDs in the urban communities.
Furthermore, the period before 2005 was identified as the pre-CBD period while the period after
2005 was the post-CBD period, figure 4. The introduction of CBDs occurred from December
2004 to February 2005 while interviews for MDHS2004 started in October 2004 and were
completed in February 2005 [59]. Although there was an overlap of two months (December and
January) between the introduction of CBDs and the data collection process, the overlap was not
expected to affect the identification strategy. This is because data collection for the MDHS2004
had just started when CBDs were being introduced, and it was likely that CBD effects had a time
lag. Therefore, the assumption was that the data collected in December 2004 and January 2005
did not capture CBD effects on contraceptive use. So, MDHS2000 and MDHS2004 were
designated as the baseline surveys and MDHS2010 and MDHS2016 as the post-intervention
surveys. However, in sensitivity analysis (Appendix A2), the effect of the overlap was checked
by redefining the pre-CBD period to the year 2000 and removing the year 2004 from the
analyses.
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Finally, the three districts (Chitipa, Ntchisi, and Chiradzulu) in which the pilot of the CBDs was
conducted (1999 to 2003) were excluded from the analysis. A change in the trend of
contraceptive use after 2004 in rural communities of these districts was not expected because
CBDs operated almost continuously from 1999 through 2016. In sensitivity analysis (Appendix
A2), the validity of the identification strategy was tested by examining contraceptive use in areas
where CBDs were expected not to have significant effects, namely, in the three pilot districts and
in urban communities.
4.7. Statistical analysis
Data were analyzed using univariable and multivariable statistical approaches. In univariable
analyses, categorical variables were described using proportions and continuous variables using
averages. In multivariable analyses, contraceptive use was modeled using multilevel logistic
regressions to account for the hierarchical structure of the data, as done previously [74], [75],
[82]. Multilevel modeling (MLM) was also warranted because CBDs were introduced at a higher
level—the community. Since MDHS' do not have a defined geographic area for communities,
primary sampling units (PSU) were used as a proxy for communities. On average, each PSU
comprised 30 households [57], [59]–[61]. The appropriateness of MLM was tested using the
likelihood ratio (LR) test in a comparison of the single-level to the MLM. The degree of
clustering in contraceptive use among women at the community and district levels was assessed
using the intra-class correlation (ICC)—a measure of the relative similarity among observations
from a sampling process and is estimated by analysis of variance and variance components [83],
[84].
All analyses were conducted incorporating weights to correct for the unequal probabilities of
selection to permit nationally representative estimates of the population. The weights provided in
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the MDHS public use files were scaled using a weight-scaling method which makes the cluster
size equal to the effective sample size to make the weights more appropriate for adjusting
estimations at higher levels of the model [63], [85]. The weight scaling method assumes that
level-1 weights are non-informative and uncorrelated with covariates multiplying the random
effect thereby yielding unbiased estimates [63].
All results are presented as log-odds and marginal effects. We did not use odds ratios because
they are difficult to interpret when logistic regression includes interaction terms [86], [87].
Therefore, we relied the study relied heavily on the marginal effects to understand the effect of
CBDs on contraceptive use and whether the effect depended on education or income. Statistical
significance of the results was determined using p-values and confidence intervals. All analyses
were performed in Stata 14.2 [88, p. 14].
4.7.1. Model specifications
4.7.1.1.

Effect of CBDs on contraceptive use

To examine the effect of CBDs on contraceptive use, the study’s primary objective, we first
estimated a single-level logistic regression and then a multilevel logistic regression in the
country's 25 districts in which the pilot of CBDs was not conducted. The multilevel logistic
regression was a 3-level random intercept model and was estimated using Stata's “melogit”
command [89]. Stata’s melogit performs optimization using the “original metric of variance
components” and was preferred to other candidate commands like the meqrlogit because model
convergence time is much shorter using the melogit command than the meqr command [89],
[90]. The single-level logistic regression for any woman is specified as follows:
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𝜋

𝑙𝑜𝑔 ( [1−𝜋𝑖 ]) = 𝛽0 + 𝛽1 (𝑅𝑢𝑟𝑎𝑙) + 𝛽2 (𝐶𝐵𝐷𝐴) + 𝛽3 (𝑅𝑢𝑟𝑎𝑙 ∗ 𝐶𝐵𝐷𝐴) + 𝜆𝑿𝑖 + 𝛼𝑷𝑗 +
𝑖

γ 𝑘 + 𝛤 + ℇ𝑖

(1)

Extending the single-level logistic regression in equation 1, the 3-level random intercept model
for the ith woman, in the jth community and kth district is specified as follows:
𝜋

𝑙𝑜𝑔 ( [1−𝜋𝑖𝑗𝑘 ]) = 𝛽0 + 𝛽1 (𝑅𝑢𝑟𝑎𝑙𝑗𝑘 ) + 𝛽2 (𝐶𝐵𝐷𝐴) + 𝛽3 (𝑅𝑢𝑟𝑎𝑙𝑗𝑘 ∗ 𝐶𝐵𝐷𝐴) + 𝜆𝑿𝑖𝑗𝑘 +
𝑖𝑗𝑘

𝛼𝑷𝑗𝑘 + 𝛤 + 𝑈𝑘 + 𝑈𝑗𝑘 + ℇ𝑖𝑗𝑘

(2)

Where;
πijk is the proportion of women using contraceptives and (1-πijk) is the proportion of
women not using any contraceptives.
Rural=1 if the community is in a rural area; Rural=0 for communities in urban areas.
CBD=1 if year =2010 or 2016; CBD=0 if year = 2000 or 2004.
Xijk is a vector of individual-level variables e.g., age (see table A1) and λ is a vector of
parameters corresponding to the individual-level characteristics.
Pjk is a vector of community-level variables e.g., community child mortality (see table
A1) and 𝞪 is a vector of parameters corresponding to the community-level variables.
Γ captures fixed effects for the years 2000, 2004, 2010 and 2016.
Uk, Ujk, and ℇijk are adjusted district random effects, community random effects, and
individual-level residuals, respectively, and they are all assumed to be independent and
normally distributed with zero means [76]. The district and community effects represent
the unobserved district and community characteristics which influence contraceptive use.
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It these unobserved factors which cause correlation in contraceptive use among women
from the same community or district [75, 76].
Thus, for a binary outcome variable Yijk, in equation 2, πijk = Pr(Yijk=1) is the probability that the
ith woman in the jth community in the kth district uses contraceptives and log (πijk/[1-πijk]) is the
natural log of using contraceptives versus not using contraceptives.
We assessed the fitness of the model in equation 2 by comparing observed vs. predicted values
of contraceptive use and deviance residuals.
4.7.1.2.

Assessing moderation

To assess whether education or income moderate (influence) the relationship between CBDs and
contraceptive use, we extended the model in equation 2 as follows:
Education as a moderator
𝜋

𝑙𝑜𝑔 ( [1−𝜋𝑖𝑗𝑘 ]) = 𝛽0 + 𝛽1 (𝑅𝑢𝑟𝑎𝑙𝑗𝑘 ) + 𝛽2 (𝐶𝐵𝐷𝐴) + 𝛽3 (𝐸𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛𝑖𝑗𝑘 ) + 𝛽4 (𝑅𝑢𝑟𝑎𝑙𝑗𝑘 ∗
𝑖𝑗𝑘

𝐶𝐵𝐷𝐴) + 𝛽 (𝑅𝑢𝑟𝑎𝑙 ∗ 𝐸𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛𝑖𝑗𝑘 ) + 𝛽6 (𝐶𝐵𝐷𝐴 ∗ 𝐸𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛𝑖𝑗𝑘 ) + 𝛽7 (𝑅𝑢𝑟𝑎𝑙 ∗ 𝐶𝐵𝐷𝐴 ∗
5
𝐸𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛𝑖𝑗𝑘 ) + 𝜆𝑿𝑖𝑗𝑘 + 𝛼𝑷𝑗𝑘 + 𝛤 + 𝑈𝑘 + 𝑈𝑗𝑘 + ℇ𝑖𝑗𝑘

(3)

Income as a moderator
𝜋

𝑙𝑜𝑔 ( [1−𝜋𝑖𝑗𝑘 ]) = 𝛿0 + 𝛿1 (𝑅𝑢𝑟𝑎𝑙𝑗𝑘 ) + 𝛿2 (𝐶𝐵𝐷𝐴) + 𝛿3 (𝐼𝑛𝑐𝑜𝑚𝑒𝑖𝑗𝑘 ) + 𝛿4 (𝑅𝑢𝑟𝑎𝑙𝑗𝑘 ∗ 𝐶𝐵𝐷𝐴) +
𝑖𝑗𝑘

𝛿 5 (𝑅𝑢𝑟𝑎𝑙 ∗ 𝐼𝑛𝑐𝑜𝑚𝑒𝑖𝑗𝑘 ) + 𝛿6 (𝐶𝐵𝐷𝐴 ∗ 𝐼𝑛𝑐𝑜𝑚𝑒𝑖𝑗𝑘 ) + 𝛿7 (𝑅𝑢𝑟𝑎𝑙 ∗ 𝐶𝐵𝐷𝐴 ∗ 𝐼𝑛𝑐𝑜𝑚𝑒𝑖𝑗𝑘 ) +
𝜆𝑿𝑖𝑗𝑘 + 𝛼𝑷𝑗𝑘 + 𝛤 + 𝑈𝑘 + 𝑈𝑗𝑘 + ℇ𝑖𝑗𝑘

(4)

We defined the parameters, variables, and variances in equations 3 and 4 as in equation 2 above.
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5. Results
5.1. Trends in contraceptive use
We examined trends in contraceptive use among rural and urban women before and after
implementation of CBDs, figure 5. Over the two periods, the proportion of women using
contraceptives increased in both rural communities (where CBDs were implemented nationally)
and urban communities. However, the increase was greater among rural women by about 8
percentage points.
5.2. Sample characteristics
We examined the characteristics of a weighted sample of 52,978 (unweighted sample=57,524)
women aged 15-49 years, table 2. About 80% of the women were from rural communities.
While the percent of women with primary or secondary education increased in both
communities, in each period rural women were more likely not to have any education. The
percent of low-income women declined in rural communities and stayed the same in urban
communities, although in both periods rural women were still less likely to have higher incomes
than urban women. In either period, both rural and urban women were more likely to be married
but rural women were higher in the percent that was married. The percent of women exposed to
family planning information declined in both rural and urban communities, but rural women
were less likely to be exposed. Both rural and urban women were most likely not to want to have
any more children in both periods, and the percent of women that wanted to delay fertility
increased in both communities. Finally, rural communities were more likely to report problems
of access to healthcare, higher community child mortality, be poor, illiterate, and want to have
more children; these indicators, however, improved after introduction of CBDs.

20

5.3. Average community and district contraceptive use
We assessed contraceptive use among women from 2,567 communities in 25 districts and found
that the odds of using contraceptives in an “average” community and district—given by the
overall intercept when district and community effects are equal to zero—was about 0.55 (95%
confidence interval (C.I.) =0.51, 0.60) corresponding to a probability of 0.36 (95% C.I.=0.34,
0.38). We also found between-district and between-community variations of 0.04 (95% C.I. =
0.02, 0.09) and 0.28 (95% C.I. = 0.23, 0.35), respectively. These estimates were obtained from
an empty multilevel model, and we present caterpillar plots with 95% confidence intervals of
average community and district contraceptive use in figures 6 and 7.
In figure 6 and 7, the line at zero represents average log-odds of using contraceptives. We found
that in many communities the 95% confidence intervals of contraceptive use overlapped with the
zero line, with about 15% of the communities significantly deviating from the overall average.
Furthermore, nearly 40% of the districts had contraceptive use that differed significantly from
the district average and one district—Mangochi—had below average outlying contraceptive use.
In sum, we found significant heterogeneity in contraceptive use at the community and district
levels, providing preliminary evidence supporting using an MLM so that each district and
community could have its own intercept.
5.4. Appropriateness of multilevel models
When the single level and multilevel logistic regressions of contraceptive use were compared, we
found that the multilevel logistic regression was more appropriate [LR Chi (2) =1852,
p<0.0001]. Next, a comparison of two- and three-level logistic regressions showed that the threelevel model should be preferred [LR Chi (1) =121, p<0.0001]. The evidence confirmed that
women do not act as independent observations in contraceptive use; they are clustered at the
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community and district levels. The clustering was about 4 times stronger among women in the
same community than among women from different communities of the same district.
5.5. Effect of CBDs on contraceptive use
We present the effect of CBDs on contraceptive use estimated from the MLM in table 3. For
comparison, we also include estimates from the single-level model. In all, the results from the
two models are consistent with each other, although estimates from the MLM are slightly higher
in many cases. Furthermore, the multilevel model had consistently larger standard errors and
wider confidence intervals than the single-level model. This suggests that were we to use the
single-level model, the probability of type 1 error (rejecting a true null hypothesis) would have
been slightly higher than the nominal level as the statistical significance of our results would
have been overstated [91], [92]. Our findings suggest that the effect of CBDs on contraceptive
use was not homogenous in rural and urban communities as the coefficient of the interaction of
CBDs and rural is statistically significant. The results also show that community factors explain
the use of modern contraceptive methods in Malawi. The effect of the CBDs on contraceptive
use is presented as marginal effects in table 4.
We found that CBDs increased contraceptive use by 6.8 percentage points among all women,
table 5. The probabilities were predicted using the fixed part of the random coefficient model
which is equivalent to setting the community and district random effects to zero. Thus, the
average probabilities are for women in the median community [76]. Before CBDs were
introduced, the probability of using contraceptives was 21.5% in rural communities and 26.3% in
urban communities. After CBDs were introduced, however, the probability of using
contraceptives in rural communities increased substantially and was higher than in urban
communities (44.9% vs. 42.9%). Subtracting the urban-rural difference before CBDs from the
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urban-rural difference after CBDs shows that CBDs increased contraceptive use by about 6.8
[95% C.I.=3.3, 9.7] percentage points, all other factors held constant. In a sub-sample of married
women, CBDs increased the probability of using contraceptives by about 8.2 [95%
C.I.=4.1,12.3] percentage points.
5.6. Assessing whether education and income are moderators of CBD effects
When we examined whether the association between contraceptive use and CBDs depended on
education and income, we found that the association depended on both these factors, table 5. The
effect of the CBDs varied by education and was significantly higher among women without any
education followed by those with primary education in comparison with women with at least a
secondary education. Similarly, the effect of CBDs was also moderated by income and was
significantly greater among women with low and medium incomes compared to women with
high income.
Figures 8 and 9 present the predicted probabilities of contraceptive use at various levels of
education and income before and after the CBDs were introduced. The CBDs increased the
probability of using contraceptives in each group of women and the percentage point changes
were as follows: women without education (+22.8); women with primary education (+17.23);
women with at least a secondary education (+9.69); low-income women (+19.85); mediumincome women (+17.00); and high-income women (+10.05). Thus, women without any
education benefitted the most from the CBDs with a 13-point net increase in the probability of
contraceptive use over and above women with at least a secondary education. Compared to urban
women, the change in contraceptive use was greater among rural women at every level of
education. In terms of income, differences in contraceptive use were not statistically different
between women in rural and urban communities.
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5.7. Sensitivity analysis of the identification strategy
Because the data used for this study were not collected for evaluating the effect of CBDs, we
performed three robustness checks to validate the identification strategy. To identify the effect of
CBDs, we made three assumptions. First, we assumed that after the national rollout, the effect of
CBDs was only in the 25 districts in which the pilot of the CBDs was not implemented. So, we
tested this assumption by examining the effect of CBDs in the three districts in which the pilot of
the CBDs was implemented, expecting the CBDs not to have significant effects in these districts.
As expected, the coefficient of the interaction between CBDs and rural was not significant at 5%
(log-odds=0.738, 95% C.I.= -0.418,1.894). A more detailed analysis of these results is presented
in appendix A2.
Second, we assumed that the introduction of CBDs was exogenous and only in rural
communities. Therefore, we expected CBDs not to have significant effects on contraceptive use
in urban communities. We tested this assumption by examining the effect of CBDs in urban
communities and whether education and/or income moderate the effect of CBDs on
contraceptive use in urban communities. We found that CBDs and its interaction with education
or income did not have a statistically significant effect on contraceptive use in urban
communities at 5%, Appendix A2. However, these variables had significant effects in rural
communities as reported earlier. This result reinforces the findings from the first sensitivity
analysis and we conclude that our strategy identifies the effect of CBDs. A more detailed
analysis of these results is presented in Appendix A2.
Third, we assumed that MDHS data collected in the years 2000 and 2004 served as the baseline
for contraceptive use in the 25 districts in which the pilot of CBDs was not implemented. In
these districts, CBDs were introduced after 2004, so MDHS2000 and MDHS2004 should not
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capture CBD effects. We tested this assumption by examining the effect of changing the baseline
years. We found that CBDs increased contraceptive use by 7.58 and 5.25 percentage points when
the baseline years are 2000 and 2004, respectively, compared with 6.8 percentage points when
both (2000+2004) are used as the baseline, Appendix A2. Thus using 2004 as the base year
underestimated the effect of CBDs which suggests that the overlap between MDHS2004 and the
introduction CBDs might be attenuating the effect of CBDs. In all, the sensitivity analyses
showed that our identification strategy is valid, and in any case, we are underestimating the
effect of the CBDs.
5.8. Model fitness
We tested model goodness-of-fit tests using two approaches both of which suggested that the
model is a good fit for the data. First, we compared observed vs. predicted values of
contraceptive use to understand how well the theoretical (binomial) distribution of the data fits
the empirical distribution. We classified all women with a <0.5 probability of using
contraceptives as not using contraceptives, while those with a ≥0.5 probability as using
contraceptives. Second, we examined deviance residuals and identified outlying values. A
residual was outlying if it lied outside two standard deviations of a mean residual value of zero.
We found that our model correctly predicted about 75% of women as either using or not using
contraceptives. However, the model had higher accuracy of predictions among nonusers of
contraceptives compared to users (>80% vs. > 60%), possibly because there were more nonusers
of contraceptives than there were users. Deviance residuals in figure 9 also confirm that the
model correctly predicted the status of contraceptive use for many women although less than 2%
of predictions were outlying.
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6. Discussion
Our primary objective was to estimate the effect of CBDs on contraceptive use in Malawi during
the period 2005-2016. As hypothesized, we found that CBDs increased the probability of using
modern contraceptives by 6.8 percentage points among rural women. Our finding is consistent
with Kalanda’s who reported that the pilot of CBDs in Malawi increased the probability of
contraceptive use by 7 percentage points [5]. Because Kalanda reported contraceptive use among
married women only and we report contraceptive use for all groups of women regardless of
marital status, we also conducted a secondary analysis of the effect of CBDs in a sub-sample of
married women only to make our findings more comparable. In the secondary analysis, we found
that CBDs increased the probability of married women using contraceptives by about 8.2
percentage points, higher than reported in the pilot.
There are two possible explanations for the bigger effect of CBDs among married women in the
national scale-up than in the pilot. First, the pilot was only for three years which may not have
been adequate to see the full effects of the CBDs; to influence people to have positive attitudes
towards contraceptives and for them to begin to use contraceptives consistently requires more
time [93], [94]. Second, the scaled-up program has been evolving to include more contraceptive
methods than there were in the pilot and increasing the number of contraceptive methods carried
by CBDs is associated with increased contraceptive use [95]. USAID reported that from 2010 the
Malawi Ministry of Health began to allow Health Surveillance Assistants—primary supervisors
of CBDs—to administer DMPA [96]. Although few Health Surveillance Assistants administer
the DMPA [96], it is probable that without this development fewer women would have reported
using modern methods. This explanation is consistent with reports from pilot studies that
including DMPA within the existing CBD programs increases contraceptive use, attracts new
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users, and equally satisfies women as DMPA obtained in health clinic [12], [17, p. 360], [18],
[36], [96], [97].
Our findings are also consistent with reports from previous studies examining the effect of
community interventions in other parts of Africa. For example, contraceptive use increased in
Mali following the introduction of village-level family planning promoters [15], in Ghana where
health workers with basic training in curative health services were deployed with community
volunteers to provide family planning services [14], in the Gambia where family planning was
promoted through traditional social and religious institutions [24], and in South Sudan where a
CBD program was implemented among displaced people [37].
Other studies have reported different results, however. In Ethiopia, Tawye et al. reported that
community-based interventions, increased contraceptive use in some regions but not in others
[20], perhaps because the study did not have a control group to serve as a counterfactual and/or
may not have properly identified effects of the community intervention [20]. In Kenya, the
African Medical and Research Foundation (AMREF) documented that traditional birth
attendants and male herbalists working as CBDs did not increase contraceptive use [39],
although AMREF attributed the null findings to the illiteracy of the CBDs. In the DRC, Bertrand
et al. reported that CPR was relatively unchanged despite the introduction of CBDs [38].
Although the study was a pretest-posttest design, Bertrand et al. did not have a control group to
fully and properly identify the effect of the intervention, unlike the current study which used a
pre- and post-test design with a control group.
The current study also adds to the literature in its assessment of whether the effect of CBDs is
moderated by education and income. As hypothesized, we found that the effect of CBDs is
moderated by both education and income; we also found that the effect of CBDs varied more
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strongly with education than with income. A surprising finding, however, was the finding that
the effect of CBDs was strongest among women with no education and declined as the education
level increased. There are two potential explanations for this finding. First, because CBDs
provide family planning information in the simplest form possible, they may be seen to work to
meet the needs of uneducated women. Second, CBDs carry a very limited number of
contraceptives—in many cases pills and condoms only—which may be less appealing to highly
educated women. As a result, highly educated women may be reluctant to seek services from
CBDs. Since highly educated women are also more likely to have higher incomes, it means they
can afford to pay for alternative methods of contraception or seek contraceptives elsewhere
which is consistent with the finding that the effect of CBDs was strongest among low-income
women. Low-income women are more likely to be receptive to commodities offered by CBDs
because they have limited contraceptive choices and contraceptive sources.
6.1. Strengths and limitations
Findings from this study must be understood in the context of the following strengths and
limitations. The key strength of our study is the use of nationally representative data to examine
the effects of the CBDs on contraceptive use. Also, the incorporation of within- and betweencommunity variation and unobserved community random effects makes our findings
generalizable beyond the women from communities in the sample [98]. Additionally, by pooling
independent cross-sections in different time periods, we can make inferences about changes in
contraceptive use at the population level. Furthermore, our study produces more valid estimates
of the effect of CBDs because the data were not reported by the CBDs themselves; data obtained
directly from CBDs can be suspect or incomplete which can introduce bias [16], [95]. Moreover,
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we performed a series of sensitivity analyses which validated our identification strategy and
suggested that our findings are robust.
The study also has many limitations. First, because the MDHS’ do not have defined geographic
areas called communities, we used PSUs as a proxy for communities which might not be precise.
Despite this limitation, it is still reasonable to think that women from the same PSU are more
likely to have shared interests and attitudes and therefore constitute a community [9], [74], [75].
Second, while communities were dichotomized as rural or urban, communities occur on the
urban-rural continuum. It is possible for some communities to have been misclassified and
because the data come with PSU already classified as rural or urban, we were unable to perform
a sensitivity analysis of our findings to changes in the urban-rural taxonomy.
Third, many variables used in the study, including contraceptive use, education, and income, are
based on women’s self-reports which may not accurately measure what we say they are
measuring [99]–[101]. Our findings are thus biased to the extent of differential bias in selfreporting between rural and urban women and/or before and after CBD implementation and if
the bias exists, its direction is unclear. Notwithstanding this limitation, we still used the selfreported measures because they are readily available and reflect the respondents’ own view.
Moreover, current contraceptive use has been validated before and women’s self-reports were
found to be more valid than men’s [102]. A fourth limitation is that the data were not collected
for purposes of evaluating the effect of CBDs on contraceptive use. Among women reporting
contraceptive use, we do not know how many got the methods from CBDs or from other sources
e.g., health centers. That said, the current analysis suggests that with a proper identification
strategy it is possible to leverage national data (e.g., MDHS) collected for other purposes to
answer programmatic questions.
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Finally, due to data limitations, we were unable to check if CBD effects spilled over from the
pilot districts to the neighboring districts during the CBD pilot project. Any spillovers are more
likely to have occurred through the diffusion of family planning information than through
contraceptive methods crossing district boundaries because the CBD agents had defined villages
in which they worked; in Malawi, village boundaries do not transcend district boundaries. If
spillover effects occurred, however, it means our estimates are biased towards the null as
contraceptive use in the districts sharing borders with the pilot districts was higher than should
have been at the time of the national scale-up of the CBDs.
6.2. Policy implications
From this research, several policy implications are evident. First, CBDs should be continued and
strengthened if the country is to sustain the gains made in contraceptive use. Among other things,
the government, the country’s development partners, and stakeholders should ensure that supply
of contraceptives to the communities is uninterrupted, CBDs receive refresher training regularly,
supervision of the CBDs is active and frequent, provision of CBD agents’ working kits (e.g.,
bicycles and gumboots) to facilitate follow-up of clientele. The availability of these facilities will
help ensure that women relying on CBDs continue to get quality services and prevent
intermittent use of contraceptives among the rural women.
Second, this work suggests that there may be a need to increase the portfolio of contraceptive
methods carried by the CBDs. As noted, methods carried out by CBDs are not meeting the needs
of women with more education and high income. With proper accountability and support, we
suggest that all CBDs and their supervisors should be carrying DMPA and natural methods (e.g.,
cycle beads) in addition to the condoms and pills. Third, given the success of CBDs in rural
communities, our results suggest that urban communities can benefit from the introduction of
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CBDs or an equivalent of the CBDs in the urban communities. For example, health posts
manned by Health Surveillance Assistants could be introduced in urban communities which have
limited access to health centers or have high population densities. As the government of Malawi
continues with efforts to increase contraceptive use, it is important that both urban and rural
communities are targeted and that the efforts should not create or perpetuate rural/urban
disparities in contraceptive use as noted in this study.
6.3. Future research
While we have reported that CBDs in Malawi increased contraceptive use, we make two
recommendations for future research. First, the value of the CBDs should be established. Doing
this would require analyzing both the costs and effects of the CBDs after the national scale-up;
we have only examined their effectiveness. Examining costs and hence the value of the CBDs is
important because prior evidence suggests that CBDs can add as much as 30% per capita to the
primary healthcare budgets [103]. Second, this study has only reported the effect of CBDs on
contraceptive use—a proximate determinant of fertility. The goal of introducing CBDs was to
reduce fertility or at least increase birthing intervals in Malawi. Therefore, future studies should
focus on evaluating the effects of CBDs on these outcomes.
7. Conclusion
Following the success of a pilot of CBDs from 1999 to 2003, the Malawi government scaled the
CBDs to all rural communities of Malawi in 2005. We have found that CBDs increased
contraceptive use during the period 2005 to 2016, and the intervention can help the country to
achieve its long-term agenda of reducing population growth. Before the implementation of the
CBDs, contraceptive use in rural communities was lower than in urban communities. After the
implementation of the CBDs, however, contraceptive use increased significantly in the rural
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communities to the extent that urban communities are now lagging. The effect of CBDs was
strongest among uneducated and poor women suggesting that delivering messages and
interventions using the communities’ local languages and structures is important if any
intervention is to reach the target population, particularly rural communities. While the CBDs
should be continued and strengthened, it is important to establish whether the CBDs have also
reduced fertility or are cost-effective.
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Table 1. Comparison of the pilot and national CBDs in Malawi
Component
Pilot
National
Training
Yes
Yes
CBD incentives
Certificates of recognition
Yes
Yes
Umbrellas, boots, raincoats, backpacks, and push bicycles
Yes
Yes
US$6 per month
Yes
No
Uniforms and badges
Yes
No
Dedicated resources for supervision*
Motor vehicle (program-specific)
Yes
No
Motorcycles
Yes
No
Push bicycles
No
Yes
District Health Management Teams
Commitment
Yes
Unknown
Information, education, and communication
Health talks, dramas, leaflets, flyers, and posters
Yes
Yes
T-shirts, radio jiggles, cassette players, and, comic books
Yes
No
Family planning commodities
Pills
Yes
Yes
Condoms
Yes
Yes
*In the pilot, project employees supervised CBDs. In national CBDs, Health Surveillance
Assistants (community health workers) employed by the government conduct the supervision.

33

Table 2: Descriptive statistics (Weighted sample size: n=52,978)
Rural (n=42,707)
Urban (n=10,272)
Pre-CBD
Post-CBD Pre-CBD
Post-CBD
Variable
(n=14,320)
(n=28,386) (n=3,200)
(n=7,073)
Personal-level factors
Current contraceptive use*
None
0.743
Modern
0.257
Education***
None
0.276
Primary
0.636
Secondary
0.087
Higher
0.001
Income (wealth)***
Low
0.410
Medium
0.355
High
0.235
Occupation***
Not employed
0.428
Self-employed
0.449
Professional
0.123
Age (years)***
15-19
0.217
20-29
0.423
30-39
0.233
40-49
0.127
Marital status***
Never married
0.169
Currently married
0.706
divorced
0.092
Widowed
0.033
Fertility desire***
wants child in < 1 year
0.091
wants child in >1 year but
<3years
0.153
wants child after 3 years
0.315
no more children
0.440
Partner's education***
None
0.313
Primary
0.549
Secondary
0.133
Higher
0.005
Exposure to family planning information*
Not exposed
0.516
Some exposure
0.484
Autonomy**

0.572
0.428

0.669
0.331

0.574
0.426

0.149
0.682
0.162
0.007

0.083
0.505
0.392
0.020

0.046
0.411
0.437
0.106

0.406
0.374
0.219

0.045
0.079
0.876

0.036
0.109
0.856

0.385
0.506
0.110

0.602
0.093
0.305

0.532
0.102
0.366

0.229
0.374
0.268
0.129

0.248
0.481
0.189
0.081

0.225
0.423
0.254
0.098

0.210
0.659
0.104
0.027

0.299
0.598
0.062
0.040

0.319
0.572
0.078
0.031

0.056

0.085

0.056

0.120
0.410
0.415

0.115
0.346
0.454

0.116
0.434
0.393

0.373
0.439
0.173
0.015

0.343
0.297
0.323
0.037

0.399
0.199
0.310
0.092

0.338
0.662

0.352
0.648

0.168
0.832
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Little or no autonomy
Semi or complete autonomy
Religion***
Catholic or Anglican
Other Christians
Muslims
Community-level factors
Healthcare access problems**
Yes
No
Community literacy***
Not literate
Literate
Community income***
Low
Medium
High
Community religion**
Catholic or Anglican
Other Christians
Muslims
Community child mortality (mean)
*

0.476
0.524

0.378
0.622

0.479
0.521

0.358
0.642

0.272
0.593
0.135

0.222
0.642
0.137

0.259
0.626
0.115

0.226
0.673
0.102

0.653
0.347

0.373
0.627

0.787
0.213

0.595
0.405

0.519
0.481

0.263
0.737

0.048
0.952

0.039
0.961

0.419
0.382
0.198

0.432
0.389
0.179

0.008
0.025
0.967

0.006
0.034
0.960

0.171
0.700
0.129
209.167

0.092
0.777
0.131
136.050

0.069
0.895
0.036
135.498

0.032
0.929
0.039
106.898

p < 0.05, ** p < 0.01, *** p < 0.001

All variables are categorical, except community child mortality, and proportions are presented in the table. For the
categorical variables, we tested whether the proportion of women under each variable was the same in the periods
before and after CBDs were introduced across both rural and urban communities. For the continuous variable,
community child mortality, we tested whether the means were different in the two CBD periods across rural and
urban communities. The tests were performed using the Wald test.
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Table 3: Effect of CBDAs on contraceptive use in Malawi (2005-2016)
Single-level model
Coefficient 95% C.I.
Dependent variable: Contraceptive use
Main explanatory variables
CBDAs
0.919*** [0.767,1.071]
Rural
-0.411*** [-0.540,-0.281]
Ref: Urban, before CBDAs
Rural, after CBDAs
0.421*** [0.272,0.571]
Individual-level factors
Age (ref: 15-19 years)
20-29yr
0.568*** [0.470,0.666]
30-39yr
0.555*** [0.446,0.663]
40-49yr
0.357*** [0.234,0.479]
Occupation (ref: unemployed)
Self-employed/agriculture
0.093**
[0.036,0.149]
Professional/formal
0.240*** [0.159,0.320]
Marital status (ref: never married)
Married
2.257*** [2.116,2.398]
Divorced
1.356*** [1.210,1.502]
Widowed
0.929*** [0.736,1.123]
Exposure to family planning information
(ref: no exposure)
Some exposure
0.210*** [0.156,0.264]
Fertility desire (ref: wants child <1y)
>1y but <3y
1.777*** [1.615,1.940]
Child after 3y
2.080*** [1.926,2.233]
No more children
2.381*** [2.228,2.534]
Autonomy (ref: no autonomy)
At least some autonomy
0.113*** [0.053,0.173]
Partner education (ref: no education)
Primary
0.127*** [0.051,0.202]
Secondary
0.189*** [0.099,0.280]
Higher
0.244*
[0.055,0.432]
Religion (ref: Catholic/Anglican)
Other Christians
-0.107*** [-0.171,-0.044]
Muslims
-0.312*** [-0.428,-0.196]
Community-level factors
Access problem (ref: no problem)
Some problem
-0.061*
[-0.119,-0.002]
Literacy (ref: illiterate)
Literate
0.055
[-0.009,0.120]
Income (ref: low)
Medium income
0.104*** [0.044,0.165]

Multi-level model
Coefficient 95% C.I.

0.954***
-0.314***

[0.706,1.202]
[-0.481,-0.147]

0.424***

[0.236,0.612]

0.588***
0.582***
0.393***

[0.486,0.689]
[0.455,0.710]
[0.242,0.544]

0.087*
0.251***

[0.018,0.155]
[0.190,0.312]

2.353***
1.389***
0.978***

[2.086,2.619]
[1.192,1.587]
[0.757,1.200]

0.216***

[0.163,0.269]

1.854***
2.170***
2.454***

[1.726,1.981]
[2.023,2.317]
[2.319,2.590]

0.111*

[0.025,0.198]

0.120**
0.166***
0.234*

[0.040,0.201]
[0.068,0.265]
[0.010,0.458]

-0.093***
-0.279***

[-0.147,-0.039]
[-0.411,-0.147]

-0.082*

[-0.138,-0.026]

0.102**

[0.037,0.166]

0.126***

[0.069,0.182]
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High income
Religion (ref: Catholic/Anglican)
Other Christians
Muslims
Community child mortality
Year fixed effects (ref: 2000)
2004
2010
Constant
AIC
BIC
Number of districts
Observations

0.135**

[0.054,0.217]

0.219***

[0.124,0.315]

0.0601
-0.299***
-0.0001

[-0.022,0.142]
[-0.429,-0.169]
[-0.0005,0.0003]

0.069
-0.185
-0.0006*

[-0.015,0.153]
[-0.382,0.012]
[-0.001,-0.0001]

-0.015
-0.776***
0.004***
57312
57587
25
52978

[-0.110,0.079]
[-0.846,-0.707]
[0.003,0.006]

0.014
-0.775***
0.003***
56619
56833
25
52978

[-0.081,0.109]
[-0.875,-0.675]
[0.002,0.004]

* p < 0.05, ** p < 0.01, *** p < 0.001
†Effect of CBDAs was estimated in the 25 districts in which the CDBA pilot was not implemented.
The table summarizes and compares the effect of CBDs (community-based distribution) on contraceptive use modeled
using a single-level logistic regression and a multilevel (3-level random intercept) logistic regression. While both
models show that the CBDs increased contraceptive use, estimates from the multilevel model are generally larger and
have wider confidence intervals. In both models, contraceptive use was significantly associated with both individualand community-level explanatory variables, but the association was stronger with individual-level variables.
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Table 4: Average predicted probabilities of contraceptive use before and after CBDs, by urban status
Rural

Before CBDs
After CBDs
First difference (D)

Probability
0.215
0.450
0.235

Urban
95% C.I.
[0.199, 0.231]
[0.430, 0.469]

Probability
0.263
0.429
0.1668

95% C.I.
[0.237, 0.288]
[0.400, 0.459]

First difference Second
difference
(D) [95% C.I.] (DD) [95% C.I.]
-0.048
0.020
0.068 [0.031, 0.098]
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Table 5: Assessment of education and income (wealth) as moderators of CBD effects on
contraceptive use in rural areas
Model 1A (Education)
Model 1B (Income)
Coefficient
95% C.I.
Coefficient
95% C.I.
Ref: Before CBDs
CBDs
1.500***
[1.310,1.691]
1.521***
[1.346,1.696]
Ref: No education
Primary
0.128**
[0.0338,0.223]
Secondary
0.113
[-0.0262,0.251]
Ref: No education, before CBDs
Primary, after CBDs
-0.172*
[-0.310,-0.0348]
***
Secondary, after CBDs
-0.505
[-0.657,-0.353]
Ref: Low income
Medium income
0.226***
[0.116,0.336]
High income
0.388***
[0.241,0.536]
Ref: Low income, before CBDs
Medium income, after CBDs
-0.229***
[-0.323,-0.135]
***
High income, after CBDs
-0.575
[-0.731,-0.419]
Observations
42865
42865
Number of districts
25
25
The table summarizes results of examining whether education and income influence the effect of CBDs on
contraceptive use. For ease of interpretability and understanding, models for education and income were run
separately. In both models, the coefficient of the interaction terms (CBD*education and CBD*income) is statistically
significant at 5% which suggests that both education and income individually influence the association between
CBDs and contraceptive use.
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Figure 1: District participation in a community-based distribution (CBD) pilot of family
planning services in Malawi, 1999-2003
This figure is a map of Malawi showing intervention and control districts in a pilot project
testing whether a comprehensive community approach to family planning could increase
contraceptive use in Malawi, 1999-2003.
Source of shapefiles: Global Administrative Areas (http://www.gadm.org)
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*CBD stands for community-based distribution of family planning service.
†Refers to women's characteristics except when the word partner is used.

Figure 2. A conceptual framework for understanding the effect of CBDs on contraceptive use in rural areas of
Malawi
The figure shows a conceptual framework of the effect of CBDs on contraceptive use in Malawi's rural areas. It also shows that
the effect of CBDs on contraceptive use is moderated by both education and income. The figure also shows that individual-level
characteristics may affect contraceptive use directly or indirectly via community characteristics.
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MDHS2010
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n=57,524

Figure 3: A flowchart for deriving a sample for examining the effect of community-based distribution (CBDs) on contraceptive use in
Malawi
The flowchart shows the exclusions applied to derive a sample of women to examine the effect of community-based distribution agents (CBDs) of
family planning on contraceptive use in Malawi. The data were drawn from four waves (2000, 2004, 2010 and 2016) of the Malawi Demographic
and Health Surveys (MDHS). The data came from women recode files of the MDHS and contained responses from all women (ages 15-49 years)
interviewed in the surveys.
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Figure 4. Timeline for implementation of community-based distribution (CBD) of family planning services and data collection in the
Malawi Demographic and Health Surveys (MDHS)
This figure shows the timeline for the scale-up of national CBDs and MDHS data collection. The blue color ( ) shows the timeline for pilot or
national CBD implementation, orange color ( ) shows the pre-CBD period while green color ( ) shows the timeline for the MDHS. Thus, the
study identified MDHS 2000/2004 as the pre-CBD period while MDHS 2010/2016 as the post-CBD period. Data collection for MDHS 2004 was
from October 2004 to January 2005. CBD scale-up was from December 2004 to February 2005, overlapping in December 2004 and January 2005.
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Figure 5: Urban-rural trends in contraceptive use before and after national CBDs in Malawi
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Figure 6: Average community contraceptive use
This figure shows contraceptive use in each community relative to the average contraceptive use in all the communities. The line at
zero represents the average log-odds of using contraceptives. We found that in many communities the 95% confidence intervals of
contraceptive use overlapped with the zero line, although a significant number deviated from the overall average.
45

Salima
Mzimba
Machinga
Nkhatabay
Balaka
Nsanje
Nkhotakota
Ntcheu
Dedza
Zomba
Mwanza
Ntchisi
Likoma
Thyolo
Karonga
Mulanje
Mchinji
Chikwawa
Blantyre
Kasungu
Chitipa
Dowa
Lilongwe
Phalombe
Neno
Rumphi
Chiradzulu

.4
.2
0
-.2

Mangochi

-.4
-.6
0

10

20

30

District rank

Figure 7: Average district contraceptive use
This figure shows contraceptive use in each district relative to the average contraceptive use in all the districts. The line at zero
represents the average log-odds of using contraceptives in all the districts. We found that four districts had below average
contraceptive use while 6 had above average contraceptive use.
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Figure 8: Predicted probability of contraceptive use by women’s education.
This figure shows that contraceptive use increased among both rural and urban women, but the increases were greater among rural
women with rural uneducated women benefitting the most from the scale-up of the CBDs.
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Figure 8: Predicted probability of contraceptive use by women’s income.
This figure shows that contraceptive use increased among both rural and urban women, but the increases were greater among women
with low incomes. The figure also shows that the increases in contraceptive use were similar for both rural and urban women at every
level of income.
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Figure 9: A goodness-of-fit test using deviance residuals
This figure shows that very few observations have outlying (above the red line) predictions, suggesting that the model is a good fit for
the data.
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Appendices
Appendix A1: Variable definition and construction
Table A1: Definition and construction of variables for examining the effect of community-based distribution agents on contraceptive use in Malawi
Variable
Key variables
Current contraceptive
use

Type

Definition

Explanation/ justification

Binary

Dependent variable: 1=using a modern
method, 0=not using a modern method.

Community-based
distribution (CBD) of
family planning services
Rural/urban status

Binary

CBD=1 if year is 2010 or 2016 (post-CBD
period) and CBD=0 if year is 2000 or 2004
(pre-CBD period).
Rural=1, urban=0.

Women were asked if they were using any contraceptives at the time of the
interview. We classified women using traditional methods (<2% of the total)
as not using any contraceptive method.
This is the key explanatory variable and it is the variable whose effect on
contraceptive use we are assessing. Our hypothesis is that CBDs increased
contraceptive use.
This is the second key explanatory variable. CBDs were introduced in rural
communities only, so we designated the rural communities as the intervention
and urban communities as the comparison group.

Binary

Individual-level variables
Maternal education
Categorical

2=secondary or higher, 1=primary, 0=no
education.

Partner's education

Categorical

2=secondary or higher, 1=primary, 0=no
education.

Income*
Age

Categorical
Categorical

3=high, 2=medium and 3=low.
4="40-49yr", 3="30-39yr", 2="20-29yr",
1="15-19yr".

Occupation (woman or
her partner)

Categorical

2=professional employment, 1=self-employed
or agriculture, 0=Unemployed.

Marital status

Categorical

Exposure to family
planning methods†

Binary

3=widowed, 2=divorced, 1=married, 0=never
married.
1=Little or no exposure 0=moderate or
substantial exposure.

Autonomy‡

Binary

0=Little or no autonomy, 1=semi or complete
autonomy.

Religion

Categorical

1=Catholic or Anglican, 2= other Christians,
3=Muslims, 4=no religion.

Highly educated women are more likely to use contraceptives. We grouped
women with higher than secondary education with those with secondary
education; <2% of the women had an education higher than secondary level.
Women with highly educated partners are more likely to use contraceptives.
We grouped partners with higher than secondary education with those with
secondary education; fewer than 2% of the women's partners had an
education higher than secondary level.
High-income women are more likely to use contraceptives.
Contraceptive use among women increases with age but begins to decline
after age 39. This age classification is consistent with other studies on
contraceptive use in Africa [8], [104], [105].
This variable is highly correlated with education and income. Women in the
professional sector or with partners in the professional are most likely to face
a higher opportunity cost of raising children.
Married women are most likely to use contraceptives.
Exposure to reproductive health messages via media in the month preceding
the surveys. Women exposed to family planning information are more likely
to use contraceptives.
Autonomy is the woman's ability to consciously make decisions about her
health and life without fear of reprisals. Autonomous women are more likely
to use contraceptives.
The religion to which a woman belongs. Some religions encourage
contraceptive use while others do not.
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Fertility desire

Categorical

4=wants no more children, 3=wants child after
3 years, 2= wants a child in >1 year but
<3years, 1=wants child in < 1 year.
Community-level and residency variables
Community literacy
Categorical 2=literate, 1=partly literate, 0=not literate.

Women desiring to have children in less than one year are less likely to use
contraceptives.

Constructed from the maternal education variable by assigning the education
category with the highest number of women to the whole community. We
created this variable because women without any education may still get
assistance from others with an education in the same community.
Community income
Categorical 3=high, 2=medium, 1=low.
We averaged wealth scores were averaged at the community level and created
percentiles for each of the survey years.
Community religion
Categorical 1=Catholic or Anglican, 2= other Christians,
Assigned to the whole community based on which religion had the largest
3=Muslims.
membership in that community.
Community access
Categorical 1=some problem, 0=no problem.
Women were asked to report if they had any problems accessing health care
problems to care
services in the 12 months preceding the study. Women with problems of
access to care are less likely to use contraceptives.
Distance to health
Continuous n/a
Distance to a health facility. Women who travel longer distances to health
facility§
clinics are less likely to use contraceptives.
Community child
Continuous n/a
Child deaths per 1,000 live births. Women in communities with high child
mortality¶
mortality are less likely to use contraceptives.
District
Categorical District dummy variables.
These are the country's 28 administrative districts.
*The Malawi Demographic and Health Surveys (MDHS) do not collect data on income; we used wealth as a proxy for the income. MDHS provides wealth scores reflecting
ownership of durable goods and housing characteristics. We created the wealth categories separately for each year to reflect income distributions in the years of the surveys.
†Exposure to family planning variable was created from the following media: radio, TV, and newspaper. Exposure to each medium was given a score of 1 and then
summed. In 2016, exposure to family planning messages via phone messages was added but for consistency with previous surveys, it was not included. Those with a zero
score were regarded as not exposed.
‡The variable was constructed based on the extent to which the woman had a final say on the following: 1) Making large household purchases; 2) Making household
purchases for daily needs; 3) Visiting family or relatives; 4) The woman's own health care; and 5) Meals prepared each day. For each of the five domains, there were 5
options on who made the decision: the woman alone; together with her partner; together with someone else; partner alone; someone else or decision was not made. The
responses were scored on a scale of 1-5 (to be consistent with the response options) and then summed to get the total score for each woman. From the total scores, 2 groups
were created with a cut-off point at the 50th percentile.
§Straight line distance (kilometers) from the community to the nearest health facility, calculated in ArcGIS 10.3.1. To calculate the distance, the MDHS files were joined to
the Malawi 2012 Service Provision Assessment file (SPA)—also a public use file. The MDHS files provided coordinates for the communities while coordinates for health
facilities came from the Malawi 2012 SPA. Since the Service Provision Assessment data only provided geographic coordinates for health facilities, we do not expect the
temporal difference between the two surveys to influence the distances between the communities and health facilities.
¶Calculated at the community level and each household in the community is assumed to face this child mortality rate regardless of whether the household itself experienced
child mortality. Community child mortality is used instead of household child mortality because the latter would be endogenous in a model of contraceptive use.
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Appendix A2: Robustness of the identification strategy
Because the data used for this study were not collected for evaluating the effect of CBDs, we
performed three robustness checks to validate our identification strategy. To identify the effect of
CBDs, we made three assumptions. First, we assumed that after the national rollout, the effect of
CBDs was only in the 25 districts in which the pilot of the CBDs was not implemented. So, we
tested this assumption by examining the effect of CBDs in the three districts in which the pilot of
the CBDs was implemented, expecting the CBDs not to have significant effects in these districts.
Second, we assumed that the introduction of CBDs was exogenous and only in rural
communities. We, therefore, expected CBDs not to have significant effects on contraceptive use
in urban communities. We tested this assumption by examining the effect of CBDs in urban
communities and whether education and/or income were moderators of the effect of CBDs on
contraceptive use in the urban communities. Third, we assumed that MDHS data collected in the
years 2000 and 2004 served as the baseline for contraceptive use in the 25 districts in which the
pilot of CBDs was not implemented. In these districts, CBDs were introduced after 2004, so
MDHS2000 and MDHS2004 should not capture CBD effects. We tested this assumption by
examining the effect of changing the baseline years. In all, the sensitivity analysis showed that
our identification strategy is valid, see detailed results below.
CBD effects in CBD-pilot districts
In the first sensitivity analysis, we applied the model in equation 2 to the three districts (Chitipa,
Ntchisi, and Chiradzulu) in which the CBDs were piloted. In these districts, the nationwide
adoption of CBDs was a continuation of the pilot. For emphasis, the model is repeated below:
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𝜋𝑖𝑗𝑘

𝑙𝑜𝑔 ( [1−𝜋

𝑖𝑗𝑘 ]

) = 𝛽0 + 𝛽1 (𝑅𝑢𝑟𝑎𝑙𝑗𝑘 ) + 𝛽2 (𝐶𝐵𝐷𝐴) + 𝛽3 (𝑅𝑢𝑟𝑎𝑙𝑗𝑘 ∗ 𝐶𝐵𝐷𝐴) + 𝜆𝑿𝑖𝑗𝑘 +

𝛼𝑷𝑗𝑘 + 𝛤 + 𝑈𝑘 + 𝑈𝑗𝑘 + ℇ𝑖𝑗𝑘

(5)

For valid identification, β3 was expected to be not statistically significant at 5% in equation 5.
Results of this analysis are presented in table A2. In the three pilot districts, the effect of CBDs
was not statistically significant at 5%. This suggests that our strategy properly identified the
effects of CBDs on contraceptive use. However, some caution is warranted: the non-significant
result of the interaction term could also be a result of the sample size being smaller in the pilot
districts rather than the scale-up of the CBDs not having a statistically significant effect in the
pilot districts. The estimate for the pilot districts was estimated with less precision, given the
wider confidence interval, than the one for the non-pilot districts.
Table A2: Effect of CBDs on contraceptive use in CBD pilot and CBD non-pilot districts
Non-pilot districts
Pilot districts
Coefficient 95% C.I.
Coefficient
95% C.I.
Contraceptive use
Main explanatory variables
CBDAs
0.954***
[0.706,1.202]
0.738
[-0.418,1.894]
Rural
-0.314***
[-0.481,-0.147]
-0.367
[-1.469,0.735]
Ref: Urban, before CBDAs
Rural, after CBDAs
0.424***
[0.236,0.612]
0.871
[-0.248,1.990]
Individual-level factors
Age (ref: 15-19 years)
20-29yr
0.588***
[0.486,0.689]
0.287
[-0.011,0.586]
30-39yr
0.582***
[0.455,0.710]
0.146
[-0.178,0.470]
40-49yr
0.393***
[0.242,0.544]
-0.097
[-0.460,0.266]
Occupation (ref: unemployed)
Self-employed/agriculture
0.087*
[0.018,0.155]
0.063
[-0.093,0.218]
Professional/formal
0.251***
[0.190,0.312]
0.119
[-0.113,0.352]
Marital status (ref: never married)
Married
2.353***
[2.086,2.619]
3.010***
[2.576,3.445]
Divorced
1.389***
[1.192,1.587]
2.016***
[1.589,2.442]
Widowed
0.978***
[0.757,1.200]
2.012***
[1.462,2.561]
Exposure to FP information (ref: no exposure)
Some exposure
0.216***
[0.163,0.269]
0.221**
[0.0714,0.370]
Fertility desire (ref: wants child <1 yr)
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>1yr but <3yr
Child after 3 yrs
No more children
Autonomy (ref: No autonomy)
At least some autonomy
Partner education (ref: no education)
Primary
Secondary
Higher
Religion (ref: Catholic/Anglican)
Other Christians
Muslims
Community-level factors
Access problem (ref: no problem)
Some problem
Literacy (ref: illiterate)
Literate
Income (ref: low)
Medium income
High income
Religion (ref: Catholic/Anglican)
SDA and Other Christians
Muslims
Community child mortality
Year fixed effects (ref: 2000)
2004
2010
Constant
Number of districts
Observations

1.854***
2.170***
2.454***

[1.726,1.981]
[2.023,2.317]
[2.319,2.590]

1.964***
2.225***
2.218***

[1.539,2.390]
[1.825,2.625]
[1.821,2.615]

0.111*

[0.025,0.198]

0.061

[-0.119,0.241]

0.120**
0.166***
0.234*

[0.040,0.201]
[0.068,0.265]
[0.010,0.458]

0.0521
-0.055
-0.213

[-0.197,0.301]
[-0.324,0.214]
[-0.742,0.317]

-0.0934***
-0.279***

[-0.147,-0.039]
[-0.411,-0.147]

-0.05
0.111

[-0.216,0.115]
[-0.347,0.568]

-0.082*

[-0.138,-0.026]

-0.164*

[-0.318,-0.009]

0.102**

[0.037,0.166]

0.00454

[-0.232,0.241]

0.126***
0.219***

[0.069,0.182]
[0.124,0.315]

0.390***
0.457***

[0.222,0.558]
[0.223,0.691]

0.069
-0.185
-0.0006*

[-0.015,0.153]
[-0.382,0.012]
[-0.001,-0.0001]

0.135
0.039
0

[-0.060,0.329]
[-0.515,0.593]
[-0.001,0.001]

0.014
-0.775***
0.003***
25
52978

[-0.081,0.109]
[-0.875,-0.675]
[0.002,0.004]

-0.099
-0.965***
-5.947***
3
4546

[-0.486,0.288]
[-1.143,-0.786]
[-7.277,-4.618]

* p < 0.05, ** p < 0.01, *** p < 0.001. †The results in non-pilot districts are the same as the multilevel results already presented
in table 3, but they are duplicated here to facilitate comparison.

Education and income as moderators of CBD effects in urban communities
In the second sensitivity analysis, we examined the effect of CBDs in urban communities and
whether this effect is moderated by education or income. This analysis was performed using the
model in equation 2 but only in urban communities of the 25 non-pilot districts. Because CBDs
were implemented in rural communities only, the effect of CBDs and the interaction of CBDs
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and education, as well as that of CBDs and income in urban communities should not be
statistically significant at 5%. In Panel 1 of table A3, we present the log odds of using
contraceptives in urban communities while in Panel 2 we reproduce the log odds for rural
communities (already presented in table 6). We found that CBDs and its interaction with
education or income did not have a statistically significant effect on contraceptive use in urban
communities; confidence intervals of these variables overlapped with a log-odds of 0 and the pvalues were greater than 0.05. As reported earlier, however, these variables had significant
effects in rural communities. This result reinforces our earlier findings from the first sensitivity
analysis and we conclude that our strategy identifies the effect of CBDs.
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Table A3: Sensitivity analysis of the moderating effects of education and income on the association between
CBDs and contraceptive use
Panel 1: Urban
Panel 2: Rural
M2A
M1A
M2B (Income)
M1B (Income)
(Education)
(Education)
Coefficient
Coefficient
Coefficient
Coefficient
[95% C.I.]
[95% C.I.]
[95% C.I.]
[95% C.I.]
Ref: Before CBDs
CBDs
1.18
0.945
1.500***
1.521***
[-1.527,3.886]
[-2.499,4.389]
[1.310,1.691]
[1.346,1.696]
Ref: No education
Primary
1.493
0.128**
[-0.654,3.639]
[0.0338,0.223]
Secondary
1.382
0.113
[-0.746,3.509]
[-0.0262,0.251]
Ref: No education, before CBDs
Primary, after CBDs
-1.077
-0.172*
[-4.126,1.971]
[-0.310, -0.0348]
Secondary, after CBDs
-0.669
-0.505***
[-3.705,2.367]
[-0.657, -0.353]
Ref: Low income
Medium income
-0.341
0.226***
[-3.937,3.255]
[0.116,0.336]
High income
-0.346
0.388***
[-3.579,2.887]
[0.241,0.536]
Ref: Low income, before CBDs
Medium income, after CBDs
-0.656
-0.229***
[-4.252,2.940]
[-0.323, -0.135]
High income, after CBDs
-0.56
-0.575***
[-3.905,2.784]
[-0.731, -0.419]
Observations
10113
10089
42865
42865
The table summarizes sensitivity analysis results of examining whether education and income influence (moderate) the
effect of CBDs on contraceptive use in urban areas. For ease of interpretability and understanding, models for education and
income were run separately. In the urban panel, the coefficient of the interaction terms (CBD*education and CBD*income)
is not statistically significant at 5% which suggests that both education and income do not individually influence the
association between CBDs and contraceptive use.
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Varying the definition of the pre-CBD period: 2000 or 2004
We earlier explained and showed in figure 4 that there was an overlap of about 2 months
between the introduction of CBDs and data collection in MDHS2004. Although we expected
CBDs not to have affected contraceptive use by the time the data were being collected, we still
checked the effect of the overlap by defining the baseline as the year 2004 or 2000. If
MDHS2004 captured the effects of the CBDs, our estimate would be biased towards the null. We
first examined whether contraceptive use was different between years 2000 and 2004. We found
that the log-odds of using contraceptives were lower in 2004 than in 2000, but the difference was
immaterial. Thus either year (2000 or 2004) could be used to define the pre-CBD period.
We present results of defining the baselines as the year 2000 or 2004 in the table A4, while
results in Panel A combine years 2000 and 2004 (like those presented earlier in table 3). We
found that, for many coefficients, the direction and strength of association with contraceptive use
were the same across the three models. We also found that CBDs increased contraceptive use by
7.58 and 5.25 percentage points when the baseline years are 2000 and 2004, respectively,
compared with 6.8 percentage points when both are used as the baseline. Thus using 2004 as the
base year underestimated the effect of CBDs which suggests that the overlap between
MDHS2004 and the introduction CBDs might be attenuating the effect of CBDs. While this
evidence points to using 2000 as the baseline, we preferred to use a model that combined 2000
and 2004 as the baseline. This is because estimates from the model in Panel A are measured with
the most precision and this model allowed us to account for year fixed effects; the other models
cannot do this because of collinearity problems among year, CBDs, and the intercept.
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Table A4: Effect of CBDs on contraceptive use in response to changing the baseline
A (main results) †
B
Baseline: 2000+2004
Baseline: 2000
Coefficient 95% C.I.
Coefficient 95% C.I.
Dep var contraceptive use
Main explanatory variables
CBDA
0.954***
[0.706,1.202]
0.870***
[0.638,1.102]
Rural
-0.314***
[-0.481,-0.147] -0.403*** [-0.587,-0.219]
Ref: Urban, before CBDAs
Rural, after CBDAs
0.424***
[0.236,0.612]
0.483***
[0.278,0.688]
Individual-level factors
Age (ref: 15-19 years)
20-29yr
0.588***
[0.486,0.689]
0.622***
[0.514,0.729]
30-39yr
0.582***
[0.455,0.710]
0.585***
[0.447,0.722]
40-49yr
0.393***
[0.242,0.544]
0.329***
[0.171,0.488]
Occupation (ref: unemployed)
Self-employed/agriculture
0.087*
[0.018,0.155]
0.098**
[0.024,0.172]
Professional/formal
0.251***
[0.190,0.312]
0.261***
[0.184,0.338]
Marital status (ref: never
married)
Married
2.353***
[2.086,2.619]
2.328***
[2.065,2.591]
Divorced
1.389***
[1.192,1.587]
1.405***
[1.218,1.593]
Widowed
0.978***
[0.757,1.200]
1.045***
[0.780,1.309]
Exposure to FP information (ref: no exposure)
some exposure
0.216***
[0.163,0.269]
0.203***
[0.145,0.261]
Fertility desire (ref: wants child
<1y)
>1y but <3y
1.854***
[1.726,1.981]
1.900***
[1.741,2.058]
Child after 3y
2.170***
[2.023,2.317]
2.198***
[2.042,2.354]
No more children
2.454***
[2.319,2.590]
2.506***
[2.349,2.664]
Autonomy (ref: No autonomy)
Some or total autonomy
0.111*
[0.025,0.198]
0.134**
[0.039,0.228]
Partner education (ref: no
education)
Primary
0.120**
[0.040,0.201]
0.116**
[0.040,0.192]
Secondary
0.166***
[0.068,0.265]
0.118*
[0.0214,0.215]
Higher
0.234*
[0.010,0.458]
0.183
[-0.039,0.405]
Religion (ref: Catholic/Anglican)
Other Christians
-0.093***
[-0.147,-0.039] -0.0784*
[-0.145,-0.011]
Muslims
-0.279***
[-0.411,-0.147] -0.265*** [-0.422,-0.108]
Community-level factors
Access problem (ref: no
problem)
Some problem
-0.082*
[-0.138,-0.026] -0.059
[-0.119,0.001]
Literacy (ref: illiterate)
Literate
0.102**
[0.037,0.166]
0.128**
[0.043,0.212]
Income (ref: low)

C
Baseline: 2004
Coefficient 95% C.I.

1.011***
-0.284*

[0.721,1.300]
[-0.536,-0.032]

0.339**

[0.114,0.564]

0.558***
0.550***
0.338***

[0.449,0.667]
[0.421,0.680]
[0.162,0.513]

0.071
0.222***

[-0.021,0.162]
[0.151,0.293]

2.480***
1.482***
1.131***

[2.159,2.800]
[1.277,1.686]
[0.866,1.396]

0.172***

[0.107,0.236]

1.871***
2.161***
2.429***

[1.691,2.051]
[1.957,2.366]
[2.222,2.635]

0.105

[-0.026,0.236]

0.113*
0.107*
0.172

[0.027,0.199]
[0.008,0.206]
[-0.086,0.430]

-0.085**
-0.305***

[-0.145,-0.024]
[-0.447,-0.163]

-0.052

[-0.107,0.003]

0.081*

[0.018,0.144]
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Medium income
0.126***
[0.069,0.182]
0.120***
[0.052,0.187]
0.137***
[0.082,0.192]
High income
0.219***
[0.124,0.315]
0.189***
[0.090,0.289]
0.232***
[0.126,0.338]
Religion (ref: Catholic/Anglican)
SDA and Other Christians
0.069
[-0.015,0.153] 0.056
[-0.053,0.165] 0.025
[-0.098,0.148]
Muslims
-0.185
[-0.382,0.012] -0.219
[-0.443,0.005] -0.305*
[-0.546,-0.064]
Community child mortality
-0.001*
[-0.001,-0.000] -0.001**
[-0.001,-0.000] -0.001
[-0.001,0.000]
Year fixed effects
2004
0.014
[-0.081,0.109]
2010
-0.775***
[-0.875,-0.675] -0.762*** [-0.867,-0.658] -0.766*** [-0.872,-0.659]
Constant
0.003***
[0.002,0.004]
Observations
52978
44503
43162
* p < 0.05, ** p < 0.01, *** p < 0.001. †These results are the are the same as the multilevel results already presented in
table 3, but they are duplicated here to facilitate comparison.
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Stata do file
///ANALYSIS
use analysis_cbda.dta, clear
set more off
log using contra_use, text replace

*setting the font for graphs to times roman new
graph set window fontface "Times New Roman"

*trends in contraceptive use
*graph bar (mean) none (mean) modern, over(year) percentages blabel(bar,
size(small) format(%9.2g)) by(, title(Urban-rural trends in contraceptive use
in Malawi)) by(rural, total)
graph bar (mean) none (mean) modern, over(cbda, label(labsize(3.0))) stack
///
by(urban, note(" ") graphregion( color(white)) plotregion(fcolor(white)
ifcolor(white))) ///
subtitle(,

fcolor(white) lcolor(white)) ///

bar(1, lpattern(solid) color(bluishgray)) bar(2, lpattern(dot)
color(eltblue)) bar(3, lpattern(solid)) blabel(bar, size(3.0)
position(center) format(%9.2g)) ///
by(, title("Figure 3: Urban-rural trends in contraceptive use before and
after national CBDs in Malawi", size(3.0) color(black))) ///
ytitle("Proportion", size(3)) scheme(s2color) ///
legend(label(1 "Not using modern contraceptives ") label(2 "Using modern
contraceptives") order(2 "Using modern contraceptives" 1 "Not using modern
contraceptives" ))
graph save Graph "U:\Home\Health Behavior and
Policy\masianosp\Dissertation\Paper_1\Analyis\Graphs\urbanruraltrends_1.gph", replace
**Conducting a test of the IIA assumption
mlogit contra_use cbda##rural , base(0)
estimates store m_1
mlogit contra_use urban##education if (contra_use != 1), base(0) /*excludes
traditional methods*/
estimates store m_2
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hausman m_1 m_2, alleqs constant /*alleqs means to test using all
equations*/
*the test statistic from the above is negative so the more appropriate test
is suest
suest m_1 m_2
test [m_1_modern=m_2_modern],
IIA assumption is met*/

common const /*we fail to reject the null, the

*test for combining categories
mlogit contra_use comm_fertpref comm_wealth comm_literacy

*random effects model
set more off
use analysis_cbda, clear

*combining nonusers and traditional users
gen contra_use_orig= contra_use
recode contra_use 2=0

*setting weights

svyset community, weight(comm_wt) || _n, weight(sampweight)

/*checking the effect of weights*/
tab region
tab region

[iweight=sampweight]

tab region

[iweight=comm_wt]

*empty or null model with 3 levels
melogit contra_use if notpilot==1 [pw=sampweight] ||district: ||community:,
pw(comm_wt) or covariance(unstructured)
estimates store null_3levels
estat icc
gen _prob=exp(_b[_cons])/(1+ exp(_b[_cons]))
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di _prob
drop _prob

*empty or null model with 2 levels
melogit contra_use if notpilot==1 [pw=sampweight] ||community:, pw(comm_wt)
or covariance(unstructured)
estimates store null_2levels

*single level logit
logit contra_use if notpilot==1 [pw=sampweight],

or

estimates store null_singlelevel

*comparing the two-level to the single-level
lrtest null_3levels null_singlelevel, force

*comparing the three level to the single level
lrtest null_3levels null_singlelevel, force

*comparing the 2-level and 3-level models
lrtest null_3levels null_2levels, force /*shows that the 3-level model should
be preferred*/

**drawing caterpiller plots from the variance components model
melogit contra_use if notpilot==1 [pw=sampweight] ||district: ||community:,
pw(comm_wt) or covariance(unstructured)
estimates replay null_3levels, or

*reffects and reses calculate the shrunken residuals/best linear unbiased
prediction of random intercepts and standard errors
predict u0dist u0comm, reffects reses(u0sedist u0secomm)

*district caterpillars
egen pickonedist=tag(district)
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sort u0dist
gen u0rankdist=sum(pickonedist)
*to draw the caterpillar graph with 95% confidence band of intercept
residuals
serrbar u0dist u0sedist u0rankdist if pickonedist==1, scale(1.96) mvopts(
msymbol(square) mlabel(district) mlabcolor(black) ///
mlabsize(*0.95) mlabposition(6) mlabgap(huge) mcolor(red)
mlabangle(vertical)) ytitle(District random effects) xtitle(District rank)
yline(0) ///
title("Figure 4b: Average district contraceptive use" , size(medium
large))
graph save Graph "J:\Home\Health Behavior and
Policy\masianosp\Dissertation\Paper_1\Analyis\Graphs\District_residuals.gph",
replace
*counting the number of districts outside average district
contraceptive use
count if ((u0dist + 1.96*u0sedist)<0 | (u0dist - 1.96*u0sedist)>0) &
pickonedist==1

*community caterpillars
egen pickonecomm=tag(community)
sort u0comm
gen u0rankcomm=sum(pickonecomm)
*to draw the caterpillar graph with 95% confidence band of intercept
residuals
serrbar u0comm u0secomm u0rankcomm if pickonecomm==1, scale(1.96) mvopts(
msymbol(smx) mcolor(red)) ///
ytitle(Community random effects) xtitle(Community rank) yline(0) ///
title("Figure 4a: Average community contraceptive use" , size(medium
large))
graph save Graph "J:\Home\Health Behavior and
Policy\masianosp\Dissertation\Paper_1\Analyis\Graphs\comm_residuals.gph",
replace
*counting the number of communities outside average average
contraceptive use
count if ((u0comm + 1.96*u0secomm)<0 | (u0comm - 1.96*u0secomm)>0) &
pickonecomm==1 /*93*/
//effect of CBDS

63

*full model standard logistic regression
global controls "i.age_cat i.occup i.marstatus i.exp_fp_inf
i.fertility_desire i.autonomy i.ptnr_education i.religion i.access_prob
i.comm_literacy i.comm_wealth i.comm_religion comm_childmort i.year"

logit contra_use

cbda##rural $controls

if notpilot==1 [pw=sampweight], or

estimates store full_std

*full model with random effects
melogit contra_use cbda##rural $controls if notpilot==1 [pw=sampweight]
||district: ||community:, pw(comm_wt) or covariance(unstructured)
estimates store full_re

//cluster specific margins or probabilities
margins, at(cbda=(0 1) rural=(0 1)) predict(mu fixed) noestimcheck post
margins r.cbda##r.rural, predict(mu fixed) contrast noestimcheck post

*average margins in a sub-sample of married women only
global controls "i.age_cat i.occup i.exp_fp_inf i.fertility_desire i.autonomy
i.ptnr_education i.religion i.access_prob i.comm_literacy i.comm_wealth
i.comm_religion comm_childmort i.year"

melogit contra_use cbda##rural $controls if notpilot==1 & marstatus==1
[pw=sampweight] ||district: ||community:, pw(comm_wt) or
covariance(unstructured)
estimates store full_marriedonly

//cluster specific margins or probabilities
margins, at(cbda=(0 1) rural=(0 1)) predict(mu fixed) noestimcheck post
margins r.cbda##r.rural, predict(mu fixed) contrast noestimcheck post

//average margins, including random effects
drop u0dist u0comm u0sedist u0secomm pickonedist u0rankdist pickonecomm
u0rankcomm
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estimates restore full
*reffects calculate the shrunken residuals/best linear unbiased prediction of
random intercepts
predict prmeandist prmeancomm, remeans reses(prsedist prsecomm)

*table 4, CBDA effects in single and multi-level models

esttab full_std full_re using CBDA_effect.rtf, nogaps wide eform b se
bic replace nonum label ///

aic

refcat(cbda "Main explanatory variables" 1.cbda#1.rural "Ref:
Urban, before CBDAs" ///
2.age_cat "Age (ref: 15-19 years)" 2.occup "Occupation (ref:
unemployed)" 1.marstatus "Marital status (ref: never married)" ///
1.exp_fp_inf "Exposure to FP inf (ref: no exposure)"
2.fertility_desire "Fertilify desire (ref: wants child <1 yr)" ///
1.autonomy "Autonomy (ref: No autonomy)" 1.ptnr_education
"Partner education (ref: no education)" ///
2.religion "Religion (ref: Catholic/Anglican)" 1.access_prob
"Access problem (ref: no problem)" ///
1.comm_literacy "Literacy (ref: illiterate)" 2.comm_wealth
"Income (ref: low)" ///
2.comm_religion "Religion (ref: Catholic/Anglican)" 2004.year
"Year fixed effects (ref: 2000)" 0.education "Individual-level factors" ///
0.access_prob "Community-level factors" , nolabel) ///
Regression")

mtitle("Single-level Logistic Regression" "Multi-level Logistic
///
title( "Table 4: Effect of CBDAs on contraceptive use") ///

collabels("Odds Ratio" "Standard errors" "95% Confidence
Interval" "Odds Ratio" "95% Confidence Interval") ///
coeflabels (eq1 ""cbda "CBDAs" 1.cbda "CBDAs" 1.rural "Rural"
1.cbda#1.rural " Rural, after CBDAs" ///
1.access_prob " Some problem" 2004.year " 2004" 2010.year " 2010"
comm_childmort "Community child mortality") ///
drop (0.rural 0.cbda
0.cbda#1.rural 2000.year ///

0.cbda#0.rural 1.cbda#0.rural

2015.year 1.age_cat 1.occup 0.marstatus 0.exp_fp_inf 0.autonomy
///
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1.fertility_desire 1.religion 0.ptnr_education 1.comm_wealth
1.comm_religion 0.comm_literacy) obslast

//The effect of education

*Mediation
*unadjusted
melogit contra_use cbda i.education if notpilot==1 [pw=sampweight]
||district: ||community:, pw(comm_wt) or covariance(unstructured)
estimates store unadj_edu
coefplot,

xline(0)

*adjusted but without education
melogit contra_use cbda rural i.wealth $controls if notpilot==1
[pw=sampweight] ||district: ||community:, pw(comm_wt) or
covariance(unstructured)
estimates store cbda_adj_noedu

*adjusted with education
melogit contra_use cbda i.education rural i.wealth $controls if notpilot==1
[pw=sampweight] ||district: ||community:, pw(comm_wt) or
covariance(unstructured)
estimates store cbda_adj_edu
coefplot,

xline(0) keep(*education)

esttab cbda_only unadj_edu cbda_adj_noedu cbda_adj_edu using
edu_mediation.rtf, eform b ci noeqlines eqlabels(none) keep(cbda
*.education) ///
coeflabels (eq1 ""cbda "CBDA" ) ///
drop(0.education) ///
refcat(1.education "Ref: No education") ///
title( "Table 6: Assessment of education as a mediator of CBDA
effects on contraceptive use") ///
mtitle("Model 1A" "Model 1B" "Model 2A" "Model 2B") label replace
nonum
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//the effect of wealth
*unadjusted
melogit contra_use cbda i.wealth if notpilot==1 [pw=sampweight] ||district:
||community:, pw(comm_wt) or covariance(unstructured)
estimates store unadj_wealth

*adjusted but without wealth
melogit contra_use cbda rural i.education $controls if notpilot==1
[pw=sampweight] ||district: ||community:, pw(comm_wt) or
covariance(unstructured)
estimates store cbda_adj_nowealth

*adjusted with wealth
melogit contra_use cbda i.education rural i.wealth $controls if notpilot==1
[pw=sampweight] ||district: ||community:, pw(comm_wt) or
covariance(unstructured)
estimates store cbda_adj_wealth

esttab cbda_only unadj_wealth cbda_adj_nowealth cbda_adj_wealth using
wealth_mediation.rtf, eform b ci noeqlines eqlabels(none) ///
keep(cbda *.wealth) nogaps ///
coeflabels (eq1 ""cbda "CBDA" ) ///
drop(1.wealth) ///
refcat(2.wealth "Income (Ref: Low income)") ///
title( "Table 6B: Assessment of income (wealth) as a mediator of
CBDA effects on contraceptive use") ///
mtitle("Model 1A" "Model 1B" "Model 2A" "Model 2B") label replace
nonum

*Moderation
global controls "i.age_cat i.occup i.exp_fp_inf i.fertility_desire i.autonomy
i.ptnr_education i.religion i.access_prob i.comm_literacy i.comm_wealth
i.comm_religion comm_childmort i.year"
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recode education 3=2

melogit contra_use cbda##ib0.education $controls if notpilot==1 & rural==1
[pw=sampweight] ||district: ||community:, pw(comm_wt)
covariance(unstructured)
estimates store moderation_education_r

melogit contra_use cbda##ib1.wealth $controls if notpilot==1 & rural==1
[pw=sampweight] ||district: ||community:, pw(comm_wt)
covariance(unstructured)
estimates store moderation_wealth_r

coefplot (moderation_education_r, label("Education") keep(*:1.cbda
1.cbda#0.education 1.cbda#1.education )) (moderation_wealth_r,
label("Income") keep(*:1.cbda#1.wealth 1.cbda#2.wealth)), bylabel(Rural) ///
||, eform cismooth levels(95 90) msymbol(S) xline(1) xscale(r(1
2)) xlabel(1(0.5)4) ylab(, labsize(3)) ///
xtitle("Odds ratios", size(2.5)) ytitle("CBDA effect by
education/income", size(3.5)) grid(none) ///
title("Figure 6: Education and income as moderators of CBDA effects",
span size(4) color(black))
graph save Graph
"U:\Dissertation\Paper_1\Analyis\Graphs\moderation_main2.gph", replace

*making a table of the moderating effects of education and wealth
esttab moderation_education_r moderation_wealth_r using
edu_wealth_moderation1.rtf, b ci wide noeqlines eqlabels(none) ///
title( "Table 6: Assessment of education and income (wealth) as
moderators of CBDA effects on contraceptive use in rural areas") ///
keep(*1.cbda *.wealth *.education) nogaps ///
refcat(1.cbda "Ref: Before CBDAs" 0.education "Ref: No education"
1.cbda#1.education "Ref: No education, before CBDAs" 1.wealth ///
"Ref: Low income" 1.cbda#1.wealth "Ref:Low income, before CBDAs")
///
coeflabels (eq1 "" cbda "CBDAs" 1.cbda "CBDAs" 1.cbda#1.education
"Primary, after CBDAs" 1.cbda#2.education "Secondary, after CBDAs" ///
1.cbda#2.wealth "Medium income, after CBDAs" 1.cbda#3.wealth "
High income, after CBDAs") ///
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mtitle("Model 1A" "Model 1B") label replace nonum aic bic

*this makes bar graphs
*coefplot moderation_education moderation_wealth, eform keep(1.cbda#*)
vertical recast(bar) barwidth(0.25) fcolor(*.5) ciopts(recast(rcap)) citop
citype(logit) xtitle(Repair Record 1978) ytitle(Proportion)

**another moderation graph, strength of the association between education and
wealth

melogit contra_use cbda##education##wealth $controls if notpilot==1 &
rural==1 [pw=sampweight] ||district: ||community:, pw(comm_wt) or
covariance(unstructured)
estimates store moderation_2

gen education1=education
recode education1 3=2
label copy education education1
label values education1 education1

*predicting probabilities
predict predprob, fixedonly

*getting average probabilities by education and income
table education1 wealth cbda, c(mean predprob)

*setting the font
graph set window fontface "Times New Roman"

graph bar (mean) predprob if rural==1, over(education1 ) over(wealth,
label(labsize(small))) over(cbda)
asyvars ///
ytitle(Predicted probability) ///
b1title("") ///
legend(rows(1) ///
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subtitle(Education level)) ///
bargap(0) ///
bar(1, lpattern(solid) color(dkorange)) bar(2, lpattern(solid)
color(brown)) bar(3, lpattern(solid) color(green) fintensity(70) ) ///
title("Figure 8: Predicted probability of contraceptive use by income
and education among rural women", size(3) color(black))
graph save Graph "U:\Home\Health Behavior and
Policy\masianosp\Dissertation\Paper_1\Analyis\Graphs\moderationbyeducation2.g
ph", replace

//*Model diagnostics

use analysis_cbda, clear
global controls "age agesq i.occup i.marstatus i.exp_fp_inf
i.fertility_desire i.autonomy i.ptnr_education i.religion i.access_prob
i.comm_literacy i.comm_wealth i.comm_religion comm_childmort i.year"
melogit contra_use cbda##rural i.education i.wealth $controls if
notpilot==1 [pw=sampweight] ||district: ||community:, pw(comm_wt) or
covariance(unstructured)
estimates store for_residuals

*goodness of fit test using predicted probabilities
predict probability, fixedonly
gen predicted_contra=0
replace predicted_contra=1 if probability>0.5
tab

contra_use predicted_contra if notpilot==1, row

count if contra_use==1 & predicted_contra==1 & notpilot==1 | contra_use==0 &
predicted_contra==0 & notpilot==1
drop probability predicted_contra

*goodness of fit test using residuals
gen n = _n
predict residuals, deviance
label var n "Observation number"
twoway (scatter residuals n if contra_use) (scatter residuals n if
!contra_use) if notpilot==1, ///
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yline(-2 2) legend(off) text(3.8 10000 "Using contraceptives") text(0.2
10000 "Not using contraceptives") ///
title("Figure 8: Goodness-of-fit test using deviance residuals",
size(4) color(black)) ///
ytitle("Deviance residuals")
graph save Graph "J:\Home\Health Behavior and
Policy\masianosp\Dissertation\Paper_1\Analyis\Graphs\deviance_residuals.gph",
replace
///***sensitivity analysis
global controls "i.age_cat i.occup i.marstatus i.exp_fp_inf
i.fertility_desire i.autonomy i.ptnr_education i.religion i.access_prob
i.comm_literacy i.comm_wealth i.comm_religion comm_childmort i.year"
melogit contra_use cbda##rural $controls if notpilot==1 [pw=sampweight]
||district: ||community:, pw(comm_wt) or covariance(unstructured)
estimates store sensitivity_pilot

melogit contra_use cbda##rural $controls if notpilot==0 [pw=sampweight]
||district: ||community:, pw(comm_wt) or covariance(unstructured)
estimates store sensitivity_notpilot

*joint test of the interaction term and the main effects
test _b[1.cbda]=_b[1.rural]=_b[1.cbda#1.rural]

esttab sensitivity_pilot sensitivity_notpilot using Sensitivity_1.rtf,
nogaps wide b ci replace nonum label ///
refcat(cbda "Main explanatory variables" 1.cbda#1.rural "Ref:
Urban, before CBDAs" ///
2.age_cat "Age (ref: 15-19 years)" 2.occup "Occupation (ref:
unemployed)" 1.marstatus "Marital status (ref: never married)" ///
1.exp_fp_inf "Exposure to FP inf (ref: no exposure)"
2.fertility_desire "Fertilify desire (ref: wants child <1 yr)" ///
1.autonomy "Autonomy (ref: No autonomy)" 1.ptnr_education
"Partner education (ref: no education)" ///
2.religion "Religion (ref: Catholic/Anglican)" 1.access_prob
"Access problem (ref: no problem)" ///
1.comm_literacy "Literacy (ref: illiterate)" 2.comm_wealth
"Income (ref: low)" ///
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2.comm_religion "Religion (ref: Catholic/Anglican)" 2004.year
"Year fixed effects (ref: 2000)" ///
0.access_prob "Community-level factors" , nolabel) ///
mtitle("Pilot districts" "Non-pilot districts")

///

title( "Table 4: Effect of CBDAs on contraceptive use") ///
collabels("Odds Ratio" "95% Confidence Interval" "Odds Ratio"
"95% Confidence Interval") ///
coeflabels (eq1 ""cbda "CBDAs" 1.cbda "CBDAs" 1.rural "Rural"
1.cbda#1.rural " Rural, after CBDAs" ///
1.access_prob " Some problem" 2004.year " 2004" 2010.year " 2010"
comm_childmort "Community child mortality") ///
drop (0.rural 0.cbda
0.cbda#1.rural 2000.year ///

0.cbda#0.rural 1.cbda#0.rural

2015.year 1.age_cat 1.occup 0.marstatus 0.exp_fp_inf 0.autonomy
///
1.fertility_desire 1.religion 0.ptnr_education 1.comm_wealth
1.comm_religion 0.comm_literacy) obslast

**Moderation: effects of education and wealth
melogit contra_use cbda##ib3.education##ib3.wealth $controls if notpilot==1
& rural==1 [pw=sampweight] ||district: ||community:, pw(comm_wt) or
covariance(unstructured)
estimates store moderation_education_u

melogit contra_use cbda##ib3.wealth $controls i.education if notpilot==1 &
rural==0 [pw=sampweight] ||district: ||community:, pw(comm_wt) or
covariance(unstructured)
estimates store moderation_wealth_u

coefplot (moderation_education_u, label("Education") keep(*: 1.cbda
1.cbda#0.education 1.cbda#1.education) ) (moderation_wealth_u,
label("Income") keep(*: 1.cbda#1.wealth 1.cbda#2.wealth) ), bylabel(Panel A:
urban) ///
|| (moderation_education_r, label("Education") keep(*:1.cbda
1.cbda#0.education 1.cbda#1.education) ) (moderation_wealth_r,
label("Income") keep(*: 1.cbda#1.wealth 1.cbda#2.wealth)), bylabel(Panel B:
rural) ///
||, eform xline(1) cismooth levels(99.999) byopts(xrescale)
msymbol(S) label ylab(, labsize(3)) ///
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xtitle("Odds ratios", size(3)) ytitle("CBDA effect by
education/income", size(3)) grid(none) ///
graphregion(color(white)) ///
title("Figure B1: CBDA effects and the role of education and
income as moderators of the effects", span size(3.3) color(black))
graph save Graph
"U:\Dissertation\Paper_1\Analyis\Graphs\moderation_senstiv2.gph", replace

**Examining the effect of using 2000, 2004 as baselines
use analysis_cbda.dta, clear

global controls "i.age_cat i.occup i.marstatus i.exp_fp_inf
i.fertility_desire i.autonomy i.ptnr_education i.religion i.access_prob
i.comm_literacy i.comm_wealth i.comm_religion comm_childmort i.year"

quietly melogit contra_use cbda##rural $controls if notpilot==1 &
year!=2004 [pw=sampweight] ||district: ||community:, pw(comm_wt) or
covariance(unstructured)
estimates store _2000

quietly melogit contra_use cbda##rural $controls if notpilot==1 &
year!=2000 [pw=sampweight] ||district: ||community:, pw(comm_wt) or
covariance(unstructured)
estimates store _2004

quietly melogit contra_use cbda##rural $controls if notpilot==1
[pw=sampweight] ||district: ||community:, pw(comm_wt) or
covariance(unstructured)
estimates store full

esttab _2000 _2004 full using year_sensitivity.rtf , nogaps eform b ci wide
replace nonum label ///
refcat(cbda "Main explanatory variables" 1.cbda#1.rural "Ref:
Urban, before CBDAs" ///
2.age_cat "Age (ref: 15-19 years)" 2.occup "Occupation (ref:
unemployed)" 1.marstatus "Marital status (ref: never married)" ///
1.exp_fp_inf "Exposure to FP information (ref: no exposure)"
2.fertility_desire "Fertility desire (ref: no more child)" ///
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1.autonomy "Autonomy (ref: No autonomy)" 1.ptnr_education
"Partner education (ref: no education)" ///
2.religion "Religion (ref: Catholic/Anglican)" 1.access_prob
"Access problem (ref: no problem)" ///
1.comm_literacy "Literacy (ref: illiterate)" ///
2.comm_religion "Religion (ref: Catholic/Anglican)" 2004.year
"Year fixed effects" 0.education "Individual-level factors" ///
0.access_prob "Community-level factors" , nolabel) ///
mtitle("Baseline: 2000" "Baseline: 2004" "Baseline: 2000+2004")
///
title( "Table S2: Effect of CBDAs on contraceptive use in
response to changing baseline") ///
coeflabels (eq1 ""cbda "CBDA" 1.cbda "CBDA" 1.rural "Rural"
1.cbda#1.rural " Rural, after CBDAs" ///
1.access_prob " Some problem" 2004.year " 2004" 2010.year " 2010"
comm_childmort "Community child mortality") ///
drop (0.rural 0.cbda
0.cbda#1.rural 2000.year ///

0.cbda#0.rural 1.cbda#0.rural

2015.year 1.age_cat 1.occup 0.marstatus 0.exp_fp_inf 0.autonomy
///
1.fertility_desire 1.religion 0.ptnr_education 1.comm_wealth
1.comm_religion 0.comm_literacy) obslast
estwrite * using results, replace
estread results
log close
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Chapter 2: Conditional cash transfers to increase the uptake of services for the prevention
of mother-to-child transmission of HIV: a trial-based cost-effectiveness analysis
Abstract
Background: Innovative strategies have been implemented to address the prevention of
mother-to-child transmission (PMTCT) of HIV in sub-Saharan Africa (SSA). A recent
randomized controlled trial found that conditional cash transfers (CCTs) to pregnant women with
HIV increases the uptake of PMTCT services. The current study evaluates the cost-effectiveness
of the CCTs.
Methods: A cost-effectiveness analysis, from the societal perspective, was conducted for a
randomized controlled trial of CCTs in 89 clinics in the Democratic Republic of the Congo
(DRC), 2013-2015. The trial had two arms. The intervention group (n=216) received the
standard of care plus US$5 at the first visit and increased by US$1 at every scheduled visit. The
control group (n=217) only received the standard of care. Health outcomes were measured using
PMTCT uptake and PMTCT retention. We expressed incremental effectiveness using the
number needed to treat (NNT). We evaluated economic costs by trial arm and relied on the trial,
negotiated drug price lists, and the literature for cost estimates. We reported the costs in 2016
International Dollars (I$). The threshold for cost-effectiveness was based on 3x GDP per capita
for the DRC in 2016 (I$2409). We used both deterministic sensitivity analyses and costeffectiveness acceptability curves to examine the uncertainty associated with the ICERs.
Results: The CCTs increased PMTCT uptake and retention, but at a higher cost. The NNT was
7.0 (95% C.I.=6.7-7.6) for PMTCT uptake and 12.1 (95% C.I.=11.6-12.8) for PMTCT retention.
The mean costs/participant in the intervention and control groups were I$516 and I$431,
representing an incremental cost of I$85 (95% C.I.=59-111). The ICER was I$595 (95% C.I.
=567-624) for PMTCT uptake and I$1026 (95% C.I.=960-1101) for PMTCT retention. In
uncertainty analyses, the CCTs were still cost-effective even in the worst case.
Conclusion: CCTs are a cost-effective way to increasing uptake of PMTCT services in the
DRC and similar settings. However, additional research is needed to understand the effectiveness
and cost-effectiveness of the CCTs in larger populations and over a longer analytic time horizon
before further scale-up of CCTs.
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1. Introduction
Despite global progress in reducing the number of new HIV infections, mother-to-child
transmission (MTCT) of HIV remains a challenge. The United Nations Joint Program on
HIV/AIDS (UNAIDS) estimated that over 440 children (ages 0-14 years) were infected with
HIV every day in 2016, mostly through vertical transmission [106]. Most of these infections
(88%) occurred in sub-Saharan Africa (SSA) where nearly 70% (26 million) of all people with
HIV lived in 2016 and uptake of services for the prevention of mother-to-child transmission of
HIV (PMTCT) is low (<70 percent overall and as low as 32 percent in countries like Nigeria)
[106], [107]. Evidence suggests that PMTCT services, which include the provision of highly
efficacious preventive antiretroviral drugs to both the mother and the infant, can reduce the risk
of MTCT to <5%. However, in the absence of PMTCT services, the risk of MTCT is about 40%
[108]–[110].
The low uptake of PMTCT services despite the advantages and wide availability of the services
in SSA poses challenges to global ambitions of eliminating the AIDS epidemic by 2030 [111].
This raises a need to find innovative and cost-effective approaches to help overcome barriers
preventing the uptake of and demand for these services. One such approach is the use of
conditional cash transfers (CCTs), an approach previously used to modify individual and
household behaviors in health and other sectors like education [112]–[114]. To test whether
CCTs can be used to increase the uptake of PMTCT services, a randomized controlled trial
(RCT) of the CCTs was implemented in the Democratic of the Congo (DRC) [115]. The
expectation was that the CCTs would help to overcome demand-side barriers, particularly
transport costs—one of the major factors preventing the uptake of PMTCT services in SSA
[116]–[119].
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Results from the DRC trial suggested that CCTs can increase the number of women taking up
PMTCT services [115], but it is unclear whether the CCTs are cost-effective. Therefore, the goal
of the present study is to conduct a trial-based cost-effectiveness analysis of the CCTs to
establish whether the CCTs represent a good value for the money. We emphasize that the main
contribution of this study is in the cost and cost-effectiveness analysis and not in establishing the
effectiveness of the intervention.
2. Overview of the trial
In 2013-2015, an RCT was launched in the DRC to test the effectiveness of paying pregnant
women with HIV cash to help overcome demand-side barriers to healthcare [115]. These barriers
include lack of transport money and the opportunity of time spent seeking PMTCT services
[117], [118]. The trial, funded by the National Institutes of Health, was conducted in Kinshasa in
89 facilities already offering PMTCT services as part of maternal and child health clinics. All
women newly diagnosed with HIV, <32 weeks of gestation, and registered for ANC at any of the
89 facilities were considered for participation.
The trial enrolled 433 women, with 216 randomized to the intervention group and 217 to the
control group. The intervention group received standard PMTCT care plus the cash incentives
while the control group only received the standard PMTCT care. At the initial visit, each
participant in the intervention group received US$5 which increased by US$1 at the next visit
but was reset to $5 if the participant missed a scheduled visit or refused a proposed service [115].
Option B+ was the standard of care at the time of the trial [115]. Under this protocol, pregnant
women with HIV—irrespective of gestation age or HIV disease stage—are initiated on
antiretroviral drugs and continue to take the drugs for life [120], [121]. Table 1 lists the
protocol’s recommendations.
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2.1. Trial outcomes
The trial had two primary health outcomes: uptake of PMTCT services and retention in PMTCT
care. Uptake was defined as timely attendance (within 5 days) of all scheduled clinic visits from
randomization through 6 weeks’ postpartum and acceptance of all proposed services listed in
table 1. Retention was defined as being in HIV care at 6 weeks’ postpartum regardless of the
reason for missing any prior scheduled visits [115].
3. Methods
3.1. Overview
We conducted a trial-based cost-effectiveness of CCTs aimed at increasing uptake of PMTCT
services and retention in PMTCT care in the DRC. We conducted the study from both the
societal and healthcare perspectives and largely followed recommendations by the World Health
Organization (WHO) for cost-effectiveness analysis in resource-limited settings [122]–[124].
Data on resource utilization came from the trial but cost data came from multiple sources. We
report economic costs in constant 2016 international dollars (I$). Costs in local currency were
first adjusted for inflation using DRC’s gross domestic product (GDP) deflator and then
converted to 2016 I$. In line with the trial, we measured the effectiveness of the CCTs using two
health outcomes: uptake of PMTCT services and retention in PMTCT care. We expressed
incremental effectiveness in terms of the number needed to treat (NNT)—the number of
participants needed to receive the cash incentives for one more participant to take up the services
or be retained in care. We did not discount the costs or effects to net present value as participant
follow-up was <1 year. The threshold for cost-effectiveness was based on 3x GDP per capita for
the DRC in 2016 (I$2409). We used both deterministic sensitivity analyses and costeffectiveness acceptability curves to examine the uncertainty in the ICERs. This study was
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approved as exempt by the Internal Review Board of Virginia Commonwealth University (IRB#:
HM20009283).
3.2. Study perspective
We conducted the study from a societal perspective as recommended by the WHO [122]. The
perspective included formal healthcare sector costs (e.g., drugs) and informal healthcare sector
costs (e.g., patient transport costs) [122]. We summarize the costs included in this study in table
2.
3.3. Identifying cost sources
As the trial was not designed for an economic evaluation and therefore, did not collect detailed
cost data, we relied on multiple sources for the cost data. The sources included peer-reviewed
studies and the grey literature from within and outside of the DRC. We searched Google, Google
Scholar, PubMed, and Medline using the terms in Appendix B1. We also manually searched
reference lists of identified studies for studies not captured by our search terms.
We restricted the search to cost sources contextually relevant to the DRC. We defined contextual
relevance in three ways: the time of the study, geography, and income—measured using GDP
per capita as classified by the World Bank. In terms of time, the search was restricted to studies
conducted from the year 2005 onward as antiretroviral drugs and PMTCT strategies were widely
introduced after 2004 [125], [126]. In terms of geography, the search was restricted to studies in
SSA. In terms of income, the search was restricted to countries with low GDP per capita, similar
to the DRC [127]. For prices of antiretroviral drugs, we relied on price lists of international
negotiated prices publicly available through the Clinton Health Access Initiative (CHAI) [128].
Appendix B2 lists the candidate cost sources.
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3.4. Identifying unit costs in base case analysis
From the list of candidate cost sources in appendix B2, we selected estimates from highquality studies to represent base case unit costs, table 3. We defined high-quality studies as peerreviewed studies and project reports which clearly articulated data sources, how costs were
assigned, followed recommended guidelines for estimating costs in cost and cost-effectiveness
analyses, and presented costs in disaggregated form—for example, cost per visit. If multiple
high-quality sources were available, we selected estimates from studies closest to 2016 as they
are likely to be more applicable to the current context.
3.5. Valuation of goods and services, inflation adjustment, and discounting
We valued the cost of the CCTs in international dollars (I$)—a hypothetical currency with the
same purchasing power as the US$ has in the United States [122], [123]. The I$ reflects the
correct value of goods because it distinguishes between tradable and non-tradable goods; without
this distinction, non-tradable goods would be undervalued countries with higher purchasing
power such as the DRC [122], [124]. Tradable goods (e.g., medications) are those goods that can
be imported or exported and converted their estimates using nominal (official) exchange rates.
On the other hand, non-tradable goods are produced locally and cannot be imported or exported
(e.g., labor) [122], [124] and converted their estimates using purchasing power parity (PPP)
exchange rates. All exchange rates came from a World Bank database [129].
As the trial was conducted for >1 year and cost estimates were extrapolated from multiple time
periods [122], we adjusted the costs for inflation and reported the costs in constant 2016 I$—the
year with the most recent conversion factors at the time of this study. To adjust for inflation, we
used the implicit gross domestic product (GDP) deflator accessible through the World Bank
database [130]. Unlike other candidate inflation-adjustment tools like the consumer price index,
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the GDP deflator covers price changes in a broader range of economic activity, including the
health sector [36]. We first applied inflation adjustment and then converted the inflation-adjusted
estimates to I$. We did not discount costs or effects as participant follow-up was <1 year [131].
3.6. Cost assignment
We assigned costs to participants based on the number of visits or services utilized and used both
micro-costing and gross-costing to estimate the costs. For example, we assigned the cost of
transport and drugs based on micro-costing and the cost of utilities and staff wages using grosscosting. Micro-costing entails conducting a detailed identification and measurement of all
activity inputs to value costs [132], [133]. Micro-costing can yield more precise estimates [132],
but it was not possible to use this method to value all costs. Thus, we also used gross-costing—
use of mean costs aggregated at a higher level from other studies to determine the value of an
activity [132]. Gross-costing is simple, tractable and quick to use [132], although it may produce
biased estimates because of overgeneralization [132], [134].
3.6.1. Medications and laboratory costs
To assign the cost of medications, we multiplied the number of days a participant was on the
medications by the unit cost of the medications. We calculated the number of days on the
medications by taking the difference between the date a participant was started on the medication
and the date the participant was last followed-up. Participants lost to follow-up at six weeks were
assumed to have taken the medications for 3 weeks (half-way between the first visit date and the
would-have-been visit at six weeks). We also estimated the cost of infant NVP suspension but
only for six weeks after delivery because thereafter participants were not followed-up. Unit
prices of medications, which came from CHAI and represent drug acquisition costs only, were
increased by 15% to cover shipping costs [135].
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Among laboratory tests, we estimated the cost of CD4 cell counting and DNA PCR testing of
infant dried blood sample (DBS). We also estimated the cost of transporting the DBS to a central
laboratory in Kinshasa where the testing was done. We did not cost HIV testing and counseling
as these services were provided to all pregnant mothers attending ANC clinics, regardless of
study participation and therefore, would not contribute to incremental costs. We did not cost viral
load tests because these tests were not performed or recorded systematically during the trial.
3.6.2. Delivery and post-delivery counseling
We estimated the cost of health facility deliveries as an episode. Separately, we also estimated
the cost of post-delivery counseling on family planning and safe infant feeding practices. We
assumed two post-delivery counseling sessions—one session soon after delivery but before the
participant was discharged from the clinic and the other at six weeks’ postpartum. We calculated
the cost of the two counseling sessions separately because some participants who delivered in
health facilities did not return at six weeks’ post-partum.
3.6.3. Labor and overhead costs
We assigned labor costs to each visit, except the visit for hospital delivery which we assumed
was included in the overall cost of the deliveries. We separately estimated labor costs for clinical
and support staff. We used a nurse salary to approximate the labor cost of clinical staff. We
assumed that a nurse saw 20 patients in a day [136] and worked for 22 days in a month.
Therefore, we divided a nurse monthly salary by 440 (20*22) to find the labor cost of each visit.
Using a similar approach, we derived the labor cost of support staff for each visit.
At each visit, we also calculated the cost of overheads—resources shared by other programs—
which included utilities and equipment. Many of the studies from which we abstracted overhead
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costs assigned costs to participants per month [137]–[139], so we assumed that the monthly cost
was for one visit. We summed the costs per visit then multiplied by the number of visits to find
the total cost of all visits per participant.
3.6.4. Patient and peer/family support costs
We also included costs incurred by participants and their supporters (peers or family) in the form
of transport costs and the opportunity cost of time spent seeking PMTCT services [133].
Evidence suggests that women with HIV receiving PMTCT services are accompanied by their
peers/family to the health facilities and they value their time and effort [140]. The trial recorded
self-reported one-way transport costs which we doubled to get the transport cost per visit. We
assigned the peer/family member the same transport cost as the participant. We also assumed
that one clinic visit took one working day of the participant’s time and that a participant’s
support lost an equal amount of time. Further, assumed the participant and their support lost 2
days for delivering in health clinics. We used a minimum day’s wage for the DRC of 1680 FC in
2016 as the opportunity cost of time [141].
3.7. Missing data
In preliminary analyses, we found that about 40% of the participants had missing transport costs
which we replaced using multiple imputations to introduce variation in the imputed values and
derive asymptotically consistent estimates [142]. We assessed the pattern of data missingness
and found that the missingness was not systematic—a key assumption is multiple imputations
[143]. We performed the multiple imputations using predictive mean matching which does not
make any assumptions about the distribution of the data [144], [145]. We included the dependent
variable and all explanatory variables from equation 1 (below) in the imputation, as
recommended [146].
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3.8. Analysis
All analyses were by intention-to-treat. That is, all participants were kept in the groups to which
they were randomized, regardless of deviations from the trial’s protocol [147]. For example, one
participant assigned to the control group and randomly selected to receive the cash incentives
was still analyzed as part of the control group. We analyzed effects and costs using univariable
and multivariable approaches and then estimated the incremental effectiveness and incremental
costs. We then multiplied the incremental effectiveness and incremental costs to derive ICERs.
3.8.1. A general statistical model for analyzing effectiveness and costs
To model the effectiveness and costs of the CCTs, we used marginal models estimated via
generalized estimating equations (GEE) and adjusted for potential clustering at the clinic level.
Ignoring the potential clustering could have led to a narrower 95% confidence interval [148] and
thus increasing the probability of type 1 error [91]. We also adjusted for baseline participant
characteristics as randomization might still fail to equalize trial arms due to sampling error [77].
GEEs produce population-averaged coefficients which are desirable because they can inform
policymakers, on average, the effectiveness or cost of the CCTs were all pregnant HIV-positive
women to receive the intervention. Other candidate models like the generalized linear mixed
models produce cluster-specific coefficients and not population-averaged coefficients [66],
[149]. Another advantage of GEE is that the coefficients from these models are robust to
misspecification of the variance structure making them appropriate for studies interested in
estimating coefficients and not the variance itself; GEEs treat the variance as a nuisance thereby
making correct variance specification less important [66], [149], [150]. While GEEs may
produce biased estimates when the number of clusters is small (<10) and study arms are not
balanced [148], [151], we have confidence in the estimates as the trial had a high number of
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clusters (89 clinics) and the arms were balanced (216 vs. 217). We implemented the models
using “xtgee” in Stata 14.2 [152].
The following was the generalized linear model:
𝐹 − (𝑂𝑢𝑡𝑐𝑜𝑚𝑒𝑖𝑗 ) = 𝛽0 + 𝛽1 𝐼𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛𝑖𝑗 + 𝑿𝑖𝑗 𝐀

(1)

where:
Outcomeij was either PMTCT uptake or PMTC retention or cost for the ith participant at
the jth clinic;
Intervention=1 if the participant received CCTs and 0 otherwise; β1 was the coefficient of
interest.
Xij is a vector of participant characteristics and A a corresponding vector of coefficients.
We specified an exchangeable within-group correlation structure for both effectiveness and
costs, but the links and distributions were different. An exchangeable structure means that the
correlation between any pair of participants receiving PMTCT services at the same clinic was
equal but non-zero [66], [149].
3.8.2. Effectiveness
To model the effectiveness of the CCTs, we specified a Poisson distribution and a logarithmic
link in equation 1. We specified a Poisson distribution because a log-binomial model could not
converge within the GEE environment in Stata 14.2. While the Poisson and log-binomial
regressions produce identical estimates, standard errors from the Poisson are larger [153], [154]
which increases the probability of failing to reject the null (type 2 error) [91]. To make the
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standard errors smaller and comparable to those from a log-binomial model, we estimated the
Poisson model with robust error variances [154].
To duplicate published results from the trial [115], we reported the effectiveness using relative
risks. Thus, for PMTCT uptake in equation 1, participants who received the CCTs had β1 times
the risk of taking up PMTCT services compared with participants who did not receive the CCTs.
Similarly, for PMTCT retention, participants who received the CCTs had β1 times the risk of
being retained in PMTCT care compared with participants who did not receive the CCTs.
3.8.3. Incremental effectiveness
Next, we estimated the incremental effectiveness of the CCTs expressed using NNT, like several
other studies in the HIV literature[155], [156]. NNT is an epidemiological measure that
quantifies the number of participants needed to receive a treatment to avoid a poor outcome
[157], for example, not taking up PMTCT services. NNT is a natural number and therefore easier
to interpret clinically than other candidate measures of incremental effectiveness like risk
differences [157]. Thus, a higher NNT means that the treatment is less effective in avoiding the
unwanted outcome. We were unable to use traditional measures of incremental effectiveness like
the disability-adjusted life years (DALY) averted because participant follow-up time was too
short, and the study was not powered to detect the effect of the CCTs on survival.
Calculation of NNT, like for relative risks, was based directly on the underlying risk of PMTCT
uptake or PMTCT retention in each trial arm. We emphasize that we could not directly estimate
the NNT using the relative risks from the Poisson regression. Therefore, after estimating the
Poisson regression in equation 1, we derived the NNT in the following steps:
1. Predicted the absolute risk for each participant.
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2. Calculated the mean absolute risk in each arm.
3. Calculated the mean absolute risk difference between the intervention and control arms.
4. Calculated the NNT, which is the reciprocal of the mean absolute risk difference [158].
We interpreted the NNT as the number of participants needed to receive the cash incentives for
one more participant to take up PMTCT services, compared to standard of care. We made a
similar interpretation for PMTCT retention.
3.8.4. Economic costs
To determine total costs in each trial arm, we multiplied resources used by each participant by
the unit cost of that resource and then added. We described costs using both the median and
mean but in multivariable regressions modeled mean costs only. While reporting of median costs
is recommended as cost data are almost always positively skewed [131], we also report mean
costs because budgeting and policy decisions are made based on expectation [159]. We tested
differences in means and medians using t-tests and rank sum tests. The t-test, which assumes a
normal distribution, is still robust when the sample size is greater than 150 or when the number
of participants in the intervention and control groups is similar [160], as in this study.
3.8.5. Incremental costs
To estimate incremental costs, we also used equation 1 with cost as the outcome. We specified
an exchangeable within-group correlation structure, a gamma distribution, and an identity link.
These specifications were based on results of testing several correlation structures and cost
distributions using the quasi-likelihood under the independence model criterion (QIC) [161]. By
specifying an identity link, β1 was in the original cost values and represented the difference in
costs between the intervention and the control arms—or the incremental cost of the CCTs.
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3.8.6. Incremental cost-effectiveness ratio
To derive ICERs, we multiplied incremental costs and incremental effectiveness (incremental
costs*NNT)2. Because the ICER is a ratio and therefore does not have standard errors to use in
calculating the 95% confidence intervals, we used Fieller’s theorem to generate the confidence
intervals [131], Appendix B4. Unlike other parametric methods which assume a normal
distribution of the ratio, Fieller’s method considers the skewed distribution of the ICER [131],
[162].
3.8.7. Are the CCTs cost-effective?
To determine whether the CCTs are cost-effective, we compared the ICER of the CCTs to costeffectiveness thresholds based on 3x the GDP per capita for the DRC in 2016 (I$2409) [163].
Thus, I$2409 represented the maximum willingness-to-pay for an additional participant to take
up PMTCT services or be retained in care. However, because of concerns that a threshold of 3x
GDP per capita may be too high [164]–[166], we also considered a lower threshold (1.5x the
GDP per capita for the DRC in 2016 or I$1205).
3.8.8. Uncertainty analysis
We also assessed uncertainty in the cost variables and the estimated ICER[122], [133], [167].
Sources of the uncertainty included: abstraction of cost data in different unit costs outside of the
trial, use of gross costing, and imputation of transport costs [143], [167], [168]. We used
deterministic sensitivity analyses to examine uncertainty in cost variables and cost-effectiveness
acceptability curves to examine uncertainty in ICERs.

In the traditional approach, ICER=ΔC/ΔE, where ΔC is the incremental cost and ΔE is the incremental
effectiveness. Estimating effectiveness using absolute risk means that the ΔE is the risk difference (RD). Thus,
ICER=ΔC/RD= ΔC*1/RD. But 1/RD=NNT. Therefore, ICER=ΔC*NNT.
2
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3.8.8.1.

One-way sensitivity analysis

In one-way sensitivity analyses, we identified the main cost drivers by varying the cost of key
components one at a time across a plausible range of values, holding other cost components at
their base values [133], [169]. A component was key if it had high unit costs or high utilization
relative to the other components, and therefore, more likely to substantially affect costs if varied
[170]. We selected values for lower and upper bound unit costs from the sources of the base case
unit costs [170]. We used the limits of the 95% confidence intervals of the base case unit costs
as the upper and lower bounds in the sensitivity analyses. If the base unit cost did not have a 95%
confidence interval, we decreased and increased base case estimate by 50% to derive the lower
and upper bound estimates, as done previously [169], [171], [172]. In each one-way sensitivity
analysis, we calculated new ICERs and report the results using tornado diagrams [173], [174].
Table 3 presents the key components and the unit costs in the sensitivity analysis.
3.8.8.2.

Multi-way sensitivity analyses: best- and worst-case scenarios

Since multiple variables may be uncertain, we examined the effect of simultaneously varying key
cost variables in multi-way sensitivity analysis [169]. We created best- and worst-case scenarios.
We combined the most optimistic unit costs (lower bound unit costs) in table 3 to create the best
case and the most pessimistic unit costs (upper bound unit costs) to create the worst case. In each
scenario, we calculated new ICERs and the associated 95% confidence intervals.
3.8.8.3.

Cost-effectiveness acceptability curve

To examine the uncertainty associated with the ICERs in the base case, we used costeffectiveness acceptability curves. These give the probability that an intervention is costeffective compared with the alternative, for varying levels of willingness-to-pay [175]. To derive
the cost-effectiveness acceptability curves, we implemented the following steps:
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1. Using simple random sampling with replacement, we drew a sample of 216 observations
from the trial data, similar to the size of the intervention arm [162], [176], [177].
2. From the resampled data, we calculated the mean cost and effectiveness [162], [176],
[177].
3. We repeated steps 1 and 2 to obtain the mean cost and effectiveness in the control arm.
4. Next, we combined the resampled datasets and calculated a new ICER.
5. We repeated steps 1-4 for 4000 times although 1500 times is recommended [178]. This is
because the bootstrapped costs and effects were normally distributed after 4000 samples.
We bootstrapped costs and effects together because of their interdependence.
6. From the 4000 ICERs, we estimated differences in costs and differences in effects.
From the differences in costs and effects in step 6, we derived the cost-effectiveness
acceptability curves. We also plotted the joint distribution of the differences in costs and effects
on a cost-effectiveness plane. To construct the CEAC, we modified an existing Stata program by
changing the program’s default confidence limits and maximum values [179].
4. Results
4.1. Effectiveness of CCTs
We found that CCTs significantly increased the uptake of PMTCT services and retention in
PMTCT care. About 68% (146/216) of women in the intervention group took up PMTCT
services compared with 53% (116/217) in the control group. About 81% (174/216) of women in
the intervention group were retained in PMTCT care compared with 72% (157/217) in the
control group. Compared to participants who did not receive the cash incentives, participants
who received the cash incentives were 28% and 12% more likely to take up PMTCT services and
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being retained in PMTCT care, respectively, table 4. Further, women with a secondary education
and those who walked to clinics were significantly more likely to take up PMTCT services.
4.1.1. The incremental effectiveness of CCTs (number-needed-to-treat)
We present incremental effectiveness (NNT) of the CCTs and the values at each step of deriving
the NNT in table 5. We emphasize that NNT cannot be derived directly from relative risks and
therefore, results in table 4 could not have been used to derive the NNT. The NNT for PMTCT
uptake was 7.0 (95% C.I.=6.7-7.6)—that is 7 participants needed to receive the cash incentives
for one more participant to take up the PMTCT services. For PMTCT retention, the NNT was
12.1 (95% C.I.=11.6-12.8).
4.2. The economic cost of the CCTs
We summarize economic costs in table 6. The mean total cost ± SD per participant in the
intervention group was I$516 (116), compared with I$431 (132) in the control group (p-value
<0.001). The median cost was also higher in the intervention group (I$540, IQR (485-590) vs. I$
468, IQR (392-512)) (p-value <0.001). As a share of mean total costs, the cost of delivering in a
health facility was the highest in both arms, although lower in the intervention group (52% vs.
58%). In the intervention arm, the cost of the CCTs ranked second tied with the cost of
medications (10%). Overall, participants in the intervention group made 35 visits (934 vs. 899),
with a mean cost per visit of I$119 (vs. I$104 in the control group).
4.2.1. The incremental cost of the CCTs
Table 7 presents the incremental costs of the CCTs. The CCTs had an incremental cost of I$85
(95% C.I.=59-111). The Incremental costs did not differ significantly by participant
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characteristics although the costs were higher among those who were married, without any
education, and walked to the clinics.
4.3. Incremental cost-effectiveness ratios of CCTs
In the following subsections, we present incremental cost-effectiveness ratios in the base case
and in uncertainty analyses.
4.3.1. Base case analysis
Table 8 presents the incremental cost-effectiveness ratios of the CCTs in the base-case analysis.
The incremental cost-effectiveness ratio of the CCTs with respect to PMTCT uptake was I$595
(95% C.I. =567-624) and I$1026 (95% C.I.=960-1101) with respect to PMTCT retention. Thus,
the CCTs were very cost-effective in increasing PMTCT uptake (ICER <1x DRC GDP per capita
or I$803) and cost-effective in increasing PMTCT retention (ICER> I$803 but <3x DRC GDP
per capita or I$2409).
I$595 (95% C.I. =567-624) for PMTCT uptake and I$1026 (95% C.I.=960-1101)
4.3.2. One-way sensitivity analysis
Figure 1, a tornado diagram, presents the results of the one-way sensitivity analysis and the
associated ICERs. The vertical line in the diagram corresponds to the ICER in the base case. The
variables are ranked so that the most influential variable is at the top. The x-axis measures the
change in ICER from the base case while the labels of the bars are the lower and upper bound
unit costs used in the sensitivity analysis. The CCTs followed by delivery in health facilities
were the main drivers of the incremental cost-effectiveness ratios. For example, paying each
participant I$20 (or US$11) at every visit while holding other variables constant increases the
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ICER from I$1026 per additional HIV+ mother retained in PMTCT care in the base case to
I$1,570, but still cost-effective.
4.3.3. Multi-way sensitivity analysis
Table 9 presents results of multi-way sensitivity analysis. In the best-case, the ICERs were <1x
GDP per capita and therefore very cost-effective. In the worst case, the CCTs were still costeffective as the 95% confidence intervals of the ICERs were < I$2409 (PMTCT uptake:
ICER=I$1175, 95% C.I. (1118-1235); PMTCT retention: ICER=I$2027, 95% C.I. (1893-2178).
4.3.4. Cost-effectiveness acceptability curves and willingness to pay for CCTs
We present the joint distribution of differences in costs and effects for PMTCT uptake in figure
2 and for PMTCT retention in figure 3. In both figures, all the data points (incremental costeffectiveness ratios) are in the northeast quadrant of the cost-effectiveness plane—thus the CCTs
increased both effectiveness and costs in all the resampled datasets. Furthermore, the clustering
of ICERs in the same part of the quadrant shows that the values of the ICERs from the resampled
datasets were close and did not greatly vary from the ICER estimate from the original trial data.
Based on the joint distribution of incremental costs and effects, we capture the uncertainty
surrounding the incremental cost-effectiveness of CCTs at different willingness-to-pay
thresholds in figure 4. This acceptability curve shows the level of uncertainty surrounding the
ICER estimate and the probability that the CCTs were cost-effective, compared to the control
group, for a given level of willingness-to-pay. Points B and F correspond to the ICER point
estimates3 reported in table 7 and all points on the solid black line in figures 2 and 3. These

3

The ICER point estimates in figures 2, 3, and 4 are slightly different from the ICERs in the main results (table 8).
This is because in resampling the original trial data 4000 times, each resampled dataset had its own ICER.
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points have 0.5 probabilities of being cost-effective. The steep slope and the rapid rise of the
curves (A to C and E to G) suggest small deviations from the original ICER estimate, and
therefore, a high degree of certainty associated with the ICERs.
In addition to showing a high degree of certainty surrounding the ICERs, figure 4 also shows that
the CCTs were cost-effective at many of the thresholds of willingness-to-pay proposed in this
study. For example, if the willingness-to-pay is I$2409 (3x GDP per capita in 2016), the
probability that the CCTs were cost-effective is almost 1. At a threshold of I$1205 (1.5x GDP
per capita in 2016), the probability that the CCTs were cost-effective is almost 1. At a threshold
of I$803 (1x GDP per capita in 2016), the probability that the CCTs were cost-effective in
increasing PMTCT uptake is almost 1 (point D), but for PMTCT retention the probability is
almost zero. At any threshold < I$570, the CCTs have no chance of being cost-effective.
5. Discussion
Uptake of PMTCT services in SSA remains low despite scale-up of Option B+ in the region
[106], posing challenges to global ambitions of eliminating MTCT of HIV. Coupled with
inadequate domestic funding and lack of growth in international financing towards the
HIV/AIDS response [181], [182], it is imperative to find innovative and cost-effective strategies
that can increase the uptake of the PMTCT services. We examined the cost-effectiveness of a
trial of one such strategy—small but increasing cash incentives aimed to increase PMTCT
uptake and PMTCT retention in the DRC. The findings suggest that the cash incentives were
cost-effective from the societal perspective. To our knowledge, this is the first study to evaluate

Therefore, figures 2, 3, and 4 present the mean of the ICERs while table 8 presents ICERs from the original trial
data. It is not unusual for ICERs from the original trial data and resampled datasets to differ slightly [180].
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the cost-effectiveness of cash incentives aimed to increase the uptake of PMTCT services and
retention in PMTCT care.
From the societal perspective, the estimated incremental cost of the cash incentives was I$85,
with corresponding ICERs of I$585 for PMTCT uptake and I$1081 for PMTCT retention. For a
willingness-to-pay threshold of 3x DRC GDP per capita in 2016 (I$2409), these estimates
suggest that the cash incentives were very cost-effective in increasing PMTCT uptake but costeffective in increasing PMTCT retention. In a sensitivity analysis, the cash incentives were the
main cost drivers and the intervention was still cost-effective even in the worst case.
The study’s finding that the cash incentives were cost-effective is consistent with reports from
previous studies which examined the cost-effectiveness of other strategies aimed at increasing
uptake of PMTCT services although some of the studies predate the Option B+ era. We
emphasize that literature on interventions aimed at increasing uptake of PMTCT services is
limited. Instead, the literature is replete with cost-effectiveness studies comparing different
treatment protocols (for example, no intervention vs Option A vs. Option B vs. Option B+) or
different HIV testing and counseling strategies [183]–[185]. For example, universal HIV testing
of all pregnant mothers during ANC clinics was cost-effective in multiple countries [186], as
were HIV rescreening late in pregnancy in South Africa [187] and couple counseling in Kenya
[188]. Evidence from studies of non-conventional models for the delivery of PMTCT services
suggests that these models are also cost-effective, although comparability is still limited because
of health outcomes used. The Futures Institute reported that low and high levels of integration of
PMTCT services with maternal, neonatal, and child health within antenatal care clinics in
Malawi, Uganda, and Mozambique were cost-effective [189]. The study reported health
outcomes using number of HIV infant infections averted over a period of 100 years [189].
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Similarly, the JSI Research and Training Institute, which used data from Kenya and reported
health outcomes using number of infant infections averted and QALYs gained, reported that
Civil Society Organizations delivered PMTCT services more cost-effectively than did public
health facilities [190]. Peer mentors like Mother2mothers—initially implemented in South Africa
and later scaled to other parts of SSA [191], [192]—increased uptake of PMTCT services,
improved health outcomes, and represent a good value for the money according to another report
by the JSI Research and Training Institute [193]. However, comparability of findings is limited
because the study had a longer analytic time horizon and was a cost-benefit analysis—that is, it
expressed incremental effectiveness in monetary terms [193].
This study contributes to a broader, although limited, literature on the cost-effectiveness of cash
incentives to improve individual/household behaviors and well-being. The findings from this
limited literature are mixed overall but suggest that the cash incentives are cost-effective in
resource-limited settings [194]–[196] or when the analytic time horizon is longer—for example
over a lifetime [197]. The lack of evidence that cash incentives are cost-effective is largely for
two reasons. First, the lack of comprehensive data about costs and effects. Second, not
considering the effects of the cash incentives more broadly [198], [199]. This is particularly true
for effects because the impact of the cash incentives is likely to go beyond the specific sector of
interest [198]–[201]. For example, in Malawi, cash incentives averted one HIV infection among
school going girls aged 13-22 years at a cost more than 15 times Malawi’s GDP per capita [202],
and therefore less cost-effective. However, the cash the incentives also increased retention of the
girls in school [202]. Thus, although less cost-effective when considered more narrowly (via the
lens of HIV financing only), the cash incentives could be cost-effective and make economic
sense when co-financing models (for example, including resources from education) are
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considered [203]. Given that this study did not include all the possible benefits of the cash
incentives, for example, increases in uptake of family planning services and improvements in
overall health-seeking behaviors, it is likely that the current study underestimates the costeffectiveness of the CCTs. Further, the evidence suggests that cash incentives are less-cost
effective in high-income countries perhaps because the size of the incentives relative to
household income is not large enough to be effective [204], [205], [206, p.]. On the other hand,
cash incentives do appear to be cost-effective in developing countries where the cash incentives
increased school enrollment and attendance and improved secondary school outcomes [194],
[195]. Cash incentives were also cost-effective in increasing household food security and child
development [196] and preventing undernutrition in emergency situations [171]. Therefore,
although the evidence is mixed, this study adds to the building evidence that cash incentives are
cost-effective and can be used to promote good social behaviors, particularly in resource-limited
settings like in many countries in SSA.
5.1. Limitations
This study has limitations. First, because the trial did not collect detailed data for each cost
component, there may be bias in the cost estimates. We relied on external sources, made a series
of assumptions, and imputed missing data to estimate the costs. However, recognizing that this
may have introduced bias [207], we conducted sensitivity analyses and the findings suggest that
the cash incentives were still cost-effective even in the worst of circumstances.
Second, we were unable to use traditional health outcome measures for incremental effectiveness
analysis like the number of DALYs [163] or HIV-infections averted. This is because participant
follow-up, which was up to six weeks post-partum, was not long enough to have definitive
results about the HIV status of infants in each trial arm. This limits the comparability of the
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study’s findings with other cost-effectiveness analysis studies. Despite the limitation, these
findings serve as a foundation for future cost-effectiveness studies that can incorporate final,
versus intermediate, health outcomes. Moreover, the success of PMTCT services in achieving
the desired goals begins with the uptake of the PMTCT services [108]–[110] and the findings
from this study suggest that the cash incentives increase PMTCT uptake and do so costeffectively.
Third, the thresholds based on GDP per capita have been criticized in the literature for not
reflecting the opportunity cost of local resources used in the interventions [164]–[166], as
recommended [208]. This suggests that most interventions deemed effective using these
thresholds, may not be cost effective if the thresholds reflected the opportunity cost of the local
resources used in the interventions. Furthermore, we emphasize that these thresholds based on
GDP per capita were developed for cost-effectiveness analyses using final health outcome like
DALYs averted or QALYs gained [163], and not intermediate outcomes like NNT. Noting these
limitations, we considered a more conservative threshold (1.5x DRC GDP per capita) in
uncertainty analysis and found that the cash incentives were still cost-effective. Moreover, results
from studies using thresholds based on GDP per capita continue to help inform policy. For
example, Option B+, an intervention already adopted and expanded by the DRC and many
countries in SSA was found to be cost-effective based on these thresholds [209]–[211].
5.2. Implications for future research
While these findings suggest that the cash incentives are cost-effective, additional research is
needed before any recommendations to scale-up the intervention can be made. First, we need to
understand the cost-effectiveness of the cash incentives using final health outcomes like DALYs
averted or life-years saved, as might be done in mathematical modeling studies. Such studies can
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also examine whether the cash incentives are still cost-effective in larger populations and with
different HIV profiles. Second, there is a need to understand whether the cash incentives can be
combined with other cost-effective strategies also aimed at increasing the uptake of PMTCT
services. This is important because the cash incentives, even if scaled widely, cannot overcome
all barriers preventing the uptake of PMTCT services. Overcoming barriers to uptake of PMTCT
services like stigmatization of people living with HIV and lack of partner support [118], [212]
would require other interventions, particularly those that are community-based. Several of these
interventions have shown effectiveness in increasing uptake of PMTCT services in Tanzania
[213], South Africa [214], [215], Nigeria [216], Malawi [217], Zimbabwe [218], and Uganda
[219]. Therefore, if these interventions are also cost-effective, future research should focus on
whether some of these interventions can be combined with the cash incentives.
6. Conclusion
Low uptake of PMTCT services is a challenge in SSA, with implications on global efforts of
realizing an HIV-free generation. Based on WHO’s thresholds for cost-effectiveness, conditional
cash transfers are cost-effective in increasing uptake of PMTCT services and retention in
PMTCT care in the DRC and similar settings. Additional research is needed to understand the
effectiveness and cost-effectiveness of the cash incentives using final health outcomes and in
larger populations before further scale-up of the intervention. Given that the cash incentives can
overcome financial, vs. social barriers like stigmatization, considerations to combine the cash
incentives with other cost-effective community-based strategies should also be made.
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Table 1: Definition of standard PMTCT care
HIV counseling and testing
HIV posttest counseling
CD4 cell count
Cotrimoxazole prophylaxis
AZT if CD4 cell count ≥350 cells/mm3 or triple ARV therapy if <350 cells/mm3*
Delivery in a health facility
Post-partum care, including counseling on infant feeding options
Nevirapine suspension for the infant
Cotrimoxazole prophylaxis for infants
DNA PCR and Serologic testing for infants
*Participants with CD4 cell counts <350 cells/mm3 were referred to an HIV clinic where they
received AZT. Source: Yotebieng et. al, 2016.
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Table 2: Included costs, societal perspective*
Sector
Type of impact
Formal healthcare sector
Health outcomes (effects)†
Uptake of PMTCT services
In PMTCT care six weeks' postpartum
Medical costs
Medications
Laboratory tests
Transportation of infant dried blood samples‡
Health facility deliveries
Post-delivery counseling
Labor (wages for clinical and support staff)
Overhead costs (utilities)
Capital costs (equipment)
Informal healthcare sector
Patient time costs
Peer/family support time costs
Patient transportation costs
Peer/family support transportation costs
*This table is based on recommendations by the second US Panel on Cost-effectiveness in
Health and Medicine [220] and not the World Health Organization. † The study had two primary
outcomes: uptake of PMTCT services and retention in PMTCT care. Uptake of PMTCT services
was defined as timely attendance (within 5 days) of all scheduled clinic visits from
randomization through 6 weeks’ postpartum and accepting all proposed services listed in box 1.
‡ Infant dried blood samples from all clinics participating in the study were transported to a
central laboratory in Kinshasa for DNA PCR testing.
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Table 3. Unit Costs, in I$2016
Cost component
Cash Incentives
Medications
AZT (mother)
ART (mother)
Cotrimoxazole (mother)
Nevirapine (infant)
Cotrimoxazole (infant)
Laboratory tests
CD4 count
DNA PCR (infant)
Transportation of DBS§
Health facility deliveries ‖
Delivery
Post-delivery counselling
Labor
Wages for clinical staff
Wages for support staff
Capital and overhead costs
Equipment
Utilities
Patient and peer/family support costs
Time
Transportation (varies by patient)

Unit of measurement
Per visit

Base case*
9-20‡

Lower bound†
9.00

Upper bound†
20.00

Reference
Trial data

Per dose (30 days)
Per dose (30 days)
Per dose (30 days)
Per dose (6 weeks)
Per dose (6 weeks)

7.48
7.83
1.08
11.63
4.14

3.74
3.92
0.51
5.82
2.07

10.87
12.58
3.25
17.45
6.21

[128]
[128]
[221]
[128]
[222]

Per test
Per test
Per sample

15.3
45.28
2.33

7.65
22.64
1.16

22.95
67.92
3.49

[138]
[138]
[223]

Per delivery
Per session

281.31
0.47

28.13
-

843.92
-

[224]
[184]

Per visit
Per visit

3.32
1.61

-

-

[225]
[226]

Per visit
Per visit

1.70
0.90

-

-

[227]
[138]

Per day
Per visit

3.00
0.19-5.75

1.50
0.19

4.49
5.75

[141]
Trial data

*Base-case values were used to derive total mean costs in each trial arm for the main analysis. †Lower and upper bounds were created from 95% confidence intervals of the
base case unit costs. If a base unit cost did not have a 95% confidence interval, the base unit cost was decreased by 50% to derive the lower bound and increased by 50% to
derive the upper bound unit cost. The lower and upper bounds were individually used in one-way deterministic sensitivity analysis and in combination to create best- and
worst-case scenarios in multi-way sensitivity analysis. ‡This range in USD is 5-11. §DBS (dry blood sample) was transported from the study clinics to a central laboratory in
Kinshasa. ‖ Health facility deliveries: as the trial did not collect data on facility type, delivery method, and employment status, we made the following assumptions. For the
base case unit cost, we assumed that all study participants delivered in secondary health centers, the baby was delivered normally and that all participants were unemployed.
For the lower bound unit cost, we assumed that all study participants delivered in primary health centers, delivery was normal and that they were all were unemployed. For
the upper bound unit cost, we assumed that all study participants delivered in primary health centers, delivery was through cesarean section and that all study participants
were employed.
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Table 4: Effectiveness of conditional cash transfers
PMTCT Uptake†
PMTCT Retention‡
Relative risk 95% C.I.
Relative risk 95% C.I.
Intervention
1.276**
[1.09,1.50]
1.12*
[1.01-1.23]
Age
1.003
[0.99,1.02]
0.99
[0.99,1.00]
Marital status (ref: not married)
Married
0.975
[0.83,1.15]
1.00
[0.89,1.13]
Education (ref: no education)
Primary
0.916
[0.73,1.15]
1.04
[0.90,1.21]
Secondary or higher
1.396**
[1.14,1.71]
1.10
[0.94,1.29]
Wealth (ref: first quintile (poorest))§
Second quintile
0.939
[0.74,1.19]
0.98
[0.83,1.15]
Third quintile
1.07
[0.86,1.331]
1.02
[0.87,1.19]
Fourth quintile
0.91
[0.69,1.20]
0.99
[0.84,1.16]
Fifth quintile (richest)
1.092
[0.85,1.40]
0.99
[0.84,1.17]
Transport mode (ref: other means)
Walk
1.209*
[1.04,1.40]
1.091
[0.99, 1.20]
Constant
0.423***
[0.27,0.66]
0.80
[0.61,1.04]
Observations
433
433
Abbreviations: PMTCT, prevention of mother-to-child transmission of HIV.
* p<0.05, ** p<0.01, *** p<0.001. † PMTCT uptake was defined as meeting the following conditions:
attended all scheduled clinic visits from enrollment date through 6 weeks' postpartum, gave birth in a study
clinic, accepted all proposed services including providing blood samples for CD4 cell count and dried blood
spot sample for early infant diagnosis of HIV at six weeks' postpartum. ‡ PMTCT retention was defined as
being in HIV care at 6 weeks’ postpartum regardless of the reason for missing any prior scheduled visits
[115]. §Wealth quintiles were created from twelve variables using principal components analysis (PCA). The
following variables were included in the PCA: maternal education, average number of household members
per room, number of beds in the household, water source for the household (private or communal) and
cooking fuel type (electrical stove, or firewood/charcoal). Ownership status of the following durable assets
was also used in the PCA: radio, television, mobile telephone, refrigerator, and car [115].
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Table 5: Number-needed-to-treat (NNT), and steps for deriving the NNT
PMTCT uptake PMTCT retention
Steps
Predicted mean absolute risk in the treatment group
0.68
0.81
Predicted mean absolute risk in the control group
0.53
0.72
Calculated absolute risk reduction*
0.14
0.08
Number-needed-to-treat (NNT) †
7.01 (6.69-7.57)‡ 12.11 (11.55-12.81)‡
The values in the table may not be exact due to rounding *We subtracted the predicted mean absolute
risks between the intervention and control groups to derive the absolute risk reduction. †We took the
reciprocal of the absolute risk reduction to derive the NNT. ‡These numbers represent the 95%
confidence intervals and were generated using Fieller’s method.

104

Table 6. Mean cost per participant, by trial arm (2016 I$)
Intervention
Control
Cost
Mean
95% C.I.
Mean
95% C.I.
p-value*
Cash Incentives
51.10
[48.56-53.64]
0.31†
[0.00-0.93]
<0.001
Medications
AZT (mother)
18.27
[16.19-20.34]
17.40
[15.33-19.47]
>0.1
ART (mother)
13.45
[11.18-15.73]
11.96
[9.81-14.1]
>0.1
Cotrimoxazole (mother)
5.04
[4.79-5.29]
4.86
[4.58-5.13]
>0.1
Nevirapine (infant)
10.12
[9.6-10.65]
9.43
[8.82-10.05]
<0.1
Cotrimoxazole (infant)
3.91
[3.78-4.04]
3.68
[3.51-3.86]
<0.05
Laboratory tests
CD4
35.99
[33.98-38]
31.66
[29.65-33.67]
>0.1
DNA PCR (infant)
30.61
[27.75-33.46]
24.21
[21.17-27.24]
<0.01
Transportation of dry blood sample 1.57
[1.43-1.72]
1.24
[1.09-1.4]
<0.01
Health facility deliveries
265.68
[257-274.36]
250.19
[238.33-262.05] <0.05
Post-delivery counselling
0.44
[0.43-0.46]
0.42
[0.4-0.44]
<0.05
Labor
Wages for clinical staff
11.21
[10.63-11.8]
10.80
[10.18-11.41]
>0.1
Wages for support staff
4.97
[4.71-5.23]
4.79
[4.52-5.06]
>0.1
Capital and overhead costs
Equipment
5.74
[5.44-6.04]
5.52
[5.21-5.84]
>0.1
Utilities
3.04
[2.88-3.2]
2.93
[2.76-3.1]
>0.1
Patient and peer/family support costs
Patient and family support’s time
35.96
[34.74-37.18]
34.02
[32.73-35.31]
<0.05
Transportation (varies by patient)
18.83
[17.22-20.43]
18.00
[16.28-19.73]
>0.1
Total cost
515.94
[500.37-531.51] 431.43
[413.75-449.11] <0.001
*The p-values were from tests of medians based on the Wilcoxon rank sum tests. †The mean cost of cash
incentives in the control group is not zero because one randomly selected participant in the control group received
an incentive of I$ 82 (or US$ 45). We truncated the confidence interval for the cash incentives in the control group
at zero; the actual confidence interval was [-0.31-0.93].
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Table 7. Adjusted costs of conditional cash transfers, I$2016
Cost
95% C.I.
Intervention
84.77***
[58.72,110.82]
Age
-1.68
[-3.64,0.28]
Marital status (ref: not married)
Married
22.8
[-9.12,54.64]
Education (ref: no education)
Primary
-1.97
[-29.94,26.00]
Secondary or higher
-0.13
[-56.11,55.84]
Wealth (ref: first quintile (poorest))†
Second quintile
-8.90
[-45.27,27.47]
Third quintile
-1.63
[-33.14,29.89]
Fourth quintile
-28.90
[-70.35,12.47]
Fifth quintile (richest)
-28.80
[-70.33,12.70]
Transport mode (ref: other means)
Walk
13.00
[-13.45,39.48]
Constant
469.00*** [408.31,529.71]
Observations
433
* p<0.05, ** p<0.01, *** p<0.001. †Wealth quintiles were created from twelve variables using
principal components analysis (PCA). The following variables were included in the PCA:
maternal education, average number of household members per room, number of beds in the
household, water source for the household (private or communal) and cooking fuel type
(electrical stove, or firewood/charcoal). Ownership status of the following durable assets was
also used in the PCA: radio, television, mobile telephone, refrigerator, and car.
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Table 8. Incremental cost-effectiveness ratios of conditional cash transfers
PMTCT Uptake
PMTCT Retention
Estimate
95% C.I.
Estimate
95% C.I.
Incremental effectiveness (NNT)*
7.01
[6.69-7.57]
12.11
[11.55-12.81]
Incremental cost (I$)
84.77
[58.72-110.82]
84.77
[58.72-110.82]
ICER*†
594.54
[567.04-624.26]
1026.23
[959.99-1101.26]
Abbreviations: PMTCT, prevention of mother-to-child transmission of HIV; NNT, number-needed-to-treat);
ICER, incremental cost-effectiveness ratio.
*Confidence intervals generated using Fieller's theorem. †At a cost-effectiveness threshold 3x DRC GDP per
capita in 2016 (I$2409), the conditional cash transfers were cost-effective.
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Table 9. Multi-way sensitivity analysis of the cost-effectiveness of CCTs: best and worst cases
PMTCT Uptake
PMTCT Retention
ICER
95% C.I.*
ICER
95% C.I.*
Base case
594.54
[567.04-624.26]
1026.23
[959.99-1101.26]
Best case†
219.78
[210.01-230.37]
379.36
[355.36-406.62]
Worst case‡
1174.51
[1118.11-1235.32]
2027.34
[1893.95-2178.09]
Abbreviations: PMTCT, prevention of mother-to-child transmission of HIV; ICER, incremental costeffectiveness ratio.
*The 95% confidence intervals generated using Fieller's theorem. †The best case was created by combining
lower-bound unit costs of the key cost components. ‡ Worst-case scenario created by combining upper-bound
unit costs of the key components. At a cost-effectiveness threshold 3x DRC GDP per capita in 2016 (I$2409),
the conditional cash transfers were still cost-effective.
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Panel 1: PMTCT uptake
Base ICER=I$595
Cash Incentives
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Panel 2: PMTCT retention
Base ICER=I$1026
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Figure 1: One-way sensitivity analysis of changes in unit costs on the ICER
This figure shows how ICERs respond to changes in unit costs of one variable while holding
costs of other variables at their baseline values. The thick vertical lines in the graphs correspond
to the ICERs derived using unit costs in the base case. The labels at the end of each bar are the
lower and upper bound unit costs used in the sensitivity analysis. The length of the bar on either
side of the vertical line represents the new ICER associated with each of the unit costs, and its
value can be read from the x-axis. Cash incentives followed by health facility deliveries were the
most influential variables in determining the ICER
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98.72
65.81
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32.91

Base ICER=I$585
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Figure 2: Differences in costs and effects, PMTCT uptake
This figure shows a joint distribution of differences in costs and effects associated with uptake of PMTCT services. A total 4000
replications of the original trial data were performed, and each dot in the graph represents one incremental cost-effectiveness ratio.
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Figure 3: Differences in costs and effects, PMTCT retention
This figure shows a joint distribution of differences in costs and effects associated with retention in PMTCT care. A total 4000
replications of the original trial data were performed, and each dot in the graph represents one incremental cost-effectiveness ratio.
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Figure 4: Society’s willingness-to-pay for uptake of PMTCT services and retention in PMTCT care
This figure shows the uncertainty surrounding the mean incremental cost-effectiveness ratios (ICER) of the cash incentives with respect
to PMTCT uptake and PMTCT retention. The steep slopes of the curves suggest a high degree of certainty surrounding the mean ICERs.
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Appendices

Appendix B1: Overview of search terms for cost estimates
"prevention of mother-to-child transmission of HIV"
OR "prevention of mother-to-child transmission" OR
"PMTCT of HIV" OR "PMTCT" OR "vertical
transmission of HIV" OR "Maternal and infant
interventions in HIV" OR "prevention of vertical
transmission of HIV" OR "mother-to-child
transmission of HIV" OR "vertical transmission of
HIV" OR "HIV"

AND
"cost" OR "cost analysis" OR "cost-effectiveness" OR
"cost-utility" or "economic evaluation" or "cost-benefit
analysis"

The study used these terms to search for cost estimates in
Google, Google Scholar, Medline, and PubMed
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Appendix B2: Candidate cost sources
Costs
Cost source

Country

Currency Estimate
and year

Original Unit

Recurrent costs
Wages
Clinical staff*

DRC

2016 USD 145.00

Arise Project

DRC
Zambia
Burkina
Faso
Zimbabwe

Scott et al.
Maheswaran et al
Tagar et al.
Tagar et al.
Tagar et al.
Tagar et al.
Jain et al.
Binagwaho et al.
Bratt et al.

Zambia
Malawi
Malawi
Ethiopia
Zambia
Rwanda
Uganda
Rwanda
Zambia

2011 USD
2014 USD
2011 USD
2011 USD
2011 USD
2011 USD
2012 USD
2009 USD
2008 USD

Toure et al.
Bikilla et al.
Jain et al.
Dutta et al.
Ishikawa et al.
Scott et al.
Jain et al.

Rwanda
Ethiopia
Uganda
LIC
Zambia
Zambia
Uganda

2009 USD
2005 USD
2012 USD
2014 USD
2013 USD
2011 USD
2012 USD

Support staff†
Lab tests‡
CD4 count

DNA PCR

IntraHealth
International
Becker-Dreps
Adebeyi & Waldron
Mccoy et al.

Common
Derived
Unit

Estimate
common
unit

Ref

per nurse per m per visit

0.33

[228]

2005 USD 1.15
2011 USD 1.32
2006 USD 204.50

per hour
per visit
per visit
per visit
per nurse per m per visit

0.58
1.32
0.46

[225]
[137]
[229]

2012 USD 1.10

per visit

1.10

[230]

0.52
1.00
365.00
117.00
386.00
806.00
240.00
3.30
0.41

per patient per
m
per nurse visit
per visit
per nurse per m
per nurse per m
per nurse per m
per nurse per m
per nurse per m
per 18 m
Per visit

per visit
per visit
per visit
per visit
per visit
per visit
per visit
per visit
Per visit

1.04
1.00
0.83
0.27
0.88
1.83
0.55
0.55
0.41

[221]
[139]
[231]
[231]
[231]
[231]
[138]
[184]
[226]

11.20
6.92
8.50
5.40
5.00
10.60
42.00

per test
per person year
per test
per person-year
per test
per test
per test

per test
per test
per test
per test
per test
per test
per test

11.20
3.46
8.50
2.70
5.00
10.60
42.00

[232]
[233]
[138]
[234]
[235]
[221]
[138]
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Appendix B2: Candidate cost sources
Costs
Cost source

Medications‡
HIV drugs (mothers) §
Zidovudine

Zidovir

Zidolam-N
(AZT/3TC/NVP)

Zidolam (AZT/3TC)

Efavirenz (EFV)

Cotrimoxazole
(mothers)

Country

Currency Estimate
and year

Original Unit

Ishikawa et al.
Fasawe et al.
Khamadi et al.

Zambia
Malawi
Kenya

2013 USD 10.00
2010 USD 32.50
2007 USD 21.50

per test
per test
per test

CHAI reference
prices
Perriens et al.
CHAI reference
prices
Perriens et al.
CHAI reference
prices
Dutta et al.
Perriens et al.
CHAI reference
prices
Scott et al.
Perriens et al.
CHAI reference
prices
Dutta et al.
Scott et al.
Perriens et al.
Fasawe et al.

LMIC

2016 USD 6.30

LMIC
LMIC

Estimate
common
unit
10.00
32.50
21.50

Ref

60 tablets per m per m

6.30

[128]

2012 USD 121.00
2016 USD 6.30

per patient per y per m
60 tablets
per m

10.08
6.30

[236]
[128]

LMIC
LMIC

2012 USD 140.00
2016 USD 8.20

per patient per y per m
60 tablets per m per m

11.67
8.20

[236]
[128]

LMIC
LMIC
LMIC

2014 USD 96.00
2012 USD 118.00
2016 USD 6.60

per patient y
per m
per patient per y per m
60 tablets per m per m

8.00
9.83
6.60

[234]
[236]
[128]

Zambia
LMIC
LMIC

2011 USD 8.41
2012 USD 140.00
2016 USD 3.80

per patient m
per m
per patient per y per m
30 tablets per m per m

8.41
11.67
3.80

[221]
[236]
[128]

LIC
Zambia
LMIC
Malawi

2014 USD
2011 USD
2012 USD
2010 USD

per patient y
per patient m
per patient per y
per m

per m
per m
per m
per m

7.75
4.30
15.25
0.40

[234]
[221]
[236]
[209]

Scott et al.

Zambia

2011 USD 0.93

per patient m

per m

0.93

[221]

93.00
4.30
183.00
0.40

Common
Derived
Unit
per test
per test
per test

[235]
[209]
[223]
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Appendix B2: Candidate cost sources
Costs
Cost source

Country

Currency Estimate
and year

Original Unit

Common
Derived
Unit

Estimate
common
unit

Ref

HIV drugs (infants)
Nevirapine

LMIC

2016 USD 7.00

per infant m

6w

9.80

[128]

Zambia
Uganda
Zimbabwe
LMIC
Rwanda
Zambia
DRC

2003 USD
2011 USD
2008 USD
2006 USD
2009 USD
2015 USD
2016 FC

6.00
11.20
4.50
0.03
12.30
0.20
15000.00

6w
6w
6w
6w
6w
6w
per delivery

8.40
11.20
6.30
1.26
1.42
0.60
15000.00

[237]
[185]
[238]
[222]
[184]
[239]
[224]

Kongo Emmanuel

DRC

2016 FC

25000.00

per delivery 25000.00

[224]

Kongo Emmanuel

DRC

2016 FC

300000.00

per delivery 300000.00

[224]

Kongo Emmanuel

DRC

2016 FC

50000.00

per delivery 50000.00

[224]

Kongo Emmanuel

DRC

2016 FC

100000.00

per delivery 100000.00

[224]

Kongo Emmanuel

DRC

2016 FC

450000.00

per m
per 6 w
per m
per d
per y
per dose
per delivery
(normal, PHC,
unemployed)
per delivery
(dystocia, PHC,
unemployed)
per delivery
(cesarean, PHC,
unemployed)
per delivery
(normal, PHC,
employed)
per delivery
(dystocia, PHC,
employed)
per delivery
(cesarean, PHC,
employed)

per delivery 450000.00

[224]

CHAI reference
prices
Maclean et al.
Kuznik et al.
Ciaranello et al.
Cotrimoxazole (infants) WHO
Binagwaho et al.
Chitah
Health facility
Kongo Emmanuel†
deliveries‖
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Appendix B2: Candidate cost sources
Costs
Cost source

Counseling after
delivery

Country

Currency Estimate
and year

Original Unit

Kongo Emmanuel

DRC

2016 FC

150000.00

Kongo Emmanuel

DRC

2016 FC

40000.00

Kongo Emmanuel

DRC

2016 FC

870000.00

Kongo Emmanuel

DRC

2016 FC

200000.00

Kongo Emmanuel

DRC

2016 FC

100000.00

Kongo Emmanuel

DRC

2016 FC

950000.00

The World Bank
The World Bank
The World Bank
The World Bank
The World Bank
The World Bank
Gibbons et al.

DRC
DRC
DRC
DRC
DRC
DRC
DRC

2005 USD
2005 USD
2005 USD
2005 USD
2005 USD
2005 USD
2008 USD

3.00
10.00
5.00
15.00
10.00
125.00
131.40

Binagwaho et al.

Rwanda

2009 USD 0.16

per delivery
(normal, SHC,
unemployed)
per delivery
(dystocia, SHC,
unemployed)
per delivery
(cesarean, SHC,
unemployed)
per delivery
(normal, SHC,
employed)
per delivery
(dystocia, SHC,
employed)
per delivery
(cesarean, SHC,
employed)
per delivery
per delivery
per delivery
per delivery
per delivery
per delivery
per delivery
(cesarean)
per session

Common
Derived
Unit
per delivery

Estimate
common
unit
150000.00

Ref

[224]

per delivery 40000.00

[224]

per delivery 870000.00

[224]

per delivery 200000.00

[224]

per delivery 100000.00

[224]

per delivery 950000.00

[224]

per delivery
per delivery
per delivery
per delivery
per delivery
per delivery
per delivery

3.00
10.00
5.00
15.00
10.00
125.00
131.40

[240]
[240]
[240]
[240]
[240]
[240]
[241]

per session

0.16

[184]
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Appendix B2: Candidate cost sources
Costs
Cost source

Transportation of DBS Khamadi et al.
Utilities
Adebeyi & Waldron
Menzies et al.
Menzies et al.

Opportunity cost of
time #
Capital costs**
Equipment (Office &
Medical)

Jain et al.
Galarraga et al.
Maheswaran et al
US Department of
State
Adebeyi & Waldron
Menzies et al.
Menzies et al.

Country

Currency Estimate
and year

Kenya
Zambia
5 PEPFAR
countries¶
5 PEPFAR
countries¶
Uganda
Benin
Malawi
DRC

Estimate
common
unit
0.50
3.15
0.40

Ref

2007 USD 0.50
2011 USD 3.15
2009 USD 4.85

Common
Derived
Unit
per sample
per sample
per visit
per visit
per y, minimum per visit

2009 USD 14.34

per y, mean

per visit

1.19

[227]

2012 USD
2009 USD
2014 USD
2016 FC

per m
per y
per visit
per day

per visit
per visit
per visit
per day

0.50
1.76
0.48
1680.00

[138]
[242]
[139]
[141]

per visit
per visit
per y, minimum per visit

2.01
0.58

[137]
[227]

per y, mean

1.72

[227]

0.50
21.10
0.48
1680.00

Zambia
2011 USD 2.01
5 PEPFAR¶ 2009 USD 6.97
countries
5 PEPFAR 2009 USD 20.61
countries¶

Original Unit

per visit

[223]
[137]
[227]

Abbreviations: DRC (Democratic Republic of the Congo); LMIC (Low-and-middle income countries); PCR (polymerase chain reaction); USD (United
States Dollar); FC (Congolese Francs); WHO (World Health Organization); CHAI (Clinton Health Access Initiative); PEPFAR (Presidential Emergency
Plan for AIDS Relief); PHC (primary health center); SHC (secondary health center). * We assumed that a patient was seen by one clinical staff (assumed
to be a nurse) at each antenatal care (ANC) visit. We further assumed that a nurse takes care of 20 patients in a day and divided the monthly wage of a
nurse by 22 because we also assumed that, as in many countries, normal work hours exclude weekends. The study by Becker-Dreps [225] provided an
hourly cost estimate, so we assumed that each visit or interaction between the nurse and the patient lasted for 30 minutes and divided the hourly estimate
by 2. † We assumed that one support staff was adequate at each ANC visit. ‡ Goods and services classified as tradable—goods that can be imported or
exported[122], [124]; the rest were classified as non-tradable. § To estimate monthly costs for drugs, we divided annual costs by 12 or multiplied daily
costs by 30. We assumed 15% for shipping and handling of the drugs [135] which we added to the estimates published by CHAI or Medicines Sans
Frontier (MSF). We did not add the shipping and handling costs to estimates from peer-reviewed literature because these were assumed to have been
included in the studies. ‖Estimates in local currency for health facility deliveries were not available, except for one study by Emmanuel Kongo [224]
which did not indicate when the estimates were collected. So, we assumed that the estimates were collected in 2015—one year before the study was
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Appendix B2: Candidate cost sources
Costs
Cost source

Country

Currency Estimate
and year

Original Unit

Common
Derived
Unit

Estimate
common
unit

Ref

published. ¶ The 5 PEPFAR countries were Uganda, Nigeria, Botswana, Ethiopia, and Vietnam. # We assumed that both the patient and their support
spent one day traveling and receiving (waiting plus actual interaction with a nurse) health care services at the clinic and quantified the cost of this time in
terms of lost wages or earnings. Because there was no data on earnings, we assumed that the patient and her support each lost the equivalent of the
statutory minimum wage (1680 Congolese Francs) for the DRC[141], [243], in 2016.
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Appendix B3: Analytic decisions and recommendations for conducting cost-effectiveness analyses
In this appendix, we outline a series of analytic decisions for estimating economic costs in the current study which were largely
informed by CEA recommendations by WHO under the Cost Effectiveness and Strategic Planning[122], [124]. For completeness, we
also present recommendations from two other organizations: The World Bank under the Disease Control Priorities Project (DCPP)
[244], [245] and The US Panel on Cost-effectiveness in Health and Medicine[220], [246].
Appendix B3: Recommendations for cost analysis and analytic decisions
Analytic
decision

Concept

Recommendations

Perspective

This is the viewpoint
for conducting a CEA.
Examples include:
societal, payer
(including donor,
employer, insurer,
and/or government),
healthcare, clinical
provider, or patient.

WHO: The study can be conducted from
multiple perspectives, but the societal
perspective should be primary. The
societal perspective means that all costs
associated with an intervention must be
valued, regardless of who is paying for
the intervention or service [122]. The
rationale for this approach is that health
and consumption of healthcare services
contribute to social welfare [122].

Debate/commentary

While many experts do not disagree with
using the societal perspective as the
primary perspective in CEA, they disagree
on the extent of the societal perspective
[247]. This is because including every
aspect of the society affected by a health
intervention may be burdensome to the
analyst (thereby violating the “rule of
reason”), particularly for interventions
which extend survival or improve the
quality of life. Additionally, while some
experts do not agree with including future
health-unrelated consumption or
World Bank/DCPP: The primary
perspectives are the donor or partner and productivity benefits or losses, the
position and guidance from other panels
beneficiary (e.g., patient) perspective,
have been evolving on this matter. For
although other perspectives like an
example, the first US Panel (1996) on
implementer’s may also be specified
CEA recommended excluding
[245]. The rationale is that the donor

Decision
implemented
We used a societal
perspective which
was limited to the
inclusion of
transport costs and
the opportunity
cost of time for
both the patient and
her support.
Productivity costs
were not included
because the RCT of
the CCTs was not
powered to
estimate effects of
the CCTs on
averting new HIV
infections or
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Appendix B3: Recommendations for cost analysis and analytic decisions
Analytic
decision

Concept

Recommendations

Debate/commentary

Decision
implemented

and the beneficiary of an intervention or
program face different costs and an
intervention which is cost-effective from
the beneficiary’s perspective may not be
cost-effective from the donor’s
perspective [245].

productivity losses associated with an
illness because such costs will have been
captured in measures of quality life [246].
However, the second US Panel (2016)
says that productivity gains or losses
should be included whenever it is possible
because there is no evidence suggesting
that the quality of life measures reflect the
productivity costs [220].

quality of life
through increased
survival.

Many low-income countries, like the
DRC, do not have properly functioning
health systems or adequate healthcare
infrastructure which pose barriers to
accessing healthcare services[250], [251].
The trial of the CCTs was borne as an
effort to help overcome barriers (e.g.,
transport costs) to accessing PMTCT
services.

We included both
direct and indirect
costs.

US Panel: CEA studies must be
conducted from two perspectives:
healthcare and societal perspectives
[220].
Cost
components

This decision is about
which cost
components to include
in the analysis. The
question is: should the
analysis include direct
(health-related) costs
only or direct and
indirect (healthunrelated) costs?

WHO: Include both direct and indirect
costs. The rationale is that costs like
caregiving, travel time, and waiting time
need to be valued as they can determine
whether an intervention is effective or
whether people will seek healthcare
services. Additionally, health and
healthcare also affect families’
consumption of other goods and
services, either immediately or in the
future[122], [124].
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Analytic
decision

Concept

Recommendations

Debate/commentary

Decision
implemented

The decision about price levels is often
confused with the decision of currency
choice[124], although in many cases the
international prices are the US$ or the I$
(international dollar). Methods for
deriving I$ are described below in a
discussion of tradable and non-tradable
and currency choice.

We used
international price
levels (in I$)
because the results
of the CEA might
also be relevant to
other countries,
particularly those
in Sub-Saharan
Africa, where

World Bank/DCPP: Include direct costs
only. The World Bank assumes that a
properly functioning health system,
defined as a health system that does not
impose additional costs on consumers, is
in place[244]. Furthermore, because
some of the indirect costs can be higher
than the cost of an intervention, some
interventions may erroneously be
deemed to be not cost-effective[244],
[248].

US Panel: Include both direct and
indirect costs. The rationale is the same
as with WHO[249].
Price level

This refers to whether
resources consumed
by the intervention
should be valued at
international or local
prices.

WHO: Two recommendations are made
by the WHO. First, to value the cost of
an intervention using local prices when
detailed cost data about the intervention
have been collected. Furthermore, to use
local prices when the intervention is
more local that international
comparisons are not necessary or
meaningful [122], [124]. Second, to
value the costs of the intervention at
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Analytic
decision

Concept

Recommendations

Debate/commentary

international prices. The rationale is that
the use of international prices can
facilitate comparison of results from
multiple studies across countries [122],
[124].

Decision
implemented
mother-to-child
transmission of
HIV remains a
challenge.

World Bank/DCPP: Like WHO, the
recommendation is to value the costs of
an intervention at international prices.
The rationale is also to facilitate
comparison of results from multiple
studies across countries[244].
Distinguishing
between
tradable vs.
nontraded
goods.

Tradable goods—for
example,
medications—are
those goods that can
be imported or
exported while nontradable goods (for
example, labor) are
those that are produced
locally and cannot be
imported or exported
[122], [124].

WHO: Tradable goods should be
distinguished from non-tradable goods.
The rationale is that these goods must be
costed differently to reflect the correct
value of the good, otherwise nontradable goods will be undervalued if
they are treated like tradable goods in
countries with higher purchasing power
[122], [124].

World Bank/DCPP: Distinguish
between tradable and non-tradable

The difference between the WHO and
World Bank/DCPP recommendations is in
the valuation of non-tradable goods.
According to the World Bank, if the cost
of a non-tradable good is in local
currency, then it must be converted to
US$ using the nominal (official) exchange
rate of that country’s local currency to the
US$. s that if the cost estimate of a nontradable good (e.g., buildings) is being
extrapolated from another setting with the
estimate already in US$, then no further
conversion is required. On the other hand,

We distinguished
between tradable
and non-tradable
goods.
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Analytic
decision

Concept

Recommendations

Debate/commentary

goods. The rationale is that tradable
(imported) goods are already in US$
while the cost of non-tradable goods
must be converted to US$ using
exchange rates[244].

the WHO recommendation is that all nontradable goods should be converted using
purchasing power parity (PPP)—the
number of units of a local currency
required to buy the same quantities of
goods and services as one US$ would do
in the United States[122]. The unit cost of
goods and services valued this way is the
international dollar (I$) and 1I$=1US$.
WHO also recommends that non-tradable
goods quoted in US$ should be converted
using the ratio of the PPP conversion
factor to the official exchange rate of that
country to the USD in the year of the cost
estimate. Thus, using the PPP exchange
rates eliminates price differences when
converting or transferring costs across
countries[123], [124]. The World Bank
argues against using the PPP because the
I$ is hypothetical and is not informative of
how much an intervention costs which is
important for budgeting purposes[244].

US Panel: Not discussed

Currency
choice

This refers to the
choice of currency for
reporting costs. This is
particularly important

WHO: 1) When the analyst has decided
to use international price levels and to
distinguish between tradable and nontradable goods, the recommendation is

While both the US$ and I$ may facilitate
international comparisons of results from
different studies, the World Bank notes
that the I$ is hypothetical and is not

Decision
implemented

We used I$
because, as argued
by the WHO, the
US$ only tells you
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Analytic
decision

Concept

Recommendations

Debate/commentary

Decision
implemented

as this study draws
estimates from
multiple sources with
the cost estimates in
different currencies.
Furthermore, the
choice of currency is
informed by two
analytic decisions
presented above: price
levels and
distinguishing between
tradable and nontradable goods.

to use I$ which is derived when the PPP
exchange rate is used (see discussion on
tradable vs. non-tradable goods). The
rationale is that using the PPP exchange
rates eliminates price differences when
converting or transferring costs across
countries [122], [124].

informative of how much an intervention
costs and is not relevant to decision
makers interested in budgeting or
expanding interventions[244]. But the
argument by WHO is that, in many cases,
the I$ accurately reflects what people can
purchase given a certain amount of
resources and the US$ fails to convey this
information.

the cost of an
intervention but it
does not tell you its
value.

Year for
This refers to the year
reporting costs. for reporting results of
the CEA

This varies from study to study and
depends on the analyst’s assessment of
what the aims of the CEA are, so there
are no clear guidelines on which year to
use.

For the current study, there are three
options: 1) 2013: Start date of the RCT of
the CCTs in the DRC; 2) 2015: End date
of the RCT in the DRC; and 3) 2016: Year
for which the most current data for
inflation adjustment and currency
conversion are available.

We used 2016 as
the base year
because it is the
year for which the
most recent
conversion data
were available.

World Bank/DCPP: To use the US$.
The rationale is that the US$ is
informative of how much an
intervention actually costs[244].
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Analytic
decision

Concept

Recommendations

Debate/commentary

Decision
implemented

Inflation
adjustment

Adjusting for inflation
removes the effect of
price changes and is
necessary when the
original cost data are
reported in different
years. Inflation
adjustment will allow
us to obtain estimates
in a constant currency.
Thus, the data from
years prior to the
chosen year will be
inflated while data
from later years will
be deflated.

WHO: Inflation adjustment to be done
using the GDP (gross domestic product)
deflator—an index number comparing
real GDP to nominal GDP. The GDP
deflator is recommended because it
covers price changes in a broad range
(almost everything) of economic
activity, including health sector costs
[122], [124], [252].

The main problem with the GDP deflator
is that in many low-income countries, like
the DRC, it fails to account for
heterogeneity among sectors and can lead
to wrong conclusions[253]. Although the
medical CPI is recommended, it is not
available for the DRC.

We adjusted for
inflation using the
GDP deflator as it
is the only
recommended
inflationadjustment method
which is readily
available.

When transferring
costs across time and
space, the order in
which inflation

WHO: Adjust for inflation before
applying exchange rates. The rationale
is that inflation in countries like the
DRC also depends on exchange rates,

The issue of whether inflation adjustment
is done before currency conversion is
almost a settled issue.

We first adjusted
for inflation before

Order for
inflation
adjustment and

World Bank/DCPP: Not discussed

US Panel: Inflation adjustment to be
done using the medical price
index[249]. The rationale is that, unlike
the general consumer price index (CPI),
the medical price index more accurately
reflects changes in prices in the
healthcare sector as it is specific to that
sector.
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Analytic
decision

Concept

Recommendations

exchange rate
application

adjustment and
exchange rates are
applied can affect the
eventual cost estimates
and whether an
intervention is costeffective.

and because of weaker currencies, the
inflation rate is much higher than in
developed countries. This means that
adjusting for inflation after currency
conversion will more likely overvalue
non-tradable goods[123].

Debate/commentary

Decision
implemented
applying exchange
rate conversion.

Julia Fox-Rushby, who has published
some of the CEA guidelines by the
World Bank, also recommend adjusting
for inflation before applying exchange
rates[254].
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Appendix B4: Fieller’s theorem for estimating confidence intervals for incremental costeffectiveness ratios.
Note: This appendix draws heavily from Glick, 2014.
Fieller’s method is a parametric method for estimating confidence intervals for ratios like the
incremental cost-effectiveness ratio (ICER). Compared to other parametric methods such as the
normal distribution interval, Fieller’s method has one advantage: the method takes into account
the skewness of the ratio as it does not require the distribution of the ICER to be normal or
symmetrical [131], [159], [162]. Briefly, the parametric Fieller’s method proceeds as follows: let
the bivariate normal distribution of the difference in mean costs and effects be represented by the
expression RQ-C with a mean of zero [131]. In this expression, R=C/Q and Q is the difference in
the mean effect and C is the difference in the mean cost [131]. Glick (2015) notes that when this
expression is standardized using its standard error and setting it equal to a critical t-value, the result
is a quadratic equation in R. If we take the square root of the quadratic equation in R, which also
includes the Pearson correlation coefficient (ρ) between C and Q, we obtain the lower and upper
confidence limits of the ICER [131]. The confidence intervals are as follows:
𝐿𝑜𝑤𝑒𝑟 𝐿𝑖𝑚𝑖𝑡
[CQ − (𝑡𝛼 )2 ρ𝑠𝑒𝑐 𝑠𝑒𝑞 ] − {[CQ − (𝑡𝛼 )2 ρ𝑠𝑒𝑐 𝑠𝑒𝑞 ] − [𝑄 2 − (𝑡𝛼 )2 𝑠𝑒 2 𝑞 )(𝐶 2 − (𝑡𝛼 )2 𝑠𝑒 2 𝑐 ]}0.5
2
2
2
2
=
2
2
2
𝑄 − (𝑡𝛼 ) 𝑠𝑒 𝑞
2

𝑈𝑝𝑝𝑒𝑟 𝐿𝑖𝑚𝑖𝑡
[CQ − (𝑡𝛼 )2 ρ𝑠𝑒𝑐 𝑠𝑒𝑞 ] + {[CQ − (𝑡𝛼 )2 ρ𝑠𝑒𝑐 𝑠𝑒𝑞 ] − [𝑄 2 − (𝑡𝛼 )2 𝑠𝑒 2 𝑞 )(𝐶 2 − (𝑡𝛼 )2 𝑠𝑒 2 𝑐 ]}0.5
2
2
2
2
=
𝑄 2 − (𝑡𝛼 )2 𝑠𝑒 2 𝑞
2

In these equations:
C and Q are the differences in mean costs and mean effects in the two groups.
𝑡𝛼 is the critical value from a student’s t-distribution; 𝑡𝛼 = 1.96 for 95% C.I.
2

2
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ρ is the Pearson correlation coefficient between C and Q.
𝑠𝑒𝑐 and 𝑠𝑒𝑞 are the standard errors for C and Q, respectively.
Interpretation of the confidence limits:
•

A statistically significant difference in effects between the two groups exists only when the
denominator is positive and the interval is lower to upper limit [131].

•

Negative denominators mean there is no statistically significant difference between the two
groups. In that case, the upper limit is smaller than the lower limit [131].

•

If there is no statistically significant difference in both effects and costs part of the numerator
for which we are taking the square root (the term in brackets) will likely be negative, making
the lower and upper limits undefined as negative numbers do not have square roots [131].
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Stata do file
/*capture log close
set more off
log using cea.log, text replace
insheet using cea_new.csv, comma clear
*listing all the variables
ds
format %12s observations
*generating treatment
gen treatment=.
replace treatment=0 if
replace treatment=1 if
label define treatment
label values treatment
tab treatment
tab treatment group

group=="Soins habituels"
group=="Intervention - Cash"
0 "Control" 1 "Treatment", replace
treatment

*working with the variables
codebook marital_status
encode marital_status, gen(marstatus)
*transport cost has some values missing
order transportcost transportcostart
tab transportcost transportcostart , m
replace transportcost=transportcostart if transportcost==.
*multiple imputation of missing transport costs
misstable patterns transportcost, bypatterns
mi set mlong
mi register imputed transportcost /*registers transportcost as the variable
to be imputed*/
mi misstable summarize treatment ses transportcost
mi impute pmm transportcost treatment uptakepmtct incaresixweek i.ses
yearofeducation ///
earlyancvisit traveltime i.transportmode i.marstatus age gestationalage,
add(20) knn(5) rseed(2232)
mi estimate: regress transportcost treatment uptakepmtct incaresixweek i.ses
///
yearofeducation earlyancvisit traveltime i.transportmode i.marstatus age
gestationalage
*checking how the imputation worked
mi estimate, vartable dftable /*as expected only travel time and SES
siginificantly predicted transport cost*/
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*keeping a single dataset of imputed transport cost data
keep if _mi_m > 0
collapse (mean) transportcost , by( pidc)
save cea_imputed, replace
export excel using "cea_imputed", firstrow(variables) replace
log close*/
***ANALYSIS BEGIN HERE
capture log close
set more off
log using cea_analysis, replace
insheet using cea_DRC_PPP_final.txt, tab clear
*formatting column widths
format %12s obs
*listing all the variables
ds
*ordering variables
order pidc group amountpaid ltfubydelivey incaresixweek ltfuat6wk uptakepmtct
///
cost_pp cost_sp datepremierevisit visitnumber artstartdate aztstartdate
cotrim_final ///
deliverydate gestationalage
*generating treatment
gen treatment=.
replace treatment=0 if group=="Control"
replace treatment=1 if group=="Intervention"
label define treatment 0 "Control (No CCTs)" 1 "Intervention (CCTs)" 2
"Control (No CCTs)", replace
label values treatment treatment
tab treatment
tab treatment group
drop if treatment==.
*correcting the variable incare at 6 wks postpartum. It seems 1s should be 0s
ans 0s 1s
tab treatment incaresixweek
recode incaresixweek 0=2
recode incaresixweek 1=0
recode incaresixweek 2=1
label define incaresixweek 0 "Not in care" 1 "In care", replace
label values incaresixweek incaresixweek
tab treatment incaresixweek
*Uptake of PMTCT services
tab treatment uptakepmtct
label define uptakepmtct 0 "No uptake" 1 "Uptake", replace
label values uptakepmtct uptakepmtct
tab uptakepmtct treatment
*Early ANC visit
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tab earlyancvisit treatment
label define earlyancvisit 0 "Late ANC" 1 "Early ANC", replace
label values earlyancvisit earlyancvisit
tab earlyancvisit treatment
*marital status and cohabitation
codebook marital_status
encode marital_status, gen(marstatus)
codebook marstatus
tab marstatus treatment
replace marstatus=0 if marstatus!=1
replace marstatus=1 if cohabitation=="yes" /*assumes that cohabiting is
marriage*/
label define marstatus 1 "Married" 0 "Not married", replace
label values marstatus marstatus
tab marstatus treatment
*first pregnancy
tab primiparus
rename primiparus firstpregnancy
label define firstpregnancy 0 "Not first pregnancy" 1 "First pregnancy",
replace
label values firstpregnancy firstpregnancy
*HIV disclosure
codebook disclosure
encode disclosure, gen(disclosure1)
drop disclosure
rename disclosure1 disclosure
recode disclosure 1=0 2=1
label define disclosure 0 "No" 1 "Yes", replace
label values disclosure disclosure
tab disclosure
*Transport mode
tab transportmode treatment
recode transportmode 2=0 3=0
label define transportmode 0 "Other means" 1 "Walk", replace
label values transportmode transportmode
tab transportmode treatment
*education
tab educlevel
rename educlevel education
label define education 0 "No education" 1 "Primary" 2 "Secondary or higher",
replace
label values education education
tab education treatment
*SES
rename ses wealth
codebook wealth
label define wealth 4 "Fifth (richest)" 3 "Fourth" 2 "Third" 1 "Second" 0
"First (poorest)", replace
label values wealth wealth
tab wealth treatment
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*labelling variables
label var pidc "Pateint ID"
label var treatment "Intervention"
label var amountpaid "Incentive paid"
label var age "Age"
label var incaresixweek "PMTCT Retention"
label var cost_pp "Cost (Payer perspective)"
label var cost_sp "Cost (Society perspective)"
label var datepremierevisit "Enrollment date"
label var disclosure "HIV disclosure"
label var gestationalage "Gestational age"
label var uptakepmtct "PMTCT Uptake"
label var traveltime "Travel time"
label var earlyancvisit "Early ANC visit"
label var yearofeducation "Education (years)"
label var wealth "Wealth quintile"
label var incentive "Incentive paid"
label var transportmode "Travel mode"
*SUMMARIZING DATA
*TABLE OF DEMOGRAPHIC CHARACTERISTICS
*checking the distribution of costs
sum cost_pp
recode treatment 0=2
hist cost_sp, by(treatment, note("")) freq subtitle(, size(medium)) ///
by(, title("Figure 1: Cost distribution in the intervention and Control
groups, societal perspective", size(medium large) col(black))) ///
xtitle(Cost (2016 I$)) ///
legend(rows(1)) ///
graphregion(fcolor(white)) ///
ylab(, nogrid)
*graphregion(color(white))
graph save "cost_distribution_sp", replace
hist cost_pp, by(treatment, note("")) freq subtitle(, size(medium)) ///
by(, title("Figure 1: Cost distribution in the intervention and Control
groups, payer perspective", size(medium large) col(black))) ///
xtitle(Cost (2016 I$)) ///
legend(rows(1)) ///
graphregion(fcolor(white)) ///
ylab(, nogrid) graphregion(color(white))
graph save "cost_distribution_pp", replace
*graph combine cost_distribution_sp.gph cost_distribution_pp.gph
recode treatment 2=0
count if cost_sp<200 & treatment==1
count if cost_sp>=450 & treatment==1
count if cost_sp>600 & treatment==1
count if cost_sp<200 & treatment==0
count if cost_sp>=450 & treatment==0
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count if cost_sp>600 & treatment==0
gen g_than_450=0
replace g_than_450=1 if cost_sp>=450
tab treatment g_than_450, row
*dpplot costparticipant, dist(gamma) param(`e(alpha)' `e(beta)')
*sample characteristics
tabstat cost_pp cost_sp, by(treatment) stats(mean sd median p25 p75)
tabstat cost_pp cost_sp age gestationalage yearofeducation traveltime,
by(treatment) stats(mean sd median p25 p75)
ttest cost_pp, by(treatment)
ttest cost_sp, by(treatment)
ranksum cost_pp, by(treatment)
ranksum cost_sp, by(treatment)
*summary of number of visits
sum visitnumber, d
tab treatment, sum(visitnumber)
hist visitnumber, by(group)
ttest visitnumber , by(treatment) level(90)
tabstat visitnumber, by (treatment) stats(mean median sum)
*cost per visit
bysort treatment: egen cost_per_visit=mean(cost_sp/visitnumber)
*TABLE SUMMARIZING COSTS
*checking the distribution of continuous variables
mvtest normal cost_pp cost_sp age traveltime yearofeducation incentive
gestationalage , bivariate univariate stats(all)
*performing the Mann-Whitney test
foreach var of varlist incentive cost* {
ranksum `var', by(treatment)
}
foreach var of varlist yearofeducation age traveltime gestationalage {
ranksum `var', by(treatment)
}

foreach var of varlist uptakepmtct incaresixweek education wealth marstatus
earlyancvisit firstpregnancy disclosure transportmode {
tab `var' treatment, col chi2
}
*effectiveness
*unadjusted risk ratios
cs incare treatment, exact
cs uptake treatment, exact
order pid cost_* incare uptake treatment treatment incentive traveltime
education marstatus firstpregnancy earlyancvisit disclosure wealth
transportmode
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*exporting the dataset to SAS for comparing analyses in Stata and those
performed in SAS
save cea_analysed_forsas, replace
saveold cea_analysed_forsasv12, version(12) replace
fdasave cea_analysed_forsas, rename replace
outsheet using cea_analysedforsas.txt, comma replace
*putting controls in a global macro
global controls "treatment earlyancvisit disclosure age i.marstatus
i.education i.wealth firstpregnancy transportmode"
*exploratory OLS multivariate model
mvreg cost_sp cost_pp = $controls
**GEE MODELS
xtset clinic
*EFFECTIVENESS
xtgee incaresixweek $controls, family(poisson) link(log) corr(exch) robust
eform
*xtgee incaresixweek $controls, family(bin) link(log) corr(exch)
estimates store incare
estimates replay, eform
/*xtgee uptake $controls, family(poisson) link(log) corr(exch) vce(robust)
eform
estimates store uptake*/
xtgee uptake $controls, family(poisson) link(log) corr(exch) robust
estimates store uptake
estimates replay, eform
**Getting the number needed to treat (this will be used in the CEA)
*incare
global controls "treatment age i.marstatus yearofeducation"
binreg incaresixweek $controls, rd vce(robust)
gen rd_incare=_b[treatment]
gen sd_rd_incare=0.0404129
gen NNT_incare=1/_b[treatment]
list NNT_incare in 1/1
*predicting risk of being in care
predict risk_incare, xb
tab treatment, sum(risk_incare)
*uptake
binreg uptake $controls, rd vce(robust)
gen rd_uptake=_b[treatment]
gen sd_rd_uptake=0.0462205
gen NNT_uptake=1/_b[treatment]
list NNT_uptake in 1/1
*predicting risk of taking up PMTCT services
predict risk_uptake, xb
tab treatment, sum(risk_uptake)
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**COSTS
*identifying the family using the modified park test
global controls "treatment age i.marstatus i.education i.wealth
transportmode"
glm cost_pp $controls, family(gamma) link(identity) vce(robust)
predict resid, dev
predict yhat, xb
gen resid_sq=resid^2
glm resid_sq yhat, family(gamma) link(identity) vce(robust)
test yhat=0
test yhat=2 /*shows that the gamma should be used. See this link for this
test:
http://www.uphs.upenn.edu/dgimhsr/documents/ispor15.glmworkshop.glick.2.pdf*/
drop resid* yhat
**Payer perspective
xtgee cost_pp $controls, family(gamma) link(identity) corr(exch) vce(robust)
estimates store cost_pp
*incremental cost
gen Inc_cost_pp=_b[treatment]
gen sd_cost_pp=11.52162 /*standard errors*/
gen sample_size=217 /*sample size*/
*predicted costs
predict pred_cost_pp, xb
**Society perspective
xtgee cost_sp $controls, family(gamma) link(identity) corr(exch) vce(robust)
estimates store cost_sp
*incremental cost
gen Inc_cost_sp=_b[treatment]
gen sd_cost_sp=13.29177 /*standard errors*/
*predicted costs
predict pred_cost_sp, xb
/*table of costs*/
esttab cost_pp cost_sp using costs.csv , plain nogaps b(a2) ci(a4) wide
replace label obslast star ///
refcat (treatment "Ref: Control group" 1.wealth "Ref: First
quintile(poorest)" ///
1.education "Ref: No education" 1.marstatus "Ref: Not married"
transportmode "Ref: Other means") ///
collabels("2016 I$" "2016 I$") ///
drop (0.wealth 0.marstatus 0.education) brackets ///
addnote("95% Confidence intervals in brackets; * p<0.05, ** p<0.01, ***
p<0.001") ///
title( "Table 5: Adjusted costs and effectiveness of conditional cash
transfers")
*table of effectiveness
esttab uptake incare using effectiveness.csv, plain eform nogaps b(a3) ci
replace label wide obslast star ///
refcat (treatment "Ref: Control group" 1.wealth "Ref: First
quintile(poorest)" ///
1.education "Ref: No education" 1.marstatus "Ref: Not married"
transportmode "Ref: Other means") ///
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collabels("Relative risk" "Relative risk") ///
drop (0.wealth 0.marstatus 0.education) brackets ///
addnote("95% Confidence intervals in brackets; * p<0.05, ** p<0.01, ***
p<0.001") ///
title( "Table 5: Adjusted effectiveness of conditional cash transfers")
**generating incremental cost effectiveness ratios
*incare
*payer perspective
gen ICER_pp_incare=Inc_cost_pp*NNT_incare
*society perspective
gen ICER_sp_inccare=Inc_cost_sp*NNT_incare
*uptake
*payer perspective
gen ICER_pp_uptake=Inc_cost_pp*NNT_uptake
*society perspective
gen ICER_sp_uptake=Inc_cost_sp*NNT_uptake
list NNT_incare NNT_uptake ICER_pp_incare ICER_sp_inccare ICER_pp_uptake
ICER_sp_uptake in 1/1
**caculating confidence intervals using the Fieller's theorem
*payer perspective
list Inc_cost_pp sd_cost_pp sample_size rd_uptake sd_rd_uptake sample_size in
1/1
list Inc_cost_pp sd_cost_pp sample_size rd_incare sd_rd_incare sample_size in
1/1
*society perspective
list Inc_cost_sp sd_cost_sp sample_size rd_uptake sd_rd_uptake sample_size in
1/1
list Inc_cost_sp sd_cost_sp sample_size rd_incare sd_rd_incare sample_size in
1/1
***BOOTSTRAPPING 95% FOR THE ICER
*recall that the following are the steps involved
*1. Generate a sample of nt cost and effect pairs from the experimental group
data with replacement. The cost and effect pairs need to be resampled
together as they are inter-dependent.
*2. Generate a sample of nc cost and effect pairs from the control group data
with replacement
*3. Calculate the ICER for this bootstrap resample.
*4. Repeat this procedure 1000 times, to get 1000 bootstrap estimates of the
ICER. These estimates then define the empirical sampling distribution of the
ICER.
*1&2. Bootsrapping to create treatment and control groups of sizes similar to
the trial
bootstrap pred_cost_pp pred_cost_sp risk_incare risk_uptake if
treatment==0, reps(217) cluster(clinic) saving(control, replace) seed(1980):
summarize
bootstrap pred_cost_pp pred_cost_sp risk_incare risk_uptake if treatment==1,
reps(216) cluster(clinic) saving(treat, replace) seed(1980): summarize
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save cea_analysed, replace
*combining the resampled datasets of treatment and control groups
use control, clear
gen treatment=0
save control, replace
use treat, clear
append using control
replace treatment=1 if treatment==.
rename _bs_1 cost_pp
rename _bs_2 cost_sp
rename _bs_3 risk_incare
rename _bs_4 risk_uptake
*3. Calculating the ICER and 95% C.I. from the bootstrap resample
program icer, rclass
version 14.2
****costs
***payer perspective
summarize cost_pp if treatment==0, meanonly
local a = r(mean)
summarize cost_pp if treatment==1, meanonly
local b = r(mean)
return scalar Inccost_pp=`b'-`a'
**incare
summarize risk_incare if treatment==0, meanonly
local c=r(mean)
summarize risk_incare if treatment==1, meanonly
local d=r(mean)
*NNT
return scalar diff_incare= `d'-`c'
return scalar NNT_incare=1/(`d'-`c')
*ICER
return scalar ICER_incarePP =(`b'-`a')/(`d'-`c')
**uptake
summarize risk_uptake if treatment==0, meanonly
local e=r(mean)
summarize risk_uptake if treatment==1, meanonly
local f=r(mean)
*NNT
return scalar diff_uptake=`f'-`e'
return scalar NNT_uptake=1/(`f'-`e')
*ICER
return scalar ICER_uptakePP =(`b'-`a')/(`f'-`e')
*society perspective
summarize cost_sp if treatment==0, meanonly
local g=r(mean)
summarize cost_sp if treatment==1, meanonly
local h=r(mean)
return scalar Inccost_sp=`h'-`g'
*in care
return scalar ICER_incareSP=(`h'-`g')/(`d'-`c')
*uptake
return scalar ICER_uptakeSP =(`h'-`g')/(`f'-`e')
end
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*4. Bootstrapping the ICERs.
bootstrap r(Inccost_pp) r(Inccost_sp) r(diff_uptake) r(NNT_uptake)
r(diff_incare) r(NNT_incare) r(ICER_incarePP) r(ICER_uptakePP)
r(ICER_incareSP) r(ICER_uptakeSP), saving(trial, replace) bca reps(1000)
seed(1980) strata(treatment) nodots: icer summarize
program drop icer
save CEA_with_CI, replace
**GENERATING CEA ACCEPTABILITY CURVES
*bootstraping differences in mean costs and mean effects. Note that above
what was bootstrapped was the ICER itself.
capture program drop bscer
program define bscer
sum `1' if `5'==1,meanonly
scalar meancostpp=r(mean)
sum `1' if `5'==0,meanonly
scalar diffcostPP=meancostpp-r(mean)
sum `2' if `5'==1,meanonly
scalar meancostsp=r(mean)
sum `2' if `5'==0,meanonly
scalar diffcostSP=meancostsp-r(mean)
sum `3' if `5'==1,meanonly
scalar meanriskincare=r(mean)
sum `3' if `5'==0,meanonly
scalar diffriskincare=meanriskincare-r(mean)
sum `4' if `5'==1,meanonly
scalar meanriskuptake=r(mean)
sum `4' if `5'==0,meanonly
scalar diffriskuptake=meanriskuptake-r(mean)
scalar
scalar
scalar
scalar

ICER_incarePP= diffcostPP/diffriskincare
ICER_uptakePP=diffcostPP/diffriskuptake
ICER_incareSP= diffcostSP/diffriskincare
ICER_uptakeSP=diffcostSP/diffriskuptake

end
scalar exper=0
clear
use CEA_analysed
bootstrap "bscer pred_cost_pp pred_cost_sp risk_incare risk_uptake treatment
clinic " "diffcostPP diffcostSP diffriskincare diffriskuptake ICER_incarePP
ICER_incareSP ICER_uptakePP ICER_uptakeSP", reps(4000) saving(Cost&Effects)
replace strata(treatment) cluster(clinic)
clear
quietly do bsceaprogs
use Cost&Effects
sum
corr
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quietly do bsceagraphs
*uptake
bscicer _bs_2 _bs_4 .95
bscicergraph
bsaccept _bs_2 _bs_4 .95
bsaccgraph
*incare
bscicer _bs_2 _bs_3 .95
bscicergraph
bsaccept _bs_2 _bs_3 .95
bsaccgraph
*CEA curve
clear
import excel "Willingess-to-pay_final.xlsx", sheet("Sheet1") firstrow
case(lower) clear
keep wtpacceptp retention uptake
scatter retention uptake wtpacceptp, connect(dot dot) msize(tiny tiny) ///
xtitle("Willingness-to-pay (WTP)", size(3.0)) ///
ytitle("% acceptable", size(3.0) height(7)) ///
graphregion(color(white)) ///
xline(402 803 1205) ///
yline(0.1 0.5 0.8) ///
legend(order(2 "Uptake" 1 "Retention")) ///
title("Figure 2: Willingness-to-pay for uptake of PMTCT services and
retention in PMTCT care", size(3.5) col(black))
graph save WTP_final, replace
log close
log2html cea_analysis, replace
**sensitivity analysis
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Chapter 3: Guideline concordance of time to follow-up of anal cancer screening in women
living with HIV at high-risk for acquiring anal cancer
Abstract
Background: In the past 2-3 decades, the incidence of anal cancer has increased significantly
among women with HIV. This calls for a better understanding of receipt of anal screening in this
population, particularly among those at increased risk of acquiring anal cancer. While some
evidence suggests that these women receive initial anal cancer screening, it is unclear whether
they also receive follow-up screening consistent with the guidelines for anal cancer screening in
this population. This study examines the guideline concordance of the time to follow-up for anal
cancer screening in women with HIV with histories of abnormal cervical tests or genital warts.
Methods: Data for this analysis came from administrative claims of Medicaid beneficiaries
ages 19–64 years who qualified for Medicaid based on income and disability and who were
continuously enrolled for ≥ 24 months. We created a 4-year retrospective cohort (2009-2012) of
high-risk women using ICD-9 codes for abnormal cervical tests or genital warts. We estimated
the follow-up time as the time from the date of the first anal cancer screen (after a high-risk
diagnosis) to the date of the second screen. Follow-up time was guideline-concordant if the
follow-up screening was performed in ≤ 6 months for those with abnormal results on the first
screen and ≤ 12 months for those with normal results on the first screen. We used the KaplanMeier to estimate the follow-up time and modeled the guideline concordance of the follow-up
time using logistic regressions. In sensitivity analysis, we restricted the sample to those
continuously enrolled for 4 years, expanded the number of ICD-9 codes used to define a sample
of high-risk women with HIV, and examined follow-up time of anal cancer screening at
thresholds higher than those stipulated in the guidelines.
Results: A total of 3,779 high-risk women were eligible for follow-up screening and
contributed 4,458 person-years. The median time to follow-up screening was 16.1 months (95%
C.I.=15.2,17.6) and was shortest among women with histories of both risk factors (median=9.3,
95% C.I.=7.6,11.0 months). The time to follow-up screening was guideline-concordant for
47.3% (95% C.I.=42.0,53%) of high-risk women with abnormal results on the first screen and
for 40.0% (95% C.I.=38.0,41.4%) for those with normal results. The time to follow-up screening
was not guideline concordant for women with one risk factor. The odds that time to follow-up
screening was guideline concordant were more than twice among women with two risk factors
compared with those with a single risk factor for anal cancer (OR=2.06, 95% C.I.=1.73,2.46).
These findings persisted in sensitivity analyses.
Conclusions: Time to follow-up anal cancer screening is not guideline-concordant overall and
for nearly two-thirds of women with a single risk factor. Training providers in high-resolution
anoscopy, gathering more evidence about the benefits of anal cancer screening to clarify the
guidelines for anal cancer screening, and creating a billable procedural code for anal cancer
screening could help to increase the rates of follow-up anal cancer screening in high-risk women.
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1. Introduction
Among all non-AIDS-defining cancers4, anal cancer has recorded the largest increase in
incidence over the past 2-3 decades [256]. These increases have been observed in all groups of
people living with HIV (PLWH), including women [257]–[259]. In that period, the incidence of
anal cancer among women with HIV increased by 40% and is still increasing [257]–[260]. The
high and rising incidence of anal cancer in women with HIV suggests that screening for anal
cancer is critical in this population. This is particularly true in this era of combination
antiretroviral therapy when PLWH have life expectancies similar to the general population but
who are at a higher risk for many diseases, including anal cancer [261]–[263]. For example, data
show that the incidence of anal cancer is 30 per 100,000 person-years in women with HIV,
which is 15 times greater than in women without HIV [264].
Anal cancer screening leads to early detection of abnormal anal cells otherwise known as anal
intraepithelial neoplasia (AIN5), making effective secondary prevention possible [267], [268].
The evidence suggests that rates of abnormal anal test results range from 12 to 42% [269]–[275]
and that AIN can develop quickly in women with HIV [273] even if the women have normal
anal cells at baseline [270]. Further evidence suggests that untreated low-grade AIN can progress
to high-grade AIN within 2 years in many PLWH [267] and that untreated high-grade AIN can
progress to anal cancer in less than one year [268]. However, among those screened and treated
for AIN, the rates of progression are much lower [267], [268]. Additional evidence also suggests

4

A cancer is AIDS-defining if its onset marks progression from HIV to AIDS [255]
AIN is used to describe biopsy-confirmed results of anal cancer screening. Less severe lesions are classified as
AIN1 while more severe ones are classified as AIN2 or AIN3 [265], [266]. On the hand, cytology results are
reported as squamous intraepithelial lesions (SIL) and are classified as low-grade or high-grade SIL [265], [266].
These classifications are based off the terminology used in cervical cancer screening [265], [266].
5
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that early detection of cancerous anal cells has survival benefits. The 5-year survival rates for
localized, regional, and metastatic anal cancers are 0.78, 0.56, and 0.18, respectively [276].
While guidelines exist for anal cancer screening [277], little is known about the timing of
screening for this cancer in women with HIV. This is particularly true for time to follow-up of
anal cancer screening among women living with HIV at increased risk of acquiring anal cancer.
Regular anal cancer screening is recommended for these at-risk women including those with
histories of abnormal cervical tests or genital warts [277]–[279], two groups whom we
collectively define as high-risk. Previous studies of anal cancer screening frequency in PLWH
mainly focused on men who have sex with other men (MSM) [280]–[286], with women rarely
included in those studies. While the few studies that included women provide some evidence of
initial anal cancer screening in high-risk women with HIV [269]–[275], it is unclear whether
high-risk women also receive follow-up screening and whether the timing of the follow-up
screening is concordant with the guidelines. Studies that examined follow-up anal cancer
screening in women with HIV had small sample sizes, were limited in geographic scope [270],
[273], [275], [282], [283], or did not stratify findings by anal cancer risk factors [287], [288].
Guidelines for anal cancer screening by the HIV Medical Association recommend screening at
baseline in all PLWH but thereafter, the screening depends on the outcome of the initial test and
the risk of the individual [277]. When abnormal anal cells are detected at the initial test, followup screening is recommended in 6 months. When the initial test is normal, a follow-up test is
recommended in 12 months but only in PLWH at high-risk for acquiring anal cancer, figure 1.
This includes women with histories of abnormal cervical tests or genital warts, two groups of
women at the center of this study.
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Given these guidelines and the limitations of previous studies, the goal of the current study is to
examine the guideline concordance of the time to follow-up of anal cancer screening in high-risk
women, and whether this varies by the risk factors for anal cancer. We overcome limitations of
previous studies by creating a large retrospective cohort of high-risk women from Medicaid
administrative claims data in the US South.
1.1. Conceptual framework
We adapted Andersen’s behavioral model of healthcare utilization to develop a conceptual
framework for understanding the frequency of follow-up anal cancer screening in high-risk
women [289], figure 2. The framework consists of three domains: individual and population
characteristics, use of health services, and outcomes. It posits that health service utilization is a
result of the interplay of three individual/population characteristics—predisposing factors,
enabling resources, and need [289]. We emphasize that the focus of the current study is on the
utilization of follow-up anal cancer screening services and not the benefits of the screening.
From left to right, the first part of the framework consists of predisposing factors—factors which
exist before a person’s need for healthcare arises. Although these factors do not define a person’s
health service utilization, they suggest the propensity that a person will need health services. The
predisposing factors—for example, age—are exogenous and only affect healthcare utilization
through enabling resources [289]–[291]. Next, enabling resources are necessary—although
insufficient—for health services utilization to occur [289], [290]. These resources, for example,
income, can facilitate follow-up anal cancer screening if available or impede it if unavailable.
Finally, individuals must have a need for healthcare if services are to be utilized. The need can
be perceived (subjective) or evaluated (objective) [289]–[291]. While women with HIV have a
need for anal cancer screening overall [292]–[296], the need is greater among those with one risk
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factor for acquiring anal cancer and much greater among those with multiple risk factors [277]–
[279]. Therefore, we expect the timing of follow-up anal cancer screening to be shorter in highrisk women with both risk factors for anal cancer but guideline-concordant in all high-risk
women, regardless of the type or number of risk factors.
2. Methods
2.1. Overview
We examined the guideline concordance of the time to follow-up anal cancer screening in a
retrospective cohort of high-risk women with HIV continuously enrolled in Medicaid for ≥ 24
months. Data for this analysis came from the Medicaid Analytic eXtract (MAX) files, which
included administrative claims of beneficiaries ages 19–64 years and who qualified for Medicaid
based on income and disability in the US South6 (2009-2012). We used the International
Classification of Diseases, Ninth Revision (ICD-9) codes to identify women with HIV, genital
warts, abnormal cervical tests, and abnormal anal cells. To identify high-risk women screened
for anal cancer, we used Current Procedural Terminology (CPT) codes for anal cytology and
high-resolution anoscopy. We estimated the time to follow-up screening as the time from the
date of the first anal cancer screen after a high-risk diagnosis (henceforth, the first screen) to the
date of the second (follow-up) screen. In each group, we estimated the percentage with
guideline-concordant time to follow-up screening. To determine whether the time to follow-up
was guideline-concordant for the whole group and to be consistent with the literature, we
compared the median follow-up time in that group to the follow-up time in the guidelines. We
compared the odds that time to follow-up screening was guideline-concordant across the groups

6

The US South encompasses 16 states (Delaware, Florida, Maryland, North Carolina, Georgia, South Carolina,
Virginia, West Virginia, Alabama, Kentucky, Mississippi, Tennessee, Arkansas, Louisiana, Oklahoma and Texas)
plus the District of Columbia.
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using logistic regressions. In sensitivity analysis, we redefined the sample of high-risk women
and examined follow-up time at thresholds higher than recommended in the guidelines.
2.2. Data sources
MAX files, available through the Centers for Medicare and Medicaid Services (CMS), were the
primary data source. These data contain person-level information on Medicaid eligibility,
utilization of healthcare services, and payments [297]. We used three MAX files: the MAX
Personal Summary (PS) file to obtain enrollees’ demographic information; MAX Other Therapy
(OT) file to identify PLWH, high-risk women, those screened for anal cancer and outcomes of
the screening; and the MAX Prescription Drug (RX) file to verify, using antiretroviral
prescriptions, enrollees with HIV. Claims for services provided to PLWH are submitted to states
by healthcare providers and in turn, each state’s health department sends the claims to CMS
every quarter [297]. MAX data is a reliable source for services received by PLWH [298], [299],
and CMS regularly validates these data [300].
We supplemented the MAX data with data from the Area Health Resources File (AHRF) and
AIDSVu for additional county-level information. In the MAX data, person-level sociodemographic information is limited to age, sex, and race/ethnicity. The AHRF, maintained by the
Health Resource Service Administration, has county-level data on income, education, and
availability of healthcare workforce [301]. We controlled for county-level education, income,
and the healthcare workforce because these variables are positively associated utilization of
health services [289], [302], [303]. AIDSVu, constructed by the Centers for Disease Control and
Prevention and maintained by Emory University, consists of county-level HIV surveillance data
in the US [304]. We controlled for county-level HIV prevalence because PLWH in counties with
a high HIV burden are more likely to access HIV providers and receive appropriate HIV care
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[305]. The study was approved by the institutional review board of Virginia Commonwealth
University and used the data in accordance with a data use agreement with the CMS (IRB#:
HM20008091, DUA#: RSCH-2017-51616)
2.3. Sample selection and eligibility criteria
We identified high-risk women from a sample of people verified to be living with HIV. Briefly,
the sample of PLWH was derived as follows: Enrollees with HIV/AIDS were identified using
ICD-9 codes 042 (AIDS diagnosis) and V08 (HIV diagnosis) [306]. In this sub-sample of
enrollees living with HIV, we excluded enrollees for whom we could not verify and confirm an
HIV-positive diagnosis. These included enrollees who only received HIV counseling, had HIVassociated ICD-9 codes that occurred <twice during the analytic time horizon or had first and last
HIV-associated claims <30 days, only received Truvada—a pre-exposure prophylaxis for HIV.
From this sample, we retained non-elderly women with HIV using the sex variable (el_sex_cd)
and restricted ages of 19-65 years7. We also excluded women enrolled in both Medicare and
Medicaid. Next, we identified high-risk women using ICD-9 codes for abnormal cervical tests
and genital warts [307], [308], Appendix C2. We also excluded those diagnosed as high-risk
before the date of the first HIV-associated ICD-9 code or on their last verified date of service.
Finally, we excluded women enrolled for <24 months to permit enough time to observe ≥2 anal
cancer screens after a high-risk diagnosis.
2.4. Identifying high-risk women screened for anal cancer
We identified high-risk women who received anal cancer screening using CPT codes for anal
cytology and high-resolution anoscopy, Appendix C3. We used these codes because there were

7

Although the data requested from the CMS was for Medicaid beneficiaries aged 19-64 years, we applied this
exclusion because transitions from Medicaid to Medicare may not be instantaneous and some beneficiaries may
receive services under Medicaid and Medicare during the transition period.
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no CPT codes for anal cancer screening during the current study’s analytic time horizon, 20092012 [309], [310]. At that time, the practice was for providers to bill payers for services and
components that constituted anal cancer screening—for example, direct smear (CPT code 88104)
or anoscopy (CPT code 46600). Although CPT code 88112 (anal cytology, liquid-based
preparation) is the most commonly used for anal cytology [311], we included the other codes
because specimens for anal cancer screening can be obtained in multiple ways and each of these
codes reflects the method used [312].
2.5. Statistical analysis
We estimated time to follow-up anal cancer screening as the time from the date of the first screen
(after a high-risk diagnosis) to the date of the second screen. We used Kaplan-Meier to estimate
the time to follow-up screening overall and by risk group to make our findings comparable to the
literature. The Kaplan-Meier estimator produces unbiased estimates even if the data are censored
or have gaps [313], [314]. Data are censored if the observation of time-to-event is incomplete
while gaps mean that a participant disappears from the study and then reappears at a later date
[315]. These issues were important because of some enrollees moving in and out of the Medicaid
program (churning) or not receiving any follow-up screening at the end of the analytic time
horizon. To report the time to any follow screening, we used the median because the follow-up
time was right-skewed (χ2 =1777(2), p-value <0.001). We tested the statistical significance of
the differences in the time-to follow-up screening between the groups using the log rank test.
2.5.1. Guideline-concordant time to follow-up screening (unadjusted)
In each of the groups of high-risk women, we report the percent of women receiving follow-up
screening at the times stipulated in the guidelines for anal cancer screening. We report these
percentages at 6 and 12 months if on the first screen the results were, respectively, abnormal and
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normal. However, for comparability with previous studies, we also report the median time—the
time at which 50% of the group received follow-up screening. We tested whether the median
time to follow-up screening was guideline-concordant by comparing it to the follow-up time
recommended in the guidelines. Therefore, a group of high-risk women (for example, women
with both risk factors) was considered to have had guideline-concordant time to follow-up
screening if the median time was ≤ 6 months for those with abnormal results on the first screen
and ≤ 12 months for those with normal results on the first screen. To ascertain whether the result
on the first screen was normal or abnormal, we used the ICD-9 codes in Appendix C4.
2.5.2. Guideline-concordant time to follow-up screening (adjusted)
We modeled the likelihood that time to follow-up screening was guideline-concordant using
logistic regressions, adjusting for other factors that can potentially influence the time to followup of anal cancer screening. We reported the results as odds ratios and probabilities. The odds
ratios compared the guideline concordance of time to follow-up screening between groups while
the probabilities determined if the time to follow-up in each group was guideline-concordant.
Time to follow-up screening was guideline-concordant if the average predicted probability for a
given group was ≥ 0.5. We created a binary variable “concordance” based on the follow-up time
recommended in the guidelines. Concordance was equal to one if the time to follow-up screening
was guideline-concordant and zero otherwise. We specified the following model:
𝜋

𝑙𝑜𝑔 ( [1−𝜋𝑖 ]) = 𝛽0 + 𝜆𝑿𝑖 + 𝛼𝑷𝑗 + 𝜞 + ℇ𝑖 --- (1)
𝑖

Where;
πi is the proportion with guideline-concordant time to follow-up screening; (1-πi) is the
proportion with time to follow-up screening not guideline-concordant.
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Xi is a vector of individual-level variables, for example, age (Appendix C1); λ is a vector
of parameters corresponding to the individual-level characteristics.
Pj is a vector of county-level variables, for example, the prevalence of HIV (Appendix C1);

𝞪 is a vector of parameters corresponding to the county-level variables.
Γ captures state fixed-effects for the 16 Southern states plus the District of Columbia.
ℇi is residuals—assumed to be independent and normally distributed with zero means.
Tests of model fitness using the Hosmer-Lemeshow test which compares observed vs. expected
frequencies and deviance residuals which can identify outlying observations [316, p. 3]
suggested the model was a good fit of the data: Hosmer-Lemeshow, χ2 (8) =6.29 (p>0.05) and
<5% (129/3,779) of observations were outlying (±2 standard deviations of the residuals’ mean—
zero). Test of multicollinearity suggested this was not a problem (mean VIF=6.10) [316], [317].
2.6. Sensitivity analysis
We conducted three sensitivity analyses. First, we restricted the sample of high-risk women to
only those continuously enrolled in Medicaid for the entire study period (2009-2012). Redefining
the sample this way helped to understand whether Medicaid enrollment length and churning
influenced the frequency of anal cancer screening. In the second sensitivity analysis, we
redefined the sample of high-risk women by including additional ICD-9 codes that might also be
used to indicate a diagnosis of abnormal cervical test or genital warts. We conducted this
sensitivity analysis to account for differences in practices in deciding which diagnoses might
qualify an individual for anal cancer screening. For example, women with a diagnosis of “other
abnormal Pap smear of cervix and cervical HPV (ICD-9 code 795.09)” may be considered as
high-risk by some practitioners but not by others. All the supplementary codes used in the
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sensitivity analysis are presented in Appendix C2. In the third sensitivity analysis, we modeled
the time to follow-up screening at thresholds higher than stipulated in the guidelines to account
for logistical delays in seeking care. We assumed a 2-month delay. Thus, in equation 1, we
examined the likelihood of follow-up screening at ≤ 14 months among women with normal
results and ≤ 8 months among those with abnormal results on the first screen.
3. Results
3.1. Descriptive statistics
Overall, we identified 6,086 high-risk women continuously enrolled in Medicaid for ≥ 24
months. Sixty-two percent (3,779/6,086) were screened for anal cancer after a high-risk
diagnosis. Therefore, we examined time to follow-up screening in 3,779 high-risk women who
accounted for a total of 4,458 person-years, table 1. Approximately three-quarters qualified for
Medicaid via the disability path, with nearly two-thirds continuously enrolled in Medicaid for 4
years. The mean (±SD) age (years) was 41.5±10.4. The sample largely comprised women with
histories of abnormal cervical tests (74%) followed by those with histories of both risk factors
(18%). Most were non-Hispanic black (68%) followed by other races/ethnicities (for example,
Pacific Islanders, Hawaiians, and Asians) (15%), non-Hispanic whites (12%), and Hispanics
(5%). The incidence of anal cancer screening was 0.39 (95% C.I.=0.26,0.37) per person-year
overall but much higher among high-risk women with both risk factors (0.62 (95%
C.I.=0.57,0.68) per person-year). The time to follow-up screening was guideline-concordant for
46% of those with abnormal results and 37% among those with normal results. Women with both
risk factors were highest in the proportion with guideline-concordant time to follow-up
screening, regardless of the result on the first screen.
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3.2. Time to any follow-up anal cancer screening (unadjusted)
The overall median time to any follow-up screening was 16.1 months (95% C.I.=15.2,17.6) but
differed by risk group (χ2(2) =115.8, p-value<0.001). The follow-up time was shortest among
women with histories of both risk factors, with a median time almost half that of the next most
screened group (women with histories of abnormal cervical tests only) (median=9.3, 95%
C.I.=7.6,11.0 months vs. median=18.6, 95% C.I.=17.6,19.9 months). Among women with
histories of genital warts only, the median follow-up time was two years (median=24.4, 95%
C.I.=16.3,39.0 months). When examined collectively, the median time to follow-up screening for
women with any single risk history was 18.9 (95% C.I.=17.8,20.3) months, figure 3. By 24
months, >75% of women with both risk histories had received follow-up screening compared
with <60% among women with only one risk factor.
3.3. Guideline concordance of the time to follow-up screening (unadjusted)
Receipt of guideline-concordant follow-up anal cancer screening—defined as receiving followup screening within 6 months and 12 months for those with normal and abnormal results after the
first screen, respectively—also differed by risk group. The time to follow-up screening was
guideline-concordant for 47.3% (95% C.I.=42.0,53%) of high-risk women with abnormal results
on the first screen and for 40.0% (95% C.I.=38.0,41.4%) for those with normal results. When
stratified by risk group, the time to follow-up screening was guideline-concordant for more than
half of high-risk women with both risk factors, figure 4 (points A and C). The percent of
women with guideline-concordant time to follow-up screening was lowest for women with a
single risk factor and normal results on the first screen (36.8%, 95% C.I.=35.0,38.7%), figure 4
(point D).
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3.4. The odds of any follow-up anal cancer screening (adjusted)
In adjusted analyses, the odds of receiving any follow-up anal cancer screening differed by the
number of risk factors, table 2 (panel 1). The odds were significantly higher in women with both
risk factors than in women with one factor (OR=2.57, 95% C.I.=2.12,3.12). At the same time,
high-risk women with an abnormal anal test on the first screen had significantly higher odds of
receiving any follow-up screening compared with those who had normal results (OR=3.22, 95%
C.I.=2.39,4.34). We also found that the odds of receiving any follow-up screening were
significantly higher among those who qualified for Medicaid via the disability path and increased
with increasing years of enrollment and age. Compared to non-Hispanic whites, Hispanics had
significantly higher odds of receiving any follow-up anal cancer screening. Non-Hispanic blacks
had similar odds of receiving any follow-up screening as non-Hispanic whites.
3.5. The odds and probability of guideline-concordant follow-up screening (adjusted)
The odds that the time to follow-up of anal cancer was guideline-concordant differed by risk
group, table 2 (panel 2). Compared with women with a single risk factor, women with both risk
factors had double the odds of having guideline-concordant time to follow-up screening
(OR=2.06, 95%=1.73,2.46). The odds were also higher among women with abnormal results on
the first screen compared with women with normal results (abnormal vs. normal, OR=1.27,
C.I.=1.00,1.63).
These results are also presented as predicted probabilities in table 3 (base case analysis). From
first to last, the average probabilities that the timing of the follow-up screening was guidelineconcordant were as follows: both risk factors and abnormal result, 56.7% (95%
C.I.=50.7,62.8%); both risk factors and normal result, 50.9 (95% C.I.=47.0-54.8%); one risk
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factor and abnormal result, 39.3% (95% C.I.=33.7,44.9%); one risk factor and normal result,
33.8% (95% C.I.=32.2,35.6%).
We also found that the odds that time to follow-up screening was guideline-concordant differed
on some individual- and county-level variables. The odds were significantly higher for older
enrollees and those who qualified for Medicaid via the disability path. However, the odds did not
significantly differ by years of continuous enrollment or race/ethnicity. In terms of county-level
variables, the odds were higher for those living in counties with higher HIV prevalence but lower
for those living in counties with more specialists. Finally, the odds were lower for high-risk
women in states with higher proportions of Medicaid managed care enrollment although the
difference was not significant.
3.6. Sensitivity analysis
When we restricted the sample of high-risk women to only those continuously enrolled in
Medicaid for the entire study period (2009-2012), the percent of women with guidelineconcordant time to follow-up screening increased but only marginally (within five percentage
points), table 3 (continuously enrolled for 4 years). For example, among women with both risk
factors and abnormal results the percent with guideline-concordant follow-up time to screening
increased from 57% (95% C.I.=51%,63%) in the main analysis to 62% (95% C.I.=56%,68%) in
the sensitivity analysis.
Table 4 presents the results of the second sensitivity analysis in which we increased the number
of ICD-9 codes used to create a sample of high-risk women, thereby relaxing the approach for
constructing our sample. The pattern suggests that the percent with guideline-concordant time to
follow-up screening decreased but was still higher in high-risk women with both risk factors.
The decreases ranged from zero to three percentage points. Overall, the percent with guideline154

concordant time to follow-up decreased by two percentage points among high-risk women with
normal results on the first screen after a high-risk diagnosis but did not decrease among those
with abnormal results. Similar patterns were observed when the time to follow-up was analyzed
by risk group.
In the third sensitivity analysis, which examined follow-up screening at the guidelinerecommended times plus 2 months, the probability of follow-up anal cancer screening increased
but marginally. The increases were by three to five points in each group, table 5. As in the main
analysis, the probability of receiving follow-up screening at the higher thresholds was highest
among women with both risk factors and abnormal results on the first screen, followed by those
with both risk factors and normal results. In these two groups, the probabilities were >0.5. In
high-risk women with one risk factor, the probabilities were <0.5, regardless of the result on the
first screen.
4. Discussion
To our knowledge, this is the first study to examine and report, by anal cancer risk factors and
screening result, the guideline concordance of the time to follow-up of anal cancer screening in
women with HIV at high-risk for acquiring anal cancer. These women include those with
histories of abnormal cervical tests or genital warts. We found that the time to any follow-up of
anal cancer screening was longer overall, although shorter among high-risk women with histories
of both risk factors. The time to follow-up screening was not guideline-concordant for most
high-risk women although it was for most high-risk women with both risk factors. These
findings persisted in sensitivity analyses. Among women at high risk of acquiring anal cancer,
the odds of guideline-concordant screening are lower in those who are younger and qualified for
Medicaid through the disability pathway.
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Overall, we found that the time to follow-up of anal cancer screening was much longer among
high-risk women with one risk factor, and it was not guideline-concordant for nearly two-thirds
of them. However, the time to follow-up was guideline-concordant for high-risk women with
both risk factors, regardless of the result on the first screen after a high-risk diagnosis. The lack
of guideline concordance of the time to follow-up overall and among high-risk women with one
risk factor is not surprising and might be for several reasons. One possible explanation is that the
guidelines for anal cancer screening are not very clear on what to do next after the initial
screening, particularly when a positive test is obtained [277], [318]. As a result, opinions and
practice patterns of experts tend to influence institutions’ anal cancer screening processes. For
example, for people treated for severe lesions (AIN2/3), the University of San Francisco’s
screening protocol recommends follow-up screening every six months with high-resolution
anoscopy (HRA)—the same as for those with untreated AIN1 [319], [320]. On the other hand,
John’s Hopkins does not have formal recommendations on follow-up time for those treated for
AIN2/AIN3 but does recommend that follow-up screening with HRA be performed every six
months in those with AIN1 [318]. Another area of uncertainty and debate is when the result of a
pap smear is determined to be ASC-US—atypical squamous cell of undetermined significance or
ASC-H— atypical squamous cell, cannot rule out high-grade lesion. For ASC-US, the University
of San Francisco recommends follow-up screening with HRA screening and if lesions not found,
an annual Pap test is recommended [319]. On the other hand, Johns Hopkins does not make any
recommendations on ASC-US. However, if the result is ASC-H, it recommends HRA and if
there is no lesion or AIN1, repeat HRA should be performed every 3 months [318]. The
University of San Francisco has no formal recommendations for ASC-H. The position of the
HIV Medical Association is unclear on these grey areas. This lack of clarity in the guidelines
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suggests that the time to follow-up will vary by providers and some providers may not
recommend follow-up screening to their clients even if the results on the initial screen are
positive.
Given the lack of clarity in the guidelines, another possible explanation is that the guidelines may
not have been sufficiently popularized and therefore, some providers may not be fully aware of
the guidelines for anal cancer screening. This lack of awareness about the guidelines would most
likely affect rates of anal cancer screening among women with histories of abnormal cervical
tests or genital warts. This is because these risk factors for anal cancer are not the most wellknown or most extensively studied. Receptive anal intercourse is [321] and hence the large
literature on anal cancer screening in MSM with HIV [267], [280]–[283]. Thus, it is probable
that providers not aware of the guidelines may prioritize anal cancer screening in MSM and
overlook high-risk women, particularly those with a single risk factor.
Another potential explanation for the low rates of follow-up screening is that while HRA is
considered the gold standard for anal cancer screening and strongly recommended for follow-up
screening [318], [320], [322], several challenges limiting its use remain. These challenges
include a shortage of colposcopies, shortage of well-trained personnel, and a long learning curve
for the technique [278], [323], [324]. For example, data show that it takes examining about 200
cases for a provider to competently detect all high-grade lesions using HRA [324]. These
technological limitations suggest that high-risk women, particularly those with abnormal results
on the first screen after a high-risk diagnosis, may not receive the follow-up screening even if
they want to.
An additional potential explanation is that physicians, particularly specialists, may not have
enough time to provide the follow-up screening services. In multivariable regressions, we found
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that high-risk women in counties with more specialists are significantly less likely to have
guideline-concordant time to follow-up screening. At the same time, the likelihood of receiving
guideline-concordant follow-up screening is higher, although not significant, in counties with
more primary care physicians. This suggests that high-risk women relying on specialists, vs.
primary care physicians, may face delays in receiving the follow-up anal cancer screening. These
delays could be due to the involvement of multiple specialties vs. a single specialty in providing
this care [325], [326]. Finally, it is possible that those with one risk factor may downplay the risk
of anal cancer given that they have one and not multiple risk factors. Therefore, they may
procrastinate in seeking follow-up screening, thinking the problem is not serious enough and
may naturally disappear.
The pattern of the time to follow-up screening among those with abnormal and normal results
(on the first screen) is consistent with reports from previous studies, although we emphasize that
the overall median follow-up time in this study is not always consistent with those studies.
Similar to the current study, previous studies reported higher follow-up screening frequencies
among women with abnormal results compared to those with normal results [273], [275], [287].
The study’s overall median follow-up time (18 months) compares favorably with findings from a
study in California which reported a follow-up time of 17 months in women with HIV [287]. In
New York, women with HIV and normal results on the previous screen received follow-up anal
cancer screening in 12 months [275], which is guideline-concordant but inconsistent with this
study’s findings. Studies of women with HIV in Boston, Connecticut, and Massachusetts,
reported a follow-up time of 6 months if the previous screen was normal [270], [273]. We
emphasize that comparisons with these studies are limited because the studies did not restrict
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their samples to women at high risk for anal cancer, had smaller sample sizes (<100 in many
cases) or were limited in geographic scope.
Finally, the finding that time to follow-up screening was guideline-concordant for <50% of the
high-risk women is consistent with other studies on the guideline concordance of care among
PLWH. Among women with HIV, <50% receive guideline-concordant depression care [328] and
<40% receive guideline-concordant cervical cancer screening [329]. Among PLWH, <40%
receive guideline-concordant opioid therapy [330], <30% receive timely medical care for HIV
symptoms [331], and <50% receive regular HIV care [332]. Therefore, this study contributes to a
broader literature suggesting that there is room for improvement in the delivery of HIV-related
care.
4.1. Limitations
This study has limitations. First, we were unable to examine the guideline concordance of the
time to follow-up screening in women with HIV and histories of receptive anal intercourse due
to data limitations. These women are also at high risk of acquiring anal cancer and are
recommended for regular follow-up screening [277]. Although ICD-9 codes for high-risk sexual
behaviors were available, we could not identify specific diagnoses of receptive anal intercourse
in the MAX data. Despite this limitation, it is likely that we captured some of these women
among those with histories of genital warts. This is because individuals with high-risk sexual
behaviors like receptive anal intercourse are more likely to acquire sexually transmitted
infections, including genital warts [333].
Second, we were unable to know if any women received follow-up anal cancer screening not
paid for by Medicaid and therefore, not captured in the MAX data. This problem was likely to
occur because of churning. Data show that individuals who churn tend to have health service
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utilization patterns different from those continuously enrolled in Medicaid [334], [335]. Thus,
the estimates are biased to the extent that the frequency of follow-up screening among those who
churned systematically differed by risk group. To mitigate this problem, we limited the study’s
sample to high-risk women continuously enrolled in Medicaid for ≥ 24 months. Moreover, the
study’s findings were robust in sensitivity analysis when we restricted the sample to only those
continuously enrolled for the entire study period (48 months).
Third, we did not have access to individual-level socio-economic data like education and
income—two factors that influence the utilization of preventive care and health outcomes among
PLWH [302], [303]. To address this limitation, we supplemented the MAX data with the AHRF
and controlled for county-level education and income.
Finally, the findings may not be generalizable to all women with HIV at high-risk of acquiring
anal cancer. This is particularly true as we used a cohort of Medicaid enrollees in the US South
and not a nationally representative sample. Thus, the time to follow-up screening reported here
may not be observed in the country’s other regions or among those privately insured or rely on
Ryan White HIV clinics. Despite these limitations, it is likely the study adequately captured the
frequency of follow-up anal screening in high-risk women with HIV given the large sample for
the study and likely reflects regional trends in the receipt of follow-up screening in this
population.
4.2. Implications for practice and policy
Time to follow-up anal cancer screening is not guideline-concordant for most high-risk women
with histories of abnormal cervical tests or genital warts, although it is for most high-risk women
with both risk factors. This problem can be addressed in several ways, including enhancing
partnerships between primary care physicians and specialists and training more providers in
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using HRA—a specialized test for anal cancer screening and recommended for follow-up
screening particularly among those with abnormal cytologic results. Use of HRA in follow-up
screening is critical because, unlike cytology, HRA can distinguish between low-grade and highgrade lesions and therefore, allows for the appropriate treatment and follow-up recommendations
[318], [320], [322].
Second, it is critical to clarify the guidelines for anal cancer screening. This can be achieved by
gathering more compelling evidence on the benefits of anal cancer screening, particularly in
individuals at high-risk for acquiring anal cancer. While experts agree that anal cancer screening
in high-risk individuals can prevent anal cancer or at least detect it early, the guidelines for anal
cancer screening have not been adopted universally [336], [337]. This is mainly because of the
lack of compelling evidence about the benefits of anal cancer screening [336], [337]. To address
this gap, a randomized controlled trial evaluating the benefits of treating high-grade lesions in
PLWH is currently in progress in the USA [338]. Thus, the evidence from that trial and perhaps
additional observational studies can help to clarify the guidelines, lead to their universal adoption
and popularization, and eliminate any confusions about the timing of follow-up screening.
Furthermore, re-examining the payment policy for anal cancer screening services can be useful
since there is no CPT code for anal cancer screening [309], [310], [312]. Thus, clinicians cannot
bill payers for anal cancer screening as a single service. The status quo is that clinicians bill
payers the bits and pieces that comprise anal cancer evaluation and management (for example,
anoscopy) [339], [340]. Payers argue that they cannot pay for anal cancer screening because its
benefits have not been evaluated in any randomized controlled trial and the screening is not
universally recommended [278], [336], [340]. It is noteworthy that payers reimburse clinicians
for cervical cancer screening despite cervical and anal cancers having many similarities and both
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lacking evidence of screening benefits from randomized controlled trials [336], [339]. The lack
of a single CPT code for anal cancer screening creates difficulties in reimbursement for the
services [309], [312] and therefore, a disincentive to the continued provision of anal cancer
screening services. Thus, it is probable that creating a billable CPT code for anal cancer
screening could eliminate the difficulties in reimbursements and increase rates of anal cancer
screening overall.
Finally, high-risk women should be made aware of the benefits of anal cancer screening,
regardless of the number of risk factors for anal cancer. Data show that 63% of people at risk for
anal cancer do not know that anal cancer screening is recommended [341], a sizable proportion
refuses the screening [341]–[343], and not all clinicians discuss this with their patients [344].
Therefore, discussions between providers and their clients at a high-risk for acquiring anal cancer
about the benefits of anal screening can increase the uptake of anal cancer screening services.
4.3. Future research
While this study contributes to a broader literature suggesting that most PLWH do not receive
guideline-concordant care, much remains to be done. Future research should focus on whether
the timing of follow-up anal cancer screening varies by health service delivery model (managed
care) or payment model (fee-for-service). This is important as many states have moved from
Medicaid fee-for-service to Medicaid managed care [345]. However, it is unclear how such
changes affect the receipt of anal cancer screening specifically and HIV-related preventive care
in general. Future research should also examine racial/ethnic disparities in the timing of followup anal cancer screening overall and in each group of high-risk women. Evidence suggests that
racial/ethnic minorities are less likely to receive HIV-related preventive care [346]–[348], be
treated for anal cancer [349], and more likely to present with advanced disease stage [350],
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[351], compared with non-Hispanic whites. Among MSM with HIV, non-Hispanic blacks are
less likely to be screened for anal cancer [286], [343], [352]. It is unclear whether these
disparities extend to follow-up anal cancer screening of high-risk women. We were unable to
investigate this question because of inadequate sample sizes for high-risk non-Hispanic whites
and Hispanics.
5. Conclusion
In the past 2-3 decades, the incidence of anal cancer among PLWH has increased significantly.
We examined the guideline concordance of the timing of follow-up anal cancer screening in two
groups of women at high-risk for acquiring anal cancer: women with HIV and histories of either
abnormal cervical tests or genital warts. The timing of the follow-up screening is not guidelineconcordant overall and among high-risk women with a history of one risk factor. However, it is
guideline-concordant among those with histories of both risk factors. These findings suggest that
high-risk women with one risk factor are in danger of being overlooked as also being at risk for
anal cancer. As a result, they may present for screening with advanced disease, making
secondary prevention difficult, and thereby limiting the chance of survival. In all, these findings
provide support for efforts, including training providers in how to effectively use HRA and
generating more evidence to help push for the universal adoption of the guidelines for anal
cancer screening, to increase rates of follow-up anal cancer screening in those at high-risk of
acquiring anal cancer.
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Table 1: Summary statistics for high-risk women living with HIV followed-up for anal cancer screening, by risk group
Variable

All high-risk women
(n=3,779)

Genital warts only
(n=292)

Abnormal cervical only
(n=2,809)

Abnormal cervical and
genital warts (n=678)

Frequency

Frequency

Frequency

Frequency

Percent

Percent

Percent

Percent

First screen after a high-risk diagnosis***
Abnormal
326
9%
34
12%
162
6%
130
19%
Normal
3453
91%
258
88%
2647
94%
548
81%
Time at risk (person-years)†
4458
100%
349
8%
3438
77%
672
15%
Received follow-up screening***
2086
55%
129
44%
1454
52%
503
74%
Incidence of follow-up screening (per person-year)
0.39
0.31
0.35
0.62
Time to follow-up screening guideline-concordant‡
1414
37%
91
31%
972
35%
351
52%
Abnormal anal test at first screening***
150
46%
10
29%
73
45%
67
52%
Normal anal test at first screening***
1264
37%
81
31%
899
34%
284
52%
Race/ethnicity***
Non-Hispanic white
454
12%
45
15%
324
12%
85
13%
Non-Hispanic black
2570
68%
175
60%
1949
69%
446
66%
Hispanic
174
5%
28
10%
99
4%
47
7%
Others
581
15%
44
15%
437
16%
100
15%
Medicaid qualification***
Income
994
26%
58
20%
788
28%
148
22%
Disability
2785
74%
234
80%
2021
72%
530
78%
Enrollment length***
Continuously enrolled for 2 years
788
21%
62
21%
602
21%
124
18%
Continuously enrolled for 3 years
585
15%
48
16%
444
16%
93
14%
Continuously enrolled for 4 years
2406
64%
182
62%
1763
63%
461
68%
Age (mean and standard deviation) ***, years
41.9
10.2
42.2
9.9
41.6
10.6
40.7
9.9
*p-value<0.05; **p-value<0.01; ***p-value<0.001. †Percentages are by row, otherwise, percentages are by column. ‡ Receipt of follow-up anal cancer screening
within 6 months for those with an abnormal anal test at the first test and within 12 months for those with normal results at the first test. §First column=mean and
second column= standard deviation. For these variables tests of statistical significance were performed using the F-test; otherwise, Chi-square were tests used.
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Table 2: Odds of guideline-concordant time to follow-up anal cancer screening in high-risk women with HIV
Panel 1
Panel 2
Guideline-concordant followAny follow-up anal cancer
up anal cancer screening†
screening
Odds Ratio
95% C.I.
Odds Ratio
95% C.I.
Individual-level factors
Number of risk factors (ref: one risk factor)‡
Both factors
2.57***
[2.12,3.12]
2.06***
[1.73,2.46]
Result at first anal cancer screen (ref: normal)
Abnormal
3.22***
[2.39,4.34]
1.27*
[1.00,1.63]
Qualification for Medicaid (ref: income)
Disability
1.23**
[1.03,1.47]
1.28***
[1.06,1.53]
Years of continuous enrollment (ref: 2 years)
3 years
1.29**
[1.03,1.62]
1.11
[0.88,1.39]
4 years
1.37***
[1.16,1.64]
0.97
[0.81,1.16]
Age (ref: 19-34 years)
35-44 years
1.39***
[1.16,1.67]
1.40***
[1.16,1.68]
***
45-54 years
1.30
[1.07,1.58]
1.24**
[1.02,1.51]
***
***
55-64 years
1.58
[1.22,2.04]
1.66
[1.28,2.14]
Race/ethnicity (ref: non-Hispanic whites)
Non-Hispanic Black
1.07
[0.86,1.34]
0.89
[0.71,1.11]
**
Hispanic
1.63
[1.11,2.41]
1.14
[0.79,1.66]
Others
1.22
[0.87,1.70]
0.83
[0.59,1.16]
County/state level controls§
Diagnosed HIV cases per 100,000 adults (ref: 0-54)
55-138
1.84
[0.61,5.55]
2.82
[0.81,9.76]
139-2426
1.27
[0.44,3.69]
1.98
[0.59,6.65]
Primary care physicians per 10,000 population (ref:
0-3.7)
3.8-6.3
1.35
[0.90,2.03]
1.22
[0.81,1.85]
6.4-47.6
1.22
[0.78,1.91]
1.18
[0.75,1.85]
Specialists per 10,000 population (ref: 0-0.92)
0.93-3.4
0.43***
[0.24,0.76]
0.41***
[0.24,0.72]
**
**
3.5-147.8
0.45
[0.24,0.83]
0.50
[0.27,0.91]
Percent living the federal poverty level (ref:0.9%13.5%)
13.6%-18.9%
0.84
[0.60,1.17]
1.13
[0.81,1.59]
19%-63.2%
0.82
[0.56,1.20]
0.94
[0.64,1.37]
Percent with less than high school education (ref:
1%-11.4%)
11.5%-18%
0.80*
[0.63,1.03]
0.86
[0.67,1.09]
18.1%-55
0.91
[0.66,1.27]
1.08
[0.78,1.51]
Percent with Medicaid managed care enrollment
(ref: <=60%)¶
61%-80%
1.02
[0.29,3.54]
0.33
[0.08,1.27]
>80%
1.1
[0.34,3.58]
0.38
[0.10,1.41]
Observations
3779
3779
p < 0.10, ** p < 0.05, *** p < 0.01. †Receipt of follow-up anal cancer screening in 6 months for those with an abnormal
anal test at the first test and within 12 months for those with normal results at the first test. ‡The risk factors are histories
of abnormal cervical tests or genital warts. §The county and state control variables are tertiles. ¶State-level variable.
*
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Table 3: The percent of women living with HIV with guideline-concordant time to follow-up screening at varying restrictions of years
of continuous enrollment in Medicaid
Base case analysis† (n=3,779)
Sensitivity analysis‡ (n=2,406)
Continuously enrolled for at least 2 years
Normal (≤12 months)
Abnormal (≤6 months)

Only those continuously enrolled for 4 years
Normal (≤12 months)
Abnormal (≤6months)

Risk factors*

Estimate (%)

95% C.I.

Estimate (%)

95% C.I.

Estimate (%)

95% C.I.

Estimate (%)

95% C.I.

Overall

37

[35-39]

42.00

[42-52]

39.61

[37-42]

46.96

[41-54]

One risk factor

34

[32-36]

39.33

[34-45]

36.30

[34-39]

44.39

[36-53]

Both risk factors

51

[47-55]

56.76

[51-63]

55.24

[50-61]

50.37

[41-61]

*Risk factors: a history of abnormal cervical tests or a history of genital warts. †The base case (main) analysis uses a sample of women living
with HIV continuously enrolled in Medicaid for at least two years. ‡ This is a sensitivity analysis in which the guideline concordance of the
follow-up time to anal cancer screening was examined only in women living with HIV continuously enrolled in Medicaid for 4 years (20092012)-the study's analytic time horizon.
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Table 4: The percent of women living with HIV with guideline-concordant time to follow-up screening, using varying numbers of
ICD-9 codes to define high-risk women
Base case analysis† (n=3,779)
Sensitivity analysis (n=4,960)
Percent receiving follow-up screening†

Percent receiving guideline-concordant‡

Normal (≤12 months)

Abnormal (≤6 months)

Normal (≤12months)

Abnormal (≤6months)

Risk factors*

Estimate (%)

95% C.I.

Estimate (%)

95% C.I.

Estimate (%)

95% C.I.

Estimate (%)

95% C.I.

Overall

40

47

[42-53]

38

[37-40]

47

[42-52]

One risk factor

37

[38-41]
[35-39]

44

[37-51]

36

[34-38]

42

[36-49]

Both risk factors

54

[50-58]

53

[44-61]

51

[47-55]

56

[48-64]

Abbreviation: ICD-9, International Classification of Diseases, Ninth Revision. *Risk factors: a history of abnormal cervical tests or a history
of genital warts. †Estimates in the base case analysis were derived from a sample of high-risk women created using a more conservative
definition (fewer ICD-9 codes) of high-risk. ‡In the sensitivity analysis, a sample of high-risk women was created using additional codes that
may or may not conclusively suggest that an individual is high-risk. ‡Receipt of follow-up anal cancer screening within 6 months for those
with an abnormal anal test at the first test and within 12 months for those with normal results at the first test
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Table 5: Average predicted probability of receiving follow-up anal cancer screening in women with HIV at different cut-off points
Base case analysis† (n=3,779)
Sensitivity analysis (n=3,779)‡
Normal (≤12 months)

Abnormal (≤6 months)

Normal (≤14 months)

Abnormal (≤8 months)

Risk factors*

Probability

95% C.I.

Probability

95% C.I.

Probability

95% C.I.

Probability

95% C.I.

Overall

0.37

[0.35-0.39]

0.42

[0.42-0.52]

0.40

[0.39-0.42]

0.47

[0.42-0.53]

One risk factor

0.34

[0.32-0.36]

0.39

[0.34-0.45]

0.37

[0.35-0.39]

0.44

[0.38-0.50]

Both risk factors

0.51

[0.47-0.55]

0.57

[0.51-0.63]

0.55

[0.51-0.59]

0.62

[0.56-0.68]

*Risk factors: a history of abnormal cervical tests or history of genital warts. †The base case analysis represents the time to follow-up
recommended in the guidelines for follow-up anal cancer screening. ‡ The sensitivity analysis represents a relaxed threshold to account for
logistical delays that may happen is seeking follow-up anal cancer screening services.
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Adapted from Chin-Hong and Palefsky. Clin Inf Dis (2002) and Leeds and Fang. World J Gastrointest Surg (2016).
Thick boxes highlight the groups of people living with HIV and anal cancer screening frequencies of interest in this study.
*Both men and women with genital warts are recommended for regular screening, but the focus is on women with genital
warts
Figure 1: Recommendations for anal cancer screening in people living with HIV at high risk for anal cancer

This figure summarizes recommendations for anal cancer screening in people with HIV at high-risk of acquiring
anal cancer. Guidelines for anal cancer screening recommend regular screening in those with histories of highrisk sexual behaviors, abnormal cervical tests, or genital warts. Follow-up screening is recommended every 12
months if the initial result is normal or every 6 months if the result is abnormal.
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Individual and population characteristics

Predisposing
characteristics
Age
Sex
Education*
Race/ethnicity

Enabling resources
Income*
PCPs/population ratio*
Specialists/population*
Insurance

Need factors
Living with HIV

Use of health services

Anal cancer screening†
Baseline
Every 6 months
Every 12 months

Outcomes

Prevention of anal cancer
Lower morbidity mortality
due to anal cancer

History of abnormal
cervical Pap
History of genital warts

Adapted from Andersen, J. Health Soc. Behav., 1995
The thick box highlights that the present study is interested in the frequency of anal cancer screening (utilization of health services) in highrisk people living with HIV. *Variable is only available at the county- and not individual-level. †The guidelines for anal cancer screening
recommend screening of all people diagnosed with HIV at baseline and then those with histories of abnormal cervical Pap or genital warts
should be screened annually if the anal cancer screening results are normal or bi-annually if the results are abnormal.
Figure 2: A framework for understanding the frequency of follow-up anal cancer screening in high-risk women living with HIV

This figure shows the interplay of individual/population factors and how they affect the utilization of anal cancer screening services. It also
shows that while people living with HIV people have a need for anal cancer screening, risk factors like having a history of genital warts
increase this need.
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100
75
50
0

25

0
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24
Analysis time (months)

36

48

3101
678

1480
250

706
101

270
42

2
0

Risk table
Single factor
Both factors

Risk factors
Single factor

Both factors

The risk factors are 1) history of abnormal cervical tests; 2) history of genital warts.

Figure 3: Kaplan-Meier estimates of the frequency of follow-up anal cancer screening, by risk group

This figure shows that the frequency of follow-up anal cancer screening was higher in women with HIV and histories of both
abnormal cervical tests and genital warts.
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100
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0
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0

12

24
Analysis time (months)

36

48

2905
548
196
130

1422
216
58
34

683
93
23
8

266
38
4
4

2
0
0
0

Risk table
Single factor & normal
Single factor & abnormal
Both factors & normal
Both factors & abnormal

Risk factor & result on previous screen
Single factor & normal

Single factor & abnormal

Both factors & normal

Both factors & abnormal

The risk factors are 1) history of abnormal cervical tests ; 2) history of genital warts.

Figure 4: Percent receiving guideline-concordant follow-up anal cancer screening, by risk group and the result of the first screen

This figure shows that the percent of women receiving guideline-concordant follow-up screening was highest among those with both
risk factors, regardless of the result of the first anal cancer screen after a high-risk diagnosis (points A and C). The percent was lowest
among those with a single risk factor and a normal result on the first test (point D).
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Appendices
Appendix C1: Variable definitions
Table C1: Definition of variables in a study of guideline concordance of follow-up anal screening in high-risk women living with HIV
Variables
Type
Definition
Justification
Source
Individual-level
Time from first anal cancer screen after a Dependent variable.
Frequency
Continuous
MAX files
variables
high-risk diagnosis to the next screen.
Receipt of guideline-concordant follow- Dependent variable
Concordance
Binary
MAX files
up screening: concordance=1 if
guideline-concordant, concordance=0
otherwise
1=history of abnormal cervical tests,
Key explanatory variable. Anal cancer screening likely MAX files
Risk group
Categorical
2=history of genital warts, 3=history of higher among women with both risk factors.
abnormal cervical tests and genital warts
Qualification for
Anal cancer screening likely higher among those
Binary
1= via income, 2= via disability.
MAX files
Medicaid
qualified via the disability path.
Continuous enrollment Ordinal
Years continuously enrolled in Medicaid: Anal cancer screening likely higher among those
MAX files
(years)
1=2 years, 2=3 years, 3=4 years.
enrolled in Medicaid for longer periods.
1=19-34 years, 2=35-44 years, 3=45-54 Older participants more likely to be screened for anal MAX files
Age (years)
Categorical
years, 4=55-64 years.
cancer.
Race/ethnicity
County-level
HIV prevalence

Categorical

Year
2008-2012
2008-2012

2008-2012

2008-2012
2008-2012
2008-2012

1=non-Hispanic white, 2=non-Hispanic Use of healthcare services differs by race [286], [343], MAX files 2008-2012
black, 3=Hispanic, 4=Others
[352].

Ordinal (tertiles) HIV cases per 100,000 adult population. People in high-burden HIV counties are more likely to AIDSVu*
receive HIV appropriate care as HIV providers are more
likely to locate there [305].
Primary care physician Ordinal (tertiles) The ratio of primary care physicians per Anal cancer screening services are more likely to be
AHRF
population (PCP) ratio
10,000 population
available in areas with a higher supply of PCPs.
Specialist population
Anal cancer screening more likely to be available in
Ordinal (tertiles) The ratio of specialists per 10,000
AHRF
ratio
population
areas with a higher supply of specialists.
Poverty
Ordinal (tertiles) The percent of people in poverty.
AHRF†
Income is an enabler of health services use [289].
Education
Ordinal (tertiles) The proportion of residents with at least a Education predisposes an individual to use healthcare AHRF
high school education.
services [289].
State-level

2010

2010
2010
2010
2010
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Medicaid managed care Ordinal (tertiles) The percent of Medicaid beneficiaries
enrollment.
enrolled in managed care.

Beneficiaries in managed care are more likely to receive KFF
preventive care [353], like anal cancer screening.

2012

Abbreviations: MAX, Medicaid Analytic eXtract file; AHRF, AHRF Area Health Resources File; KFF, Kaiser Family Foundation. *AIDSVu, maintained by
Emory University, consists of county-level surveillance data on diagnosed HIV cases in the US [304]. †AHRF is maintained by the Health Resource
Service Administration [301].
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Appendix C2: Identifying high-risk women from a sample of women living with HIV
To identify high-risk women among those with HIV, we used diagnosis codes for abnormal
cervical tests or genital warts [307], [308]. We searched Google for commonly used ICD-9 codes
for abnormal cervical tests or genital warts which we validated using the literature and expert
opinions. For abnormal cervical tests, codes traditionally used for abnormal cervical Pap smears
or cervical intraepithelial neoplasia were the main codes [354]–[357], table C2. However, other
codes such as 795.01 (Papanicolaou smear of cervix with atypical squamous cells of
undetermined significance) were also included to account for coding errors or misdiagnoses. The
supplementary codes in table C2 were used in sensitivity analysis only. For genital warts, while
ICD-9 code 078.11 is specific to genital warts, two codes are also commonly used: 078.10 for
unspecified viral warts and 078.19 for other specified viral warts [358]. The supplementary
codes were used in sensitivity analyses only. We did not restrict the ICD-9 code to a specific
position.
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Table C2: Codes for identifying women with HIV at high-risk for acquiring anal cancer
Identifying women living with HIV*
ICD-9 Code
Description
042
AIDS diagnosis
V08
HIV diagnosis
Abnormal cervical Pap test/cervical intraepithelial neoplasia
ICD-9 Code (Main)† Description
795.02
Papanicolaou smear of cervix with atypical squamous cells cannot exclude high grade squamous
intraepithelial lesion (ASC-H)
795.03
Papanicolaou smear of cervix with low grade squamous intraepithelial lesion (LGSIL)
795.04
Papanicolaou smear of cervix with high grade squamous intraepithelial lesion (HGSIL)
795.05
Cervical high-risk human papillomavirus (HPV) DNA test positive
795.06
Papanicolaou smear of cervix with cytologic evidence of malignancy
622.10
Dysplasia of cervix, unspecified
622.11
Mild dysplasia of the cervix
622.12
Moderate dysplasia of the cervix
233.1
Carcinoma in situ of cervix uteri
233.32
Carcinoma in situ vulva
V13.22
History of cervical dysplasia
ICD-9 Code
Description
(Supplementary)‡
622.1
623
79.4
795.00
795.01

Dysplasia of cervix, uteri
Dysplasia of vagina
HPV infection, unspecified site
Abnormal glandular Papanicolaou smear of cervix
Papanicolaou smear of cervix with atypical squamous cells of undetermined significance (ASCUS)
795.07
Satisfactory cervical smear but lacking transformation zone
795.08
Unsatisfactory cervical cytology smear
795.09
Other abnormal Pap smear of cervix and cervical HPV
History of genital warts
ICD-9 Code (Main)
Description
078.11
Condyloma acuminatum
078.10
Viral warts, unspecified
078.19
Other specified viral warts
ICD-9 Code
Description
(Supplementary)‡
078.12
Plantar warts
Abbreviations: ICD-9, International Classification of Diseases, Ninth Revision. *ICD-9 codes V01.79 (exposure to HIV
virus) and 795.71 (nonspecific serologic evidence of HIV) were not included in identifying women with HIV because
these codes do not confirm HIV disease. †These are the main codes for this diagnosis but added supplementary codes to
account for coding errors. ‡ The supplementary codes were used in sensitivity analysis only.
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Sample of people living with HIV
N=71,090

Exclusions
1. Males; N=34,560
2. Unknown sex=583
3. Women 19 years ≤ age ≤ 64 years, N=87
4. Eligible for Medicare and Medicaid. N=1,549

Sample of non-elderly women living with HIV
N=34,318
1. Not high-risk for anal cancer (without histories of
abnormal cervical test or genital warts); N=25,751
2. Maximum date for a high-risk diagnosis less than
minimum date of HIV-associated ICD-9 code; N=638
3. Diagnosed high-risk on the last service date, N=12

Sample of high risk non-elderly women living with HIV
N=7,917
1. Not continuously enrolled for ≥24 months; N=1,831

Analytic sample of high-risk non-elderly women living
with HIV continuously enrolled for at least 24 months
N=6,086

History of abnormal cervical tests
N=5,977

History of genital warts
N=889

History of both abnormal cervical
tests and of genital warts
N=1,051

Figure C2: Algorithm for identifying high-risk HIV-infected women from Medicaid Analytic eXtract (MAX) files
This figure shows the process of deriving a sample of women at high-risk for acquiring anal cancer from a sample of women enrolled in
Medicaid and validated to be living with HIV. The analytic sample comprised 6,086 of whom 5,977 had a history of abnormal cervical
tests, 889 had a history of genital warts, and 1,051 had histories of both abnormal cervical tests and genital warts.
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Appendix C3: Identifying high-risk women screened for anal cancer
To identify high-risk women screened for anal cancer, we used CPT codes that suggest that an
anal cancer screen was performed, table C3. Unlike similar services such as cervical cancer
screening, there is no single CPT code for anal cancer screening [309], [310], [312]. For
example, CPT code 88104 “fluid requiring simple smear preparation” suggests that anal cancer
screening was performed using a Pap smear. We searched Google, Google Scholar, and PubMed
for commonly used CPT codes that suggest anal cancer screening was performed. Examples of
terms used include “CPT code” used in combination with “anal cytology” or “anal cancer
screen” or “high-resolution anoscopy”.
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Table C3: CPT codes for anal cancer screening
Anal cytology
CPT* code
Description
87207
Stain for inclusion bodies
88104
Fluid requiring simple smear preparation
88108
Fluid requiring concentration technique
88112
Fluid requiring thin layer preparation
88160
Smear prepared by the client
88161
Smear requiring preparation
88162
Multiple smears (5 or more) requiring extended study
88172
Determination of adequacy of specimen
88173
FNA (fine needle aspiration) interpretation
88305
Fluid requiring cell block preparation
Anoscopy
CPT code
Anoscopy, with or without collecting a specimen
46600
46601
Anoscopy; diagnostic, with high-resolution magnification (HRA)
46606
Anoscopy with multiple biopsy specimens
46607
Diagnostic anoscopy and biopsy
HCPCS code†
Description
G2078
Anoscopy, high resolution (with magnification and chemical agent enhancement)
G6027
High-resolution anoscopy with specimen collection
G6028
High-resolution anoscopy with biopsy
Abbreviations: CPT, Current Procedural Terminology; HCPCS, Healthcare Common Procedure Coding System.
*CPT codes are used to report medical, surgical and diagnostic procedures rendered by physicians and other
healthcare professionals. †HCPCS codes are in two levels. Level 1 comprises CPT codes while level 2 is for
supplies, medications, and services provided to patients outside the physician's office and not included in the
CPT code.
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Appendix C4: Ascertaining whether a result of an anal cancer screen was abnormal
To ascertain whether the outcome of the anal cancer screen was abnormal, we used ICD-9 codes
suggesting that an abnormal result was found during the screening. If an enrollee received the
screening but none of the codes we found were recorded, we assumed that abnormal or
suspicious anal cells were not found. We searched Google, Google Scholar, and PubMed for the
ICD-9 codes. For the search, we used the terms “ICD-9 or in combination with “anal squamous
intraepithelial lesion” or “dysplasia of anus” or “anal intraepithelial neoplasia”, among other
terms.
Table C4: ICD-9 codes for identifying women with abnormal results after anal cancer screening
ICD-9 Code Description
796.70
Abnormal glandular Papanicolaou smear of anus
796.71
Papanicolaou smear of anus with atypical squamous cells of undetermined significance
(ASC-US)
796.72
Papanicolaou smear of anus with atypical squamous cells cannot exclude high grade
squamous intraepithelial lesion (ASC-H)
796.73
Papanicolaou smear of anus with low grade squamous intraepithelial lesion (LGSIL)
796.74
Papanicolaou smear of anus with high grade squamous intraepithelial lesion (HGSIL)
796.75
Anal high-risk human papillomavirus (HPV) DNA test positive
796.76
Papanicolaou smear of anus with cytologic evidence of malignancy
796.77
Satisfactory anal smear but lacking transformation zone
796.78
Unsatisfactory anal cytology smear
796.79
Other abnormal Papanicolaou smear of the anus and anal HPV
569.44
Dysplasia of anus (mild, moderate, AINI and II)
230.5
Carcinoma in situ of the anal canal
230.6
Carcinoma in situ of anus, unspecified
211.4
Benign neoplasm of rectum and anal canal
569.49
Other specified disorders of rectum and anus
Abbreviation: ICD-9, International Classification of Diseases, Ninth Revision.
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Stata do file
///Analysis of initial anal cancer screening
cd /mnt/isilon/data/hpr/yang/HIV/STEVEN/DATA/CLAIM/Working_folder/Stata/

log using summaries, replace

set more off

use hiv+_hirsk_patient_analysis, clear

*examining the characteristics of those enrolled for two years and those who
were not
tab continuously_2yr riskgroup, chi exp row
tab continuously_2yr race, chi exp row
tab continuously_2yr scrnd_for_AC, chi exp row
tab race scrnd_for_AC if continuously_2yr==0, chi exp row
tab race scrnd_secondtime if continuously_2yr==0, chi exp row

*keeping only those enrolled for at least two years
tab continuously_2yr, m
keep if continuously_2yr==1

*checking the association between routine care and anal cancer screening
tab routinecare
tab routinecare scrnd_for_AC, chi
tab routinecare scrnd_for_AC, col
tab routinecare scrnd_for_AC, col row

*setting the font
graph set window fontface "Times New Roman"
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***********
*Initial anal cancer screening

**understanding the data

*tsetting the data
stset time_exit1, origin(time_entry1) failure(scrnd_for_AC ==1) id(msis_id)
scale(30)

tab _d, m
*tab _d scrnd_for_AC, m
gsort- _d
order scrnd_for_AC srvc_bgn_dt srvc_end_dt time* date_first_hirsk _d
srvc_date_first srvc_date_last

*describing the data
stdescribe

forval i=1/3 {
stdescribe if riskgroup==`i'
}

forval i=1/4 {
stdescribe if race==`i'
}

*summarizing the data
stsum, by(riskgroup)
stsum, by(race)
stsum, by(riskgroup race)
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*checking if any of the variables are timevarying
stvary

*using the log-rank and unadjusted cox model to check variables for inclusion
///
*usually if p value >.2, the variable should not be included
*log rank test is for categorical variables, while Cox is for continuous one
*log rank
foreach var of varlist riskgroup race eligibility {
sts test `var'
}
* Cox
stcox age
stcox enrollment

***summary statistics
summarize

enrollment age

*Oneway ANOVA
oneway age riskgroup, tab
oneway enrollment riskgroup, tab

*kruskall Wallis test, by risk group
tabstat enrollment age, by(riskgroup) stats(p50 iqr)
kwallis enrollment, by(riskgroup)
kwallis age, by(riskgroup)

foreach var of varlist scrnd_for_AC scrnd_secondtime abnanal race eligibility
continuously_3 continuously_4 {
tab `var' riskgroup, chi
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}

*ranksum tests
median age, by (riskgroup)
**
**table 2 of descriptives (by race)
*kruskall Wallis test, by race
tabstat enrollment age, by(race) stats(p50 iqr)
kwallis enrollment, by(race)
kwallis age, by(race)

oneway age race, tab
oneway enrollment race, tab

foreach var of varlist scrnd_for_AC scrnd_secondtime abnanal riskgroup
eligibility continuously_3 continuously_4 {
tab `var' race, chi
}
**the bivariate analyses
*the bivariate analyses will be only among those continuously enrolled for at
least 24 months

*table 3: bivariate analyses
foreach var of varlist riskgroup race continuously_3 continuously_4 {
stsum, by(`var')
stci, by(`var')
stci, rmean by(`var')
sts test `var'
}

*drawing Kaplan-Meier graphs: interest is in failure (success) and not
survival
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sts graph, gwood failure risktable(, color(black) size(2.5) order(1 "All
women") title("Risk table", size(3.0))) ///
yline(0.5, lwidth(0.002) lcolor(black) lpattern(-)) ylab(, labsize(2.5))
xline(13.6, lwidth(0.002) lcolor(black) lpattern(-)) ///
xtitle("Analysis time (months)", size(3.0)) ytitle("% screened for anal
cancer", size(3.0) height(7)) xlabel(,labsize(3.0)) ///
xlabel(0 (12) 48) ///
graphregion(fcolor(white)) ///
legend(rows(1) label(1 "(95% C.I.") label(2 "Screening function") size(2.5)
order(2 "Screening function" 1 "95% C.I.")) ///
title("Figure 1: Kaplan-Meier (KM) estimates of initial anal cancer screening
rates", size(3) color(black)) ///
graphregion(color(white))
graph save all_women, replace

*by riskgroup but I start by estimating unadjusted relative risks to see if
separate failure (sucess) curves are warranted
glm scrnd_for_AC i.riskgroup, fam(bin) link(log) eform /*shows that separate
success curves are warranted*/
stcox i.riskgroup

sts graph, failure by(riskgroup) risktable(, color(black) size(2.5) order(1
"Warts only" 2 "Abn. cerv only" 3 "Both") title("Risk table", size(3.0)))
///
yline(0.5, lwidth(0.002) lcolor(black) lpattern(-)) ylab(, labsize(2.5)) ///
xline(4.2 14.8 43.9, lwidth(0.002) lcolor(black) lpattern(-)) ///
legend(rows(1) subtitle("Risk group", size(3.0)) label(1 "Warts only")
label(2 "Abn. cerv only") label(3 "Both") size(2.5)) ///
xtitle("Analysis time (months)", size(3.0)) ytitle("% screened for anal
cancer", size(3.0) height(7)) xlabel(,labsize(3.0)) ///
graphregion(fcolor(white)) ///
xlabel(0 (12) 48) ///
plot1opts(lpattern(longdash_dot) lcolor(blue)) ///
plot2opts(lpattern(dash) lcolor(maroon)) ///
plot3opts(lpattern(dash_dot) lcolor(green)) ///
caption("Abnormal cervical: HR=1.48, 95% C.I.=1.30-1.69; Both: HR=2.28, 95%
C.I.=1.97-2.63", size(3.0)) ///
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title("Figure 1: KM estimates of initial anal cancer screening rates" "after
a high-risk diagnosis, by risk group", size(3.0) color(black)) ///
graphregion(color(white))
graph save byriskgroup_kaplan, replace

*estimating baseline hazards (read about this on page 142 and 143 of intro to
survival analysis using stata)
stcox i.riskgroup i.race i.eligibility log_enrol age number_pcp specialists
proportion_college med_hh_inc countycases

*stcurve, hazard at(riskgroup=1) at(riskgroup=2) at(riskgroup=3)
kernel(gaussian) width(4) noboundary

stcurve, cumhaz at(riskgroup=1) at(riskgroup=2) at(riskgroup=3) ///
legend(rows(1) subtitle("Risk group", size(3.0)) label(1 "Warts only")
label(2 "Abn. cerv only") label(3 "Both") size(2.5)) ///
xtitle("Analysis time (months)", size(3.0)) ytitle("Cumulative risk (hazard)
of anal cancer screening", size(2.5) height(7)) xlabel(,labsize(3.0)) ///
clpattern(longdash dash longdash_dot) clcolor(blue maroon green) ///
xlabel(0 (12) 48) ///
caption("Abnormal cervical: HR=1.51, 95% C.I.=1.32-1.72; Both: HR=2.48, 95%
C.I.=2.15-2.87", size(2.8)) ///
title("Figure 2: Adjusted risk of initial anal cancer screening (CPH)" "after
a high-risk diagnosis, by risk group", size(3.5) color(black)) ///
graphregion(color(white))
graph save byriskgroup_CPH, replace

*by race
glm scrnd_for_AC i.race, fam(bin) link(log) eform /*shows that separate
success curves are not warranted*/
stcox i.race
stcox i.riskgroup i.race i.eligibility log_enrol age number_pcp specialists
proportion_college med_hh_inc countycases

*unadjusted (KM)
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sts graph, failure by(race) risktable(, color(black) size(2.5) order(1
"Whites" 2 "Blacks" 3 "Hispanics" 4 "Others") title("Risk table",
size(3.0))) ///
yline(0.5, lwidth(0.002) lcolor(black) lpattern(-)) ylab(, labsize(2.5))
xline(6.3 8.2 8.5, lwidth(0.002) lcolor(black) lpattern(-)) ///
legend(rows(1) subtitle("Race/ethnicity", size(3.0)) label(1 "Whites")
label(2 "Blacks") label(3 "Hispanics") label(4 "Others")size(2.5)) ///
xtitle("Analysis time (months)", size(3.0)) ytitle("% screened for anal
cancer", size(3.0) height(7)) xlabel(,labsize(3.0)) ///
xlabel(0 (12) 48) ///
graphregion(fcolor(white)) ///
caption("Blacks: HR=0.95, 95% C.I.=0.87-1.04; Hispanics: HR=0.89, 95%
C.I.=0.76-1.04 Others: HR=0.45, 95% C.I.=0.41-0.51", size(2.2)) ///
title("Figure 2: KM estimates of initial anal cancer screening rates, by
race", size(3) color(black)) ///
plot1opts(lpattern(longdash_dot) lcolor(blue)) ///
plot2opts(lpattern(dash) lcolor(maroon)) ///
plot3opts(lpattern(dash_dot) lcolor(green)) ///
plot4opts(lpattern(longdash) lcolor(black)) ///
graphregion(color(white))
graph save byrace_kaplan, replace

*adjusted (CPH)
stcurve, cumhaz at(race=1) at(race=2) at(race=3) at(race=4) ///
legend(rows(1) subtitle("Race/ethnicity", size(3.0)) label(1 "Whites")
label(2 "Blacks") label(3 "Hispanics") label(4 "Others")size(2.5)) ///
xtitle("Analysis time (months)", size(3.0)) ytitle("Cumulative risk (hazard)
of anal cancer screening", size(2.5) height(7)) xlabel(,labsize(3.0)) ///
xlabel(0 (12) 48) ///
clpattern(longdash_dot dash dash_dot longdash) clcolor(blue maroon green
black) ///
caption("Blacks: HR=0.97, 95% C.I.=0.88-1.06; Hispanics: HR=0.84, 95%
C.I.=0.72-0.99; Others: HR=0.65, 95% C.I.=0.57-0.73", size(2.2)) ///
title("Figure 7: CPH adjusted risk of anal cancer screening, by
race/ethnicity", size(3.5) color(black)) ///
graphregion(color(white))
graph save byrace_CPH, replace
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stci, rmean by(riskgroup)
stci, emean by(riskgroup)
stci, p(20) by(riskgroup)
stci, by(riskgroup)
stci, by(riskgroup abnanal)
stci, emean by(riskgroup) /*gives the extended mean*/

stci,

emean graph

stci,

emean tmax(100) graph

*estimating the hazard function using the adjusted Cox PH model
stcox i.riskgroup i.race i.eligibility enrollment age

*finding the correct functional form
predict mg, mgale
lowess mg age /*no major concerns here*/
lowess mg enrollment /*no major concerns here*/
drop mg

******overall hazards
stcox i.riskgroup i.race i.eligibility log_enrol age number_pcp specialists
proportion_college med_hh_inc countycases
estimates store overall

esttab overall using overall.rtf, nogaps wide eform b se
nonum label

aic bic replace

**hazards at different time periods
*estimating hazard rates at different time intervals
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log using summaries1, replace
stptime,

by(riskgroup) at (1 6 12 24 48)

stptime,

by(race) at (1 6 12 24 48)

stsplit time, at(1 6 12 24)
stcox i.riskgroup i.race eligibility age log_enrol
med_hh_inc proportion_college countycases

number_pcp specialists

bysort time: stcox i.riskgroup i.race eligibility age log_enrol
specialists med_hh_inc proportion_college countycases

number_pcp

drop time
log2html summaries1, replace

*estimating the cumulative baseline hazard
stcox i.riskgroup i.race i.eligibility log_enrol age
predict H0, basechazard
line H0 _t, c(J) sort
label variable H0 "Warts only"
label variable _t "Analysis time (months)"

*getting the baseline hazard for each risk group
gen H2=H0*(exp(_b[2.riskgroup]))
label variable H2 "Abnormal cervical only"

gen H3=H0*(exp(_b[3.riskgroup]))
label variable H3 "Both warts and abnormal cervical"

line H0 H2 H3 _t, c(J J J) sort ///
legend(rows(1) size(2.0)) ///
xtitle(, size(3.0)) ytitle("Cumulative risk (hazard) of anal cancer
screening", size(2.5) height(7)) xlabel(,labsize(3.0)) ///
title("Figure 5: Adjusted risk of anal cancer screening", size(3.5)
color(black))

drop H0 H2 H3
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*stcurve, cif at(riskgroup=1) at(riskgroup=2) at(riskgroup=3)

/*survivor functions (these might not be needed)
predict S0, basesurv
line S0 _t, c(J) sort

gen S2=S0*exp(_b[2.riskgroup])
gen S3=S0*exp(_b[3.riskgroup])
line H0 H2 H3 S0 S2 S3 _t, c(J J J J J J) sort
*/

*testing the PH assumption

*Global test for all and each variable after Cox regression
stphtest, rank detail

*graphs for each variable
stphtest, plot(age) ///
title("Age", position(12) ring(0) size(3.5) color(black)) ///
xtitle("Analysis time (months)", height(4) size(2.8) ) ///
xlabel(0 (12) 48) ///
ytitle(, height(7) size(2.8)) ///
graphregion(color(white)) ///
note("")
graph save age_ph.gph, replace

stphtest, plot(log_enrol) ///
title("Enrollment", position(12) ring(0) size(3.5) color(black)) ///
xtitle("Analysis time (months)", height(4) size(2.8)) ///
xlabel(0 (12) 48) ///
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ytitle("scaled Schoenfeld - enrollment", height(7) size(2.8)) ///
graphregion(color(white)) ///
note("")
graph save enrollment_ph.gph, replace

stphplot, by(riskgroup) ///
title("Risk group", position(12) ring(0) size(3.5) color(black)) ///
ytitle(, height(7) size(2.8)) ///
xtitle(, height(4) size(2.8)) ///
plot1opts(lwidth(thin) msize(vsmall)) ///
plot2opts(lwidth(thin) msize(vsmall)) ///
plot3opts(lwidth(thin) msize(vsmall)) ///
graphregion(color(white)) ///
legend(off)
graph save riskgroup_ph.gph, replace

stphplot, by(race) ///
title("Race/ethnicity", position(12) ring(0) size(3.5) color(black)) ///
ytitle(, height(7) size(2.8)) ///
xtitle(, height(4) size(2.8)) ///
plot1opts(lwidth(thin) msize(vsmall)) ///
plot2opts(lwidth(thin) msize(vsmall)) ///
plot3opts(lwidth(thin) msize(vsmall)) ///
plot4opts(lwidth(thin) msize(vsmall)) ///
graphregion(color(white)) ///
legend(off)
graph save race_ph.gph, replace

graph combine riskgroup_ph.gph race_ph.gph age_ph.gph enrollment_ph.gph,
title("Figure 5: Test of PH assumption", size(4.0) color(black)) ///
graphregion(color(white))
graph save combined_ph.gph, replace
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******
*testing overall fitness of the model
*Cox-snell residuals
*note that without the mgale option the results would be different
set more off

*before transforming enrollment
stcox i.riskgroup i.race i.eligibility enrol age, mgale(mg)

predict cs, csnell
stset cs, failure(scrnd_for_AC ==1)
sts generate H = na
line H cs cs, sort xlab(0 1 to 4) ylab(0 1 to 4) ///
title("Figure 7a: Overall model fitness using Cox-snell residuals" ///
"Before variable transformation", linegap(2) size(3.5) color(black)) ///
graphregion(color(white))
graph save gof_ph.gph, replace
drop mg cs H

*after transforming enrollment

stcox i.riskgroup i.race i.eligibility log_enrol age, mgale(mg)

predict cs, csnell
stset cs, failure(scrnd_for_AC ==1)
sts generate H = na
line H cs cs, sort xlab(0 1 to 4) ylab(0 1 to 4) ///
title("Figure 7b: Overall model fitness using Cox-snell residuals" ///
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"After variable transformation (final model)", linegap(2) size(3.5)
color(black)) ///
graphregion(color(white))
graph save gof1_ph.gph, replace

stcox i.riskgroup i.race ib5.eligibility age enrollmnent, mgale(mg)

stcox i.riskgroup i.race ib5.eligibility age log_enrol, mgale(mg)
predict cs, csnell
stset cs, failure(scrnd_for_AC ==1)
sts generate H = na
line H cs cs, sort xlab(0 1 to 4) ylab(0 1 to 4) ///
title("Figure 7: Overall model fitness using Cox-snell residuals", size(3.5)
color(black))
drop mg cs H
*******LOGISTIC REGRESSIONS: EXAMINING GUIDELINE CONCORDANCE OF FOLLOW-UP
SCREENING****
cd /mnt/isilon/data/hpr/yang/HIV/STEVEN/DATA/CLAIM/Working_folder/Stata/

use for_logistic_regressions, clear

*tsetting the data
stset time_exit2, scale(30) origin(time_entry2) failure(scrnd_secondtime==1)
id(msis_id)
order _t _st
tab _st
keep if _st==1

*testing the normality/skewness of time
mvtest normal _t, univariate

****MAIN ANALYSIS****
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**creating some variables
*any follow-up screening
tab scrnd_secondtime

gen any_fup_screen=scrnd_secondtime
label define any_fup_screen 0 "Not screened" 1 "Screened", replace
label values any_fup_screen any_fup_screen
tab any_fup_screen scrnd_secondtime

*concordance
gen concordant=.
replace concordant=1 if abnanal==0 & _t<=12 &
abnanal==1 & _t<=6 & scrnd_secondtime==1

scrnd_secondtime==1 |

replace concordant=0 if concordant==.
label define concordant 1 "Concordant" 0 "Not concordant", replace
labe values concordant concordant
order abnanal _t concordant
tab concordant abnanal, col chi exp
tab concordant riskgroup, col chi exp
tab concordant race, col chi exp

*Categorical age variable
gen age_cat=.
replace age_cat=1 if age<=34
replace age_cat=2 if age>34 & age<=44
replace age_cat=3 if age>44 & age<=54
replace age_cat=4 if age>54
label define age_cat 1 "19-34 years" 2 "35-44 years" 3 "45-54 years" 4 "55-64
years", replace
label values age_cat age_cat
tab age_cat
oneway age riskfactor, bonferroni tab
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*enrollment_variable, categorical
gen continuous_enrollment=continuously_1yr + continuously_2yr +
continuously_3yr +continuously_4yr
label define continuous_enrollment 2 "2 years" 3 "3 years" 4 "4 years",
replace
label values continuous_enrollment continuous_enrollment
tab continuous_enrollment
tab concordant continuous_enrollment, chi exp row col

*summary statistics
tab abnanal riskfactor, chi
tab scrnd_secondtime riskfactor, chi
tab concordant riskfactor
tab concordant riskfactor

if abnanal==1, chi

tab concordant riskfactor

if abnanal==0, chi

tab race riskfactor, chi
tab eligibility riskfactor, chi
tab continuous_enrollment riskfactor, chi
stsum, by(riskfactor)
stptime,

by(riskfactor)

*working with MCO enrollment variable
gen mco=.
replace mco=1 if mco_enrollment <=0.6
replace mco=2 if mco_enrollment >0.6 & mco_enrollment<=0.8
replace mco=3 if mco_enrollment >0.8 & mco_enrollment<=1
label define mco 1 "<=60%" 2 "61%-80%" 3 ">80%", replace
label values mco mco
tab mco

*creating numeric state variable
encode state, gen(state_num)

195

*Any follow up screening

*without state fixed-effects
logit any_fup_screen i.riskgroup i.abnanal i.eligibility
i.continuous_enrollment i.age_cat i.race i.HIVrate_tert i.pcp_tert
i.spec_tert i.poverty i.less_than_HS i.mco , noconst or
estimates store anyfup_no_fe

*with state-fixed effects
logit any_fup_screen i.riskgroup i.abnanal i.eligibility
i.continuous_enrollment i.age_cat i.race i.HIVrate_tert i.pcp_tert
i.spec_tert i.poverty i.less_than_HS i.mco i.state_num , noconst or
estimates store anyfup_with_fe

**guideline concordance
*without state fixed-effects
logit concordant i.riskgroup i.abnanal i.eligibility i.continuous_enrollment
i.age_cat i.race i.HIVrate_tert i.pcp_tert i.spec_tert i.poverty
i.less_than_HS i.mco , or nocons
estimates store concordant_no_fe

*with state-fixed effects
logit concordant i.riskgroup i.abnanal i.eligibility i.continuous_enrollment
i.age_cat i.race i.HIVrate_tert i.pcp_tert i.spec_tert i.poverty
i.less_than_HS i.mco i.state_num , or nocons
estimates store concordant_with_fe

margins abnanal
margins, at(riskgroup=(1 2) abnanal=(0 1)) post
margins abnanal

esttab concordant_with_fe anyfup_with_fe using logits.rtf, nogaps wide eform
b(2) ci(2) label replace nonum star(* 0.10 ** 0.05 *** 0.01) ///
collabels("Odds Ratio" "95% Confidence Interval" "Odds Ratio"
"95% Confidence Interval") ///
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mtitle("Guideline-concordant follow-up anal cancer screening"
"Any follow-up anal cancer screening") ///
title( "Table 1: Predictors of guideline-concordant follow-up anal
cancer screening in high-risk women living with HIV") ///
refcat(2.riskgroup "Risk factors (ref: one risk factor)"
1.abnanal "Result at first test (ref: normal)" ///
2.race "Race/ethnicity (ref: non-Hispanic whites)" 2.eligibility
"Qualification for Medicaid (ref: income)" ///
3.continuous_enrollment "Continuous enrollment (ref: 2 years)"
2.pcp_tert "Physician 10,000 population (ref: 0-3.7)" ///
2.spec_tert "Specialists per 10,000 population (ref:0-0.92)"
2.less_than_HS "Less than high school (ref: 1%-11.4%)" ///
2.poverty "Percent poor (ref:0.9%-13.5%)" 2.HIVrate_tert "HIV
prevalence per 100,000 adults (ref: 0-54)" ///
2.mco "Medicaid managed care enrollment (ref: <=60%)" 2.age_cat
"Age (ref:19-34 years)", nolabel) ///
drop (1.riskgroup 0.abnanal 1.race 1.eligibility
2.continuous_enrollment 1.pcp_tert 1.spec_tert 1.less_than_HS ///
1.poverty 1.HIVrate_tert 1.mco 1.age_cat *state_num)

*checking for multicollinearity
collin riskgroup abnanal race eligibility continuous_enrollment age
number_pcp specialists proportion_college med_hh_inc countycases state_n

**goodness of fit measures
logit concordant i.riskgroup i.abnanal i.race i.eligibility
i.continuous_enrollment age number_pcp specialists proportion_college
med_hh_inc countycases, or

*Hosmer lemeshow
estat gof, group(10)
lfit, group(20)

*predicted probabilities
predict probability , pr
gen conc_pred=0
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replace conc_pred=1 if probability>=0.5
tab concordant conc_pred, row chi

*plotting residuals
gen n=_n
predict residuals, deviance
sum residual
gen county_n=countyname if residuals>2 & residuals<10
gen county_m=countyname if residuals<-2
label var n "Observation number"
twoway (scatter residuals n if concordant==1 , mlabel(county_n) mlabsize(2))
(scatter residuals n if !concordant, mlabel(county_m) mlabsize(2)), ///
yline(-2 2) legend(off) text(1.9 1000 "Concordant") text(0 1000 "Not
concordant") ///
title("Fig 1: Goodness-of-fit test using deviance residuals", size(4))
///
ytitle("Deviance residuals")
count if county_n!="" | county_m!=""

drop probability conc_pred residuals county_n county_m

tab

conc_pred concordant, chi

roctab

concordant conc_pred, detail table

/////SENSITIVITY ANALYSIS
//sensitivity analysis 2
*continuously enrolled for 4 years

sts list if continuously_4yr==1, failure by(abnanal) at (6 12)

sts list if continuously_4yr==1, failure by( riskgroup abnanal) at (6 12)
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logit concordant i.riskgroup i.abnanal i.eligibility i.age_cat i.race
i.HIVrate_tert i.pcp_tert i.spec_tert i.poverty i.less_than_HS i.mco
i.state_num, or nocons
estimates store two_years_main
logit concordant i.riskgroup i.abnanal i.eligibility i.age_cat i.race
i.HIVrate_tert i.pcp_tert i.spec_tert i.poverty i.less_than_HS i.mco
i.state_num if continuously_4yr==1, or nocons
estimates store four_years

esttab two_years_main four_years, nogaps wide eform b(2) ci(2) label replace
nonum star(* 0.10 ** 0.05 *** 0.01) ///
collabels("Odds Ratio" "95% Confidence Interval" "Odds Ratio"
"95% Confidence Interval") ///
mtitle("Guideline-concordant follow-up anal cancer screening"
"Any follow-up anal cancer screening") ///
title( "Table 1: Predictors of guideline-concordant follow-up anal
cancer screening in high-risk women living with HIV") ///
refcat(2.riskgroup "Risk factors (ref: one risk factor)"
1.abnanal "Result at first test (ref: normal)" ///
2.race "Race/ethnicity (ref: non-Hispanic whites)" 2.eligibility
"Qualification for Medicaid (ref: income)" ///
2.pcp_tert "Physician 10,000 population (ref: 0-3.7)" ///
2.spec_tert "Specialists per 10,000 population (ref:0-0.92)"
2.less_than_HS "Less than high school (ref: 1%-11.4%)" ///
2.poverty "Percent poor (ref:0.9%-13.5%)" 2.HIVrate_tert "HIV
prevalence per 100,000 adults (ref: 0-54)" ///
2.mco "Medicaid managed care enrollment (ref: <=60%)" 2.age_cat
"Age (ref:19-34 years)", nolabel) ///
drop (1.riskgroup 0.abnanal 1.race 1.eligibility 1.pcp_tert
1.spec_tert 1.less_than_HS ///
1.poverty 1.HIVrate_tert 1.mco 1.age_cat *state_num)

tab
*concordance
drop concordant
gen concordant=.
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replace concordant=1 if abnanal==0 & _t<=14 &
abnanal==1 & _t<=8 & scrnd_secondtime==1

scrnd_secondtime==1 |

replace concordant=0 if concordant==.
label define concordant 1 "Concordant" 0 "Not concordant", replace
labe values concordant concordant
order abnanal _t concordant
tab concordant abnanal, col chi exp
tab concordant riskgroup, col chi exp

*without state fixed-effects
logit concordant i.riskgroup i.abnanal i.eligibility i.continuous_enrollment
i.age_cat i.race i.HIVrate_tert i.pcp_tert i.spec_tert i.poverty
i.less_than_HS i.mco , or
estimates store concordant_no_fe

*with state-fixed effects
logit concordant i.riskgroup i.abnanal i.eligibility i.continuous_enrollment
i.age_cat i.race i.HIVrate_tert i.pcp_tert i.spec_tert i.poverty
i.less_than_HS i.mco i.state_num , or
estimates store concordant_with_fe
margins abnanal
margins, at(riskgroup=(1 2) abnanal=(0 1)) post
esttab concordant_with_fe, wide eform ci
log close
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Chapter 5: Conclusion
This dissertation examined the effectiveness of interventions aimed at increasing uptake of
family planning services and HIV-related preventive care among women in low-income settings.
The studies show that uptake of these services is low overall but find that interventions at the
clinic or community levels are effective in increasing the uptake of these services. However, the
studies also emphasize several areas for future research. For example, paper 1 which reports that
contraceptive use increased among rural women following the national scale-up of CBDs in rural
Malawi, the paper suggests that future research should focus on examining the cost-effectiveness
of the national CBDs given that resources in these settings are very limited. The trial-based costeffectiveness of conditional cash transfers in the DRC suggests that future research should focus
on examining the cost-effectiveness of the cash incentives in larger populations and over a longer
analytic horizon before further scale-up of the intervention in sub-Saharan Africa. Similarly,
gathering more evidence about the benefits of anal cancer screening in people living with HIV at
high risk for anal cancer in the USA can help solidify the guidelines for anal cancer screening
and improve the rates overall follow-up anal cancer screening.
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